Abstract
Premenstrual dysphoric disorder (PMDD) is a cyclical condition of severe mood change, irritability and tension in the days before menstruation, usually easing when, or shortly after, bleeding begins. Its forerunner sat in a DSM-III-R appendix of categories needing study; DSM-5 made it a full depressive disorder, ICD-11 classes it as a genitourinary disease, and historical analyses have described it as a socially constructed label. Diagnosis rests on prospective daily ratings over at least two cycles, and prevalence falls to a few percent once diagnosis is confirmed this way. The leading account, currently supported, is a differential sensitivity to normal ovarian-hormone change, and suicidality is elevated in mostly cross-sectional studies. Serotonin reuptake inhibitors are among the best-supported treatments, alongside combined oral contraceptives in one scoping review; drospirenone-containing pills and, for severe cases, ovarian suppression are further options.
Keywords: premenstrual dysphoric disorder, premenstrual syndrome, menstrual cycle, hormone sensitivity, daily symptom ratings
Premenstrual dysphoric disorder (PMDD) is a recurring disorder in which severe low mood, irritability and tension build before menstruation and usually ease when it begins or soon after, with physical or emotional symptoms heavier and more disabling than those of premenstrual syndrome (MeSH, D065446). This page covers the premenstrual disorder that DSM-5 classes as a depressive disorder; depressive mood in general is covered on the depression page, and the most common depressive diagnosis is covered on the major depressive disorder page. DSM-5 lists it among the depressive disorders (American Psychiatric Association, 2013), and confirming it requires daily ratings kept prospectively for at least two symptomatic cycles (Hantsoo & Epperson, 2015). When the diagnosis is confirmed in that way, pooled prevalence is about 3.2%, against 7.7% when it is only provisional (Reilly et al., 2024). Schmidt et al. (1998) concluded from a double-blind crossover study that symptoms are an abnormal response to normal hormonal change: symptoms eased under ovarian suppression in women with premenstrual syndrome, and came back with estradiol or progesterone add-back in the ten whose symptoms had improved, while the same hormones left the mood of unaffected women unchanged (Schmidt et al., 1998).
The article begins with What Premenstrual Dysphoric Disorder Is, the History of the Concept, and Symptoms, Diagnosis and Measurement, then turns to The Experience of Premenstrual Dysphoric Disorder in women's own accounts and to the Types of Premenstrual Dysphoric Disorder and related presentations. It goes on to Prevalence, Course and Burden, The Differential Hormone-Sensitivity Model of Premenstrual Dysphoric Disorder, and the Serotonergic, Stress and Sociocultural Accounts that sit beside it, before examining Emotion, Attention and Cognition Across the Cycle, Testing Cause and Consequence, and the Validity of Diaries, Laboratory Tasks and Cycle-Phase Measures. Sections on The Biology of Premenstrual Dysphoric Disorder, Sleep and Circadian Rhythms, Brain Networks and Imaging, and Culture, Society and Disparities follow, then The Debate over the Diagnosis, Comorbidity, Suicide and Self-Harm, and Related Conditions and Normal Premenstrual Change. The treatment sections cover Treatment Evidence, How Treatments Work, Somatic Treatments: Ovarian Suppression and Surgery, Lifestyle and Complementary Approaches, and Emerging Treatments, and a Worked Example sets a screening questionnaire against a daily diary in the same women.
Key Takeaways
- Late luteal phase dysphoric disorder, the forerunner of PMDD, entered a DSM-III-R appendix for categories needing further study amid controversy. DSM-5 made PMDD a full depressive disorder and DSM-5-TR kept it, while ICD-11 classes it as a genitourinary disease. A historical analysis described the label as socially constructed, while a review of the concerns raised against inclusion judged that the evidence favoured placement in the main text.
- In interviews with 17 UK women with PMDD, some described two bad weeks before menstruation followed by two good weeks, with relief once the period came, while others had only a few days of normality after bleeding. The women described misdiagnosis, including as depression or bipolar disorder, and an average delay of 20 years before diagnosis; these figures describe that small sample only.
- Diagnosis rests on daily ratings kept prospectively over two cycles, because no objective test exists and retrospective reports predicted the scored diagnosis poorly; in one small study, beliefs about the premenstrual phase were linked to inflated recall. In one sample of 127 women a retrospective screen classed 34.6% as having PMDD and the daily record 3.9%. A meta-analysis of 44 studies pooled 3.2% for confirmed diagnosis and 7.7% for provisional diagnosis, with very high heterogeneity across all studies; restricted to community-based samples with confirmed diagnosis, the figure was 1.6%.
- Population-based surveys in Korea and China and a clinic-based screening survey in Japan put PMDD in the low single digits. In US surveys of Asian, Latina and Black women, foreign-born women had lower odds of PMDD, a cross-sectional finding the authors read as an apparent acculturation effect. No study here examines socioeconomic pathways, discrimination or sexual and gender minorities directly.
- The differential hormone-sensitivity model is currently supported: symptoms remitted under ovarian suppression and returned with blinded add-back in affected women only, and a later single-blind study tied them to hormonal change rather than steady levels. Samples were small, the allopregnanolone and GABA-A receptor mechanism is proposed rather than established, and the cause of the sensitivity is unknown. Twin studies find premenstrual symptoms partly heritable, but the specific gene and cell-line findings are preliminary; serotonin is seen as complementary to the model, and the stress evidence is inconsistent.
- Sleep studies report poorer subjective sleep and lower melatonin, and imaging points to limbic and prefrontal differences whose phase and direction vary between studies. On cognition, a preliminary study found a luteal negative bias in reading faces, a 2025 review found only limited and inconsistent performance differences, and executive deficits appear only late in the luteal phase in some studies and in every phase in others, so state versus trait is unresolved.
- PMDD co-occurs with mood and anxiety disorders, trauma and PTSD, bipolar disorder and bulimia nervosa, mostly in cross-sectional or self-reported data; prospective evidence that a factor comes first exists for trauma, anxiety history, daily hassles and subthreshold PMDD. Systematic reviews link PMDD with suicidal ideation, plans and attempts, but none of the studies reviewed here tests whether an intervention lowers that risk in PMDD.
- SSRIs are among the best-supported treatments, alongside combined oral contraceptives in one scoping review, and were rated moderate certainty in a 2024 Cochrane review, with more adverse events than placebo; luteal-phase dosing beats placebo, but whether it matches continuous dosing is unsettled. Drospirenone-containing pills may help on low-quality evidence with more adverse effects, cognitive behavioural therapy is possibly beneficial on low-quality evidence, venlafaxine beat placebo in one trial, progesterone is unproven, sepranolone missed its primary endpoint and ulipristal acetate awaits replication. For severe cases GnRH agonists give short-term relief and surgery is a last resort; exercise, calcium, vitamin B6 and Vitex were studied mainly in premenstrual syndrome on weak evidence, and bright light had a small, uncertain effect in PMDD.
What Premenstrual Dysphoric Disorder Is
MeSH defines premenstrual dysphoric disorder as a condition of severe depression, irritability and tension before menstruation, with physical or emotional symptoms more severe and debilitating than those of premenstrual syndrome, including at least one mood-related symptom, that usually stop when or shortly after menstruation begins (MeSH, D065446). MeSH introduced the descriptor in 2015, indexing the topic under premenstrual syndrome before then, files it under both premenstrual syndrome and depressive disorder, and lists premenstrual dysphoric syndrome as its entry term.
Premenstrual dysphoric disorder (PMDD) is a severe form within the wider family of premenstrual disorders, which a 2024 review described as common and costly for the women who have them; the functional impact of PMDD, on that review's reading, is comparable to that of major depression (Cary & Simpson, 2024). The same review cautioned that the condition is under-recognised and poorly treated, and that defining, diagnosing and managing it is still difficult (Cary & Simpson, 2024).
A Depressive Disorder in DSM-5
DSM-5, the manual's fifth edition, places PMDD with the depressive disorders (American Psychiatric Association, 2013). That placement followed a literature review by an eight-member work group, which concluded that the condition qualified as a full DSM-5 category (Epperson et al., 2012). The group weighed antecedent, concurrent and predictive validators, the classes of evidence used to judge whether a proposed category holds together, against the DSM-IV Appendix B criteria and its own suggested DSM-5 criteria (Epperson et al., 2012). It set prevalence at 2%–5% of premenopausal women: studies using probability samples came in near 2% and the full body of studies nearer 5% (Epperson et al., 2012). It was also candid about gaps, noting that no biomarker was clearly associated with the disorder and that neuroimaging work was in its infancy (Epperson et al., 2012).
The 2022 text revision, DSM-5-TR, continues to carry the category (American Psychiatric Association, 2022). That revision was a three-year effort involving more than 200 experts across 20 review groups; it added new entities such as prolonged grief disorder and revised criteria elsewhere, though most criteria changes were relatively minor (First et al., 2022).
The criteria turn on three things: when the symptoms occur, what they are, and what they cost. As for timing, the symptoms arise in the luteal phase (the interval from ovulation to the next period), subside early in the period itself, and have largely or entirely cleared by the postmenstrual week (Carlini et al., 2022; Hantsoo & Epperson, 2015). The pattern must be a regular one, present in most menstrual cycles of the past year, which the work group framed as at least half of the cycles in the previous year (Hantsoo & Epperson, 2015; Epperson et al., 2012).
On content, the criteria separate a core of affective symptoms from a wider set that counts toward the total. The core comprises four: affective lability, meaning abrupt swings of mood; irritable mood or anger; depressed mood or a sense of hopelessness; and anxiety or tension, the feeling of being keyed up or on edge (Carlini et al., 2022; Hantsoo & Epperson, 2015). The wider set reaches into thinking and motivation, with trouble concentrating, loss of interest in usual activities, tiredness or low energy, and a sense of being overwhelmed or out of control. It also takes in the body: changes in appetite or food cravings, sleeping too much or too little, and physical complaints that include breast tenderness, bloating and pain (Carlini et al., 2022; Hantsoo & Epperson, 2015). The total must reach five symptoms or more, and one or more must be affective (Carlini et al., 2022); the earlier DSM-IV rules, as an international expert consensus group summarised them before DSM-5 appeared, likewise set the threshold at five of 11 listed symptoms (O'Brien et al., 2011). On cost, the symptoms must cause significant impairment (Hantsoo & Epperson, 2015).
Two lines of evidence were put forward as informative for the DSM-5 criteria. A secondary analysis of prospective daily ratings from a community cohort and a treatment-seeking cohort, carried out to inform DSM-5, found that severity peaked around menstruation rather than only before it, in windows such as four days before through the first two days of menses (Hartlage et al., 2012). In that analysis four or more symptoms was the cutoff that best tracked impairment, although the best number differed between the two cohorts, and depressed mood was reported less often than the other affective symptoms (Hartlage et al., 2012). The work group likewise noted that the psychological symptoms most commonly reported are mood lability and irritability rather than depressed mood (Epperson et al., 2012). An earlier review had argued that a diagnosis consists of determining timing, change across the cycle and severity, and that no hormone or laboratory test indicates the diagnosis; it observed that DSM-IV demanded five specified symptoms where the ICD-10 definition of premenstrual syndrome needed only one distressing symptom, and that many women fell between the two sets of criteria (Freeman, 2003).
The work group also reported that, in twin data, 86% of the genetic variance in premenstrual symptoms was not shared with major depression, though the heritability studies relied on retrospective reports (Epperson et al., 2012). How PMDD is told apart from a recurrent depressive episode and from ordinary premenstrual change is the subject of Related Conditions and Normal Premenstrual Change.
ICD-11 and the Gynaecological Classifications
The World Health Organization's classification takes a different route. ICD-11 treats PMDD as a disease of the genitourinary system, whereas DSM-5 treats it as a psychiatric condition (Osborn et al., 2020). ICD-11 reorganised the mental disorders chapter, taking global applicability and clinical utility as its aims and adding categories that ICD-10 lacked (Reed et al., 2019); WHO's companion guide to that chapter, setting out its clinical descriptions and diagnostic requirements, goes by the abbreviation CDDR (World Health Organization, 2024).
Gynaecology and reproductive psychiatry had meanwhile produced classifications of their own. An international multidisciplinary expert group proposed updated diagnostic criteria for premenstrual syndrome in 2007, noting that no criteria were universally accepted and that the cause remained unclear, and expressed the hope that its proposal would be widely adopted and taken into ICD-11 (Halbreich et al., 2007). The International Society for Premenstrual Disorders (ISPMD) then reached a consensus, drawing on presentations of the evidence and, where evidence did not exist, a brief modified Delphi technique, that divides premenstrual disorders into a core disorder and several variants, among them premenstrual worsening of another condition and symptoms arising with non-ovulatory ovarian activity (O'Brien et al., 2011). The group judged the ACOG and ICD-10 criteria more liberal than the DSM-IV definition of PMDD, and noted that ICD-10 premenstrual syndrome, unlike its core disorder, required no impact on daily life (O'Brien et al., 2011). Its members were divided on the strength of evidence for a non-ovulatory variant, and also on which patient rating technique was most suitable, though many favoured the DRSP (O'Brien et al., 2011). A later ISPMD meeting in London in 2011 moved to management guidance built on the core and variant scheme, and it rejected subtypes defined by symptom profile because little empirical evidence supported them (Nevatte et al., 2013). The variants are described in Types of Premenstrual Dysphoric Disorder.
The classifications therefore place the disorder differently: the DSM files PMDD as a psychiatric condition, and ICD-11 files it as a genitourinary disease (Osborn et al., 2020).
Prospective Ratings at the Centre of Diagnosis
Recall is not enough to make the diagnosis. The criteria require daily ratings kept prospectively across at least two symptomatic cycles (Epperson et al., 2012; Hantsoo & Epperson, 2015), and reviews from both the psychiatric and the gynaecological traditions set two cycles of daily monitoring as the minimum (O'Brien et al., 2011; Yonkers & Simoni, 2018). The ISPMD consensus explained why: there is no objective test, so the woman's own ratings remain necessary, even though such ratings depend on her subjective view (O'Brien et al., 2011).
Retrospective accounts are a poor guide. When the Carolina Premenstrual Assessment Scoring System (C-PASS) was first validated as a companion protocol for scoring the Daily Record of Severity of Problems, women's recalled accounts of their symptoms proved a poor guide to who would receive a C-PASS diagnosis (Eisenlohr-Moul et al., 2017). Applied to two to four months of daily ratings from 200 women, the system's overall correct classification against expert clinical diagnosis was estimated at 98%, and its authors presented it as a reliable and valid companion to the daily record, set against variable diagnostic practices (Eisenlohr-Moul et al., 2017). A diagnosis made before such ratings is provisional, and provisional diagnoses run through the research literature: a 2021 meta-analysis of suicidality noted that the studies it pooled used nonstandardized and self-report measures, and that some included PMDD diagnoses were provisional (Prasad et al., 2021). Types of Premenstrual Dysphoric Disorder treats the provisional diagnosis as a category in its own right, and Suicide and Self-Harm reports that meta-analysis.
The cycle matters beyond PMDD itself. A 2025 perspective argued that menstrual cycle phase bears on psychiatric symptoms across diagnoses, citing more psychiatric admissions around menstruation and more suicide attempts during it, and called for clinicians to ask about the cycle routinely (Marwick et al., 2025). Its authors noted that definitions of cycle phase vary between studies and that cycles show marked variation between and within women (Marwick et al., 2025). The requirement for prospective ratings is part of the current criteria, while the ISPMD consensus group's opinion, as reported in 2011, was divided on the most suitable rating technique (O'Brien et al., 2011; Eisenlohr-Moul et al., 2017). The rating instruments, including the Daily Record of Severity of Problems, are described in Symptoms, Diagnosis and Measurement.
History of the Concept
The idea that the days before menstruation can bring a distinct pattern of distress is older than any diagnostic manual. A 1931 paper by Frank dealt with the hormonal causes of premenstrual tension (Frank, 1931). Two decades later Greene and Dalton wrote about what had hitherto been called premenstrual tension (Greene & Dalton, 1953).
From a Syndrome to a Prospective Measure
Early accounts leaned on women's recollections. Rubinow and colleagues in 1984 selected twice-daily self-rating for the prospective confirmation of menstrually related mood change. Twenty women who had diagnosed themselves with premenstrual syndrome rated their mood two times each day, marking each rating on a 100-mm visual analogue line, in what Rubinow and colleagues presented as a preliminary application; for eight of them (40%), average depression scores across the premenstrual week exceeded those of the week following the end of menses by 30% (Rubinow et al., 1984). The authors presented the scale as suited to this kind of tracking. The work was preliminary, and the sample was small and self-diagnosed.
A Contested Entry into the DSM
Psychiatry's first formal listing came with late luteal phase dysphoric disorder. A committee account records its addition to the DSM-III-R appendix, which holds categories that need further study, and calls it perhaps the most controversial aspect of that revision (Spitzer et al., 1989). A sociological case study of the 1986 American Psychiatric Association decision found that the listing was not settled by science alone, and that the disorder took different forms in each of three domains: health and mental health, women, and science (Figert, 1995). Historical analysis has since described premenstrual syndrome and premenstrual dysphoric disorder as socially constructed labels (Chrisler & Caplan, 2002).
Evidence kept accumulating alongside the argument. A randomized, double-blind, placebo-controlled trial across seven Canadian clinics found fluoxetine, at 20 mg or 60 mg a day, better than placebo for tension, irritability and dysphoria (Steiner et al., 1995). The Treatment Evidence section covers this finding and its limits.
Promotion to a Full Diagnosis
A history of DSM revisions, built from interviews with psychiatrists and psychologists central to the DSM-IV process, traces the category through DSM-III-R and DSM-IV to DSM-5. It reports that premenstrual dysphoric disorder entered DSM-5 with notably less controversy than it had met in the two earlier editions (Zachar & Kendler, 2014). Members of the DSM-5 work group reviewed the evidence and concluded that the disorder merits a full category (Epperson et al., 2012). A review of 55 articles identified 38 concerns about inclusion, addressed the six raised most often, and judged that the evidence favoured placement in the main text (Hartlage et al., 2014). The arguments on both sides are set out in The Debate over the Diagnosis.
Current Status
Premenstrual dysphoric disorder now sits among the depressive disorders in DSM-5 (American Psychiatric Association, 2013) and in DSM-5-TR (American Psychiatric Association, 2022).
Symptoms, Diagnosis and Measurement
Premenstrual dysphoric disorder is identified from how a woman's symptoms are timed against her cycle, how far they depart from her usual state, and how much they impair her. This section covers the symptom picture and its timing, the daily rating instruments that capture it, the screening tools that only approximate it, and the reasons why recalled and daily-recorded symptoms disagree.
Symptoms and Their Timing
Symptoms in severe premenstrual syndrome and premenstrual dysphoric disorder do not form a single block. A factor analysis of 174 prospective symptom diaries from women with severe premenstrual syndrome or the disorder yielded six clusters: affective dysphoria, somatic dysphoria, irritability, breast and body sensitivity, pain, and eating behavior (Kaiser et al., 2018). Internal consistency ranged from 0.83 to 0.91 across the clusters, with the pain cluster lower at 0.69, and pain and eating behavior were unstable across cycles. The clusters related differently to impairment, and somatic dysphoria showed the strongest positive association. The authors concluded that different symptom patterns should be considered, and the finding rests on diaries kept during an eight-week waiting period.
Timing is as defining as content. Daily ratings from a community cohort and a treatment-seeking cohort put the worst symptoms at the junction of two cycles, spanning four days before menses to the second day of bleeding in one analysis and three days before to the third day in the other (Hartlage et al., 2012). Symptoms were therefore perimenstrual, not only premenstrual. Depressed mood was less frequent than the other affective symptoms. Having 4 or more symptoms went with functional impairment, and that number was the optimal cutoff, although the symptom count differed between the two cohorts.
A diagnosis of premenstrual syndrome or the disorder needs three elements at once: the timing of symptoms, a change from the woman's usual state, and sufficient severity (Freeman, 2003). No hormone or laboratory test diagnoses premenstrual syndrome. The review compared the DSM-IV definition of the disorder with the ICD-10 definition of premenstrual syndrome and noted that the former demands more specified symptoms, and that clinically significant premenstrual syndrome is separated from normal cycle changes by severity. It also observed that many women fall between the criteria and that standard criteria were still needed.
An international multidisciplinary expert group addressed that gap with proposed updated diagnostic criteria for premenstrual syndrome, hoping for wide acceptance and for inclusion in ICD-11 (Halbreich et al., 2007). The group noted that etiology was unclear and that no universally accepted criteria existed. The categories themselves appear in the manuals (American Psychiatric Association, 2022; World Health Organization, 2024).
Daily Rating Instruments
The DRSP is a diary that a woman fills in herself each day, prospectively. Two validation studies, one with 27 subjects and one with 243 women with the disorder, found it reliable and valid, with sensitivity to change shown in the larger study, and the authors described it as a sensitive, reliable and valid measure (Endicott et al., 2006). Earlier prospective work had used a 100-mm visual analogue scale rated twice daily. In a preliminary application with 20 women with self-diagnosed premenstrual syndrome, 8 (40%) had a mean depression rating in the premenstrual week that was 30% higher than in the postmenstrual week (Rubinow et al., 1984).
The C-PASS, by contrast, records nothing itself: it is an algorithm that converts DRSP ratings into a diagnostic decision. In its initial validation, 200 women completed two to four months of ratings, and C-PASS diagnoses matched those of expert clinicians in 98% of cases (Eisenlohr-Moul et al., 2017). Retrospective symptom reports predicted the C-PASS diagnosis poorly. Its developers concluded that, as an add-on to the DRSP, it was both reliable and valid.
Confirming a cyclical pattern from daily ratings
Daily severity ratings over two menstrual cycles. Adjust how much symptoms rise in the last week before bleeding, and the percentage change between the post-menstrual and premenstrual weeks that counts as a marked increase.
| Cycle 1: post-menstrual mean 1.41, premenstrual mean 3.07 | +117% marked |
| Cycle 2: post-menstrual mean 1.44, premenstrual mean 3.10 | +115% marked |
Both cycles show a marked premenstrual increase, the pattern prospective diagnosis looks for.
Use of daily ratings across the research literature is uneven. A systematic review of 75 studies of women meeting criteria for late luteal phase dysphoric disorder or the disorder found low consistency among the diaries used, frequent analysis of only part of the cycle, and variable diagnostic procedures and criteria (Bosman et al., 2016). The review excluded women with premenstrual syndrome alone and women without a diagnosis. Its conclusion was that daily ratings are valuable but that diaries need improvement. A consensus group of 19 members, for its part, set a symptom diary kept for 2 months among its auditable standards for the premenstrual disorders (Ismaili et al., 2016).
Screening Instruments
The PSST is a screening questionnaire for clinicians that asks how severe symptoms are and how much they interfere with daily life. Its developers presented it as a quick and effective way to identify severe premenstrual syndrome and the disorder, taking less time than two cycles of prospective charting, and called it an important starting point for further assessment (Steiner et al., 2003). The prevalence it gave was in line with prospective studies.
Agreement with the daily record proved poor. Among 127 women aged 20 to 45 with premenstrual complaints, of 282 eligible who answered the PSST, the DRSP classified 74.8% as having premenstrual syndrome and 3.9% as having the disorder, whereas the PSST classified 41.7% and 34.6% respectively (Henz et al., 2018). Agreement between the instruments was low (kappa = 0.12; PABAK = 0.39). The PSST therefore found fewer cases of the syndrome and far more of the disorder than the diary did, while the two gave similar counts for women without either. A caveat applies: only 127 of the 282 women returned the DRSP, so many were lost, and the PSST is retrospective and was not collected over time. The authors concluded that the PSST screens only and that a positive result should be confirmed with the DRSP.
Both studies describe the screen as a starting point for further assessment, and the later study found that it overestimated PMDD relative to the daily record (Steiner et al., 2003; Henz et al., 2018).
Retrospective Versus Prospective Report
Retrospective and prospective reports disagree for a reason that goes beyond forgetting: beliefs about the premenstrual phase shape what is remembered. In a within-subject comparison of 49 women, retrospective reports of premenstrual change exceeded prospective ones, and the belief that most women have premenstrual syndrome was linked to this recall bias (Marván & Cortés-Iniestra, 2001). The authors read the pattern as stereotype-driven misperception that inflates recalled change, and they measured symptoms with the Moos Menstrual Distress Questionnaire. The pattern concerns recall in particular, not symptom experience in general.
An earlier experiment separated belief from physiology. Women told they were premenstrual reported more physical symptoms, such as water retention, than women told they were intermenstrual, whatever their actual phase (Ruble, 1977). The author concluded that earlier conclusions may need reexamination, since self-report questionnaires can bias them.
The gap shows in community data too. Of 1246 women drawn by probability sampling, just 1.3% satisfied DSM-IV criteria once symptoms were rated prospectively, while relying on retrospective symptom accounts alone would have qualified 54% (Gehlert et al., 2009). The prevalence figure itself is reported under Prevalence, Course and Burden. The wider critique of diaries, including how cycle phase is coded and how laboratory tasks are scheduled, is taken up in Validity of Diaries, Laboratory Tasks and Cycle-Phase Measures. The position that follows from the evidence here is that daily prospective ratings are the standard against which a recalled report is checked.
The Experience of Premenstrual Dysphoric Disorder
The symptomatic phase, as women with premenstrual dysphoric disorder (PMDD) describe it, is closer to an inner war than to a list of complaints. In a thematic analysis of interviews with 17 UK women whose PMDD a specialist had diagnosed, the accounts spoke of distressing mood swings, sadness, despair, anxiety, anger and tearfulness. Many felt like a different person, an alter ego. Relationships were damaged and women withdrew, and some described shame, self-hate and feeling worthless. Several masked symptoms at work and let them out at home. Relief came once the period arrived; some women described two bad weeks before menstruation followed by two good weeks, while others had only a few days of normality after bleeding (Osborn et al., 2020). The same women ranged from 20 to 56 years of age, with a mean of 37, and they reported an average delay of 20 years before diagnosis. The age range, the mean age and the delay before diagnosis all come from those 17 women alone (Osborn et al., 2020).
Reaching a Diagnosis
Misdiagnosis, delay and stigma run through the first-person accounts. In the UK interviews, women reported being labelled with other conditions, including depression and bipolar disorder, before PMDD was named, and receiving the diagnosis brought relief. Women described feeling more confident and of greater worth once they could separate themselves from their symptoms (Osborn et al., 2020). The sample was specialist-diagnosed, mostly white British and a particularly afflicted group. Its authors caution that the sample may not be representative of all PMDD (Osborn et al., 2020).
Interviews with 32 US adults who identified as having PMDD describe the same problem as a system. Multilevel barriers produced a cycle of delayed care, which the authors frame as patient, diagnostic and treatment delay along a PMDD care continuum. Some participants described medical gaslighting and said they had seen up to 10 different providers. The authors conclude that more research is needed. The study had three acknowledged limits: participants showed little racial diversity, people without a diagnosis proved difficult to enlist, and no intercoder reliability scores were computed (Chan et al., 2023).
Managing Distress over Time
Distress in these studies is not a fixed state. Sixty women who defined themselves as premenstrual syndrome sufferers described it as a negotiated process. The authors suggest that reframing, coping and self-monitoring may reduce distress (Ussher & Perz, 2013). That sample concerns premenstrual syndrome, not PMDD, so it bears on the topic by analogy.
A systematic review and thematic synthesis pooled 17 qualitative papers on living with premenstrual disorders, covering 479 women, with ten papers on premenstrual syndrome and six on PMDD. The women experienced the symptoms as life-controlling and felt their sense of self fractured. Themes included learning to cope, feeling dismissed by healthcare professionals, changed motherhood, navigating relationships and the impact on occupation. Seven of the eight subthemes appeared in both groups, while taking back control appeared only in the PMDD papers. The reviewers conclude that premenstrual disorders are life-changing and that professionals working with women in crisis should assess for them and signpost towards specialist services (Brown et al., 2024). Its caveats include English-language papers only, possible publication bias and diagnosis that was self-reported in ten papers (Brown et al., 2024).
Work
Interviews with 15 women with PMDD found that symptoms at work led to presenteeism and absenteeism. Symptoms at work arose in the premenstrual episode phase, whereas over-compensatory behaviour followed in the post-episode phase. The authors conclude that organisations need more awareness and support (Hardy & Hardie, 2017).
What These Samples Are
These are qualitative samples, chosen to show what the experience is like and how it is organised. They are not prevalence estimates, and their counts of women say nothing about how common any experience is. None of the studies reviewed in this section examines partners or children directly. Relationships appear only through the women's own reports.
Types of Premenstrual Dysphoric Disorder
A type here means a recognised presentation or classification, and the types need not be distinct diseases. The Medical Subject Headings (MeSH) vocabulary lists no subtypes of the disorder; it carries the entry term Premenstrual Dysphoric Syndrome as an indexing synonym. The fifth edition of the DSM names a single disorder (American Psychiatric Association, 2013). The International Society for Premenstrual Disorders (ISPMD) draws a further line between core premenstrual disorder and variant forms (O'Brien et al., 2011; Nevatte et al., 2013).
Around these categories sit a milder boundary presentation, the premenstrual worsening of another disorder, provisional cases awaiting confirmation, and mood disorders of other reproductive transitions that sources link to hormone sensitivity. Cognitive findings exist for some of these types and are thin or absent for others. Each type below says which.
Table 1
Types of Premenstrual Dysphoric Disorder and Related Presentations
| Type | Standing | Key instrument |
|---|---|---|
| Premenstrual Dysphoric Disorder | DSM-5 depressive disorder | Carolina Premenstrual Assessment Scoring System with the Daily Record of Severity of Problems |
| Premenstrual Syndrome | Milder boundary presentation | Steiner premenstrual syndrome screening tool |
| Premenstrual Exacerbation of Another Disorder | Premenstrual worsening of another disorder | – |
| Core and Variant Premenstrual Disorders | ISPMD classification | Prospective daily rating; the group was divided on technique, many members favouring the Daily Record of Severity of Problems |
| Provisional and Subthreshold Presentations | Provisional diagnosis | Prospective symptom monitoring |
| Perimenopausal and Other Reproductive-Transition Mood Presentations | Related reproductive-transition presentation | – |
Premenstrual Dysphoric Disorder
Premenstrual dysphoric disorder is the DSM-5 category (American Psychiatric Association, 2013), and the DSM-5 work group's literature review concluded that it qualified as a full diagnostic category (Epperson et al., 2012). Its criteria are set out in What Premenstrual Dysphoric Disorder Is and are not repeated here. Diagnosis is confirmed from ratings kept day by day as the cycle unfolds; when one scoring system was run on DRSP records from 200 women, its verdicts matched those of expert clinicians for 98% of them (Eisenlohr-Moul et al., 2017).
Cognitive Implications
The cognitive findings in PMDD are the subject of the section Emotion, Attention and Cognition Across the Cycle, and only their headline belongs here. A narrative review concluded that findings on cognitive functioning across the menstrual cycle were inconsistent and that cognitive research in premenstrual disorders was still in its infancy (Le et al., 2020). A 2025 systematic review of 21 papers and 1222 participants likewise reported a limited and inconsistent difference in cognitive performance between PMDD and control groups, and suggested that process, content and behaviour measures may be more informative (Henderson et al., 2025). The same review reported that negative attentional bias was associated with the PMDD experience.
Premenstrual Syndrome
Premenstrual syndrome is the milder and more common presentation. In a population survey of 3,913 Swiss women aged 15 to 54, 91% reported at least one premenstrual symptom, 10.3% met the screening tool's definition of PMS, and 3.1% that of PMDD (Tschudin et al., 2010). An ISPMD consensus report noted marked variation in published estimates, for example 80 to 95% for physiological premenstrual symptoms, 30 to 40% for PMS and 3 to 8% for PMDD, which it attributed to differences in how significant symptoms are interpreted (O'Brien et al., 2011). Most women therefore notice some premenstrual change, and the boundary lies in severity and impairment. The ISPMD consensus noted that the ICD-10 criteria for PMS require no impact on functioning (O'Brien et al., 2011).
Severity does not separate the categories cleanly in every sample. In a survey of 984 urban adolescent girls, subthreshold PMDD matched full PMDD in symptom intensity and frequency, and both groups scored higher on depression and anxiety than girls with moderate to severe PMS or with none to mild PMS (Yang et al., 2014). In the authors' conclusion, confirming the diagnosis requires symptoms to be charted prospectively, day by day. An international expert group proposed updated diagnostic criteria for PMS, hoping for wide acceptance and inclusion in ICD-11, and noted that no criteria were universally accepted (Halbreich et al., 2007).
Cognitive Implications
The cognitive literature on PMS is small, and its samples concern PMS or mixed PMS and PMDD groups. In a case-control study of 55 women with PMS and 55 controls, the PMS group showed primarily larger emotional Stroop effects for picture and facial stimuli in the luteal phase, with a paradoxical Stroop facilitation effect for faces and no group difference for words (Eggert et al., 2017). The cognition section gives the full account. In a small case-control study of 13 women with PMS and 27 controls, moderate to severe PMS went with poorer accuracy on the 0-back and more omission errors on the 0-back and 2-back, and the authors described subtle deficits in working memory and selective attention that persisted into the follicular phase (Slyepchenko et al., 2017). A laboratory study of women varying in anxiety sensitivity, which was not a PMS-defined sample, found that high anxiety sensitivity went with more severe menstrual symptoms (Sigmon et al., 2000).
Premenstrual Exacerbation of Another Disorder
Premenstrual exacerbation is the worsening of an existing disorder in the premenstrual phase. It differs from PMDD because the underlying illness is present across the cycle. In a community cohort of 900 females rating symptoms daily over two cycles, follicular-phase depression severity was higher in clinically and subclinically depressed participants than in non-depressed ones, and older age predicted more exacerbation (Hartlage et al., 2004). The authors suggested that exacerbation may affect depressed women broadly.
Bipolar disorder shows the same pattern. Of 293 women with bipolar disorder who were premenopausal and were tracked for a year, 191 (65.2%) showed premenstrual exacerbation; compared with the rest, they had more mood episodes, most of them depressive, and relapsed sooner, though the link with relapse lost significance once retrospectively reported rapid cycling was adjusted for (Dias et al., 2011). The relapse link was not significant after adjustment for rapid cycling, so the authors proposed only that exacerbation may mark a relapse-prone, symptomatic phenotype. In ADHD, a 35-day diary study of 32 regularly cycling young women found that low estradiol combined with high progesterone or high testosterone predicted next-day ADHD symptoms, most strongly in women high in trait impulsivity (Roberts et al., 2018).
Across disorders the evidence is mixed and limited. A systematic review of 35 prospective studies found perimenstrual worsening in psychotic, panic, eating, depressive and borderline personality disorders, a less consistent pattern in anxiety, and a different pattern in bipolar disorder; it suggested that a hormone-sensitive subgroup may be affected (Nolan & Hughes, 2022). Reviews agree that larger, prospective studies are needed (Kuehner & Nayman, 2021; Lin et al., 2024). Telling exacerbation from PMDD depends on ratings across the whole cycle (Kuehner & Nayman, 2021).
Cognitive Implications
None of the studies reviewed here reports cognitive testing in premenstrual exacerbation as such. The ADHD diary study tracked self-rated ADHD symptoms, not performance on cognitive tasks (Roberts et al., 2018).
Core and Variant Premenstrual Disorders
The ISPMD consensus separates core premenstrual disorder from variant forms (O'Brien et al., 2011; Nevatte et al., 2013). Four variants are named. Premenstrual exacerbation is the worsening of an existing disorder described above. Premenstrual disorder due to non-ovulatory ovarian activity covers symptoms linked to cycles in which no ovulation occurs. Progestogen-induced premenstrual disorder is named for progestogen as the inducing agent. Premenstrual disorder with absent menstruation covers symptoms in women who do not menstruate.
Symptom-based subtypes were rejected for lack of empirical evidence (Nevatte et al., 2013). In the fourth ISPMD consensus, 18 of the 19 group members submitted 66 auditable standards, which the group ranked in order of priority, and the diagnostic standards call for a symptom diary kept for 2 months (Ismaili et al., 2016). The studies reviewed here do not settle whether either classification adopted the variants, or what became of the 2007 criteria proposal, so both questions remain open.
Cognitive Implications
None of the studies reviewed here reports cognitive findings for the variant forms.
Provisional and Subthreshold Presentations
A diagnosis made before two cycles of prospective ratings is provisional; What Premenstrual Dysphoric Disorder Is gives the rule. A meta-analysis of 44 studies found that confirmed diagnosis gave a lower prevalence than provisional diagnosis, and its authors concluded that provisional diagnosis likely inflates prevalence (Reilly et al., 2024); the figures are in Prevalence, Course and Burden. Retrospective reports are a poor basis for the confirmed diagnosis, since they predicted the scored diagnosis badly (Eisenlohr-Moul et al., 2017).
Subthreshold presentations are common. In a community sample of 1246 women, 5.5% showed mood change alone and 1.8% showed it with interference, against 1.3% who met full criteria on prospective ratings (Gehlert et al., 2009). The same study found 54% when reports were retrospective, and its authors thought retrospective reports likely over-diagnose. Not all cyclical change is premenstrual either: a two-cycle diary study of 213 university students identified a mid-cycle peak pattern in some women (Kiesner, 2011).
Cognitive Implications
None of the studies reviewed here tests cognition in provisional or subthreshold cases. The expectancy and recall findings in Symptoms, Diagnosis and Measurement bear on why provisional diagnoses run high.
Perimenopausal and Other Reproductive-Transition Mood Presentations
These presentations are not types of PMDD. Sources tie them to the same hormone sensitivity, and the evidence on their relation to PMDD is partly contradictory.
Postpartum
In a two-stage screening of postpartum women, premenstrual symptoms, assessed retrospectively, raised the odds of postpartum depression (OR = 1.97) (Buttner et al., 2013). A clinic sample of 215 women with PMDD found that PMDD and postpartum depression did not frequently co-occur (Kepple et al., 2016). Sixteen euthymic women took part in a double-blind experiment that manipulated their hormones; five of the eight with a history of postpartum depression, and none of the eight comparison women, developed significant mood symptoms during steroid withdrawal (Bloch et al., 2000).
Perimenopause
Premenstrual dysphoria was more common in 70 depressed than in 35 nondepressed perimenopausal women (21% against 3%), though the authors found it not an invariant accompaniment of perimenopausal depression (Richards et al., 2006). Women who had PMS at the start of a five-year study of 436 women were more likely to go on to report hot flushes, depressed mood, poor sleep and reduced libido (Freeman et al., 2004). Estradiol withdrawal precipitated depressive symptoms only in women with past perimenopausal depression, not in controls (Schmidt et al., 2015). A heuristic model proposes that in some women, shifting neurosteroid levels combined with weak GABA-A control of inhibitory tone may disturb the HPA axis and so raise vulnerability to depression (Gordon et al., 2015).
Standing of the Proposed Grouping
A narrative review proposed reproductive depression as a distinct subtype of major depression (Payne et al., 2009), and a review with the authors' own laboratory findings proposed a Hormonal Sensitivity Syndrome across the reproductive lifespan (Pope et al., 2017). Both remain proposals. The Kepple finding that PMDD and postpartum depression do not frequently co-occur does not suggest shared pathophysiology beyond both being ovarian-steroid-triggered mood disorders (Kepple et al., 2016).
Cognitive Implications
None of the studies reviewed here tests cognition across these transitions. The shared element proposed is hormone sensitivity, not a shared cognitive profile.
Prevalence, Course and Burden
How many women meet the criteria for premenstrual dysphoric disorder depends heavily on how the diagnosis was made. This section sets out the prevalence estimates and why they differ, what is known about onset and course, and the burden the condition places on health and work. The criteria themselves are covered under Symptoms, Diagnosis and Measurement, and the debate over whether the category is valid has its own section later in the article.
How Common It Is
Estimates of prevalence span an order of magnitude, and the spread is largely methodological. The most comprehensive attempt to account for it is a systematic review and meta-analysis of 44 studies, 48 independent samples and 50,659 participants. Its pooled prevalence for confirmed diagnosis was 3.2% (95% confidence interval 1.7% to 5.9%), against 7.7% (5.3% to 11.0%) for provisional diagnosis. Restricting the analysis to community-based samples with confirmed diagnosis gave a lower figure, 1.6% (1.0% to 2.5%). Heterogeneity was very high for the pooled estimate (I2 = 99%) and lower for the community-based estimate (I2 = 26%). Continent, sample type, risk of bias and diagnostic method each moderated prevalence. The authors concluded that provisional diagnosis probably inflates prevalence, and they noted that few studies had used full DSM criteria in community settings (Reilly et al., 2024).
How the diagnostic method changes the count
Apply published prevalence estimates to a population of women of reproductive age and compare the number counted under each diagnostic method.
| Provisional diagnosis (meta-analysis) | Reilly et al. (2024) |
| Confirmed diagnosis (meta-analysis) | Reilly et al. (2024) |
| Confirmed, community samples (meta-analysis) | Reilly et al. (2024) |
| Full prospective criteria, one US probability sample | Gehlert et al. (2009) |
In 10,000 women, provisional diagnosis counts 770 and confirmed diagnosis 320: about 2.4 times as many.
The individual studies show the same gradient. A community probability sample of 1246 women aged 13 to 55 at four US sites, rated prospectively against DSM-IV research criteria, found 1.3% with the full disorder (95% CI 0.001 to 0.025). That was well below the 3-5% DSM-IV estimate and far below the 54% obtained from retrospective reports, which the authors judged likely to over-diagnose. Among oral contraceptive users the prevalence was 0.8%, against 1.5% in non-users, and the authors reported that the 1.3% rate for the whole sample did not differ significantly from the 1.5% rate in women not taking oral contraceptives (Gehlert et al., 2009).
A prospective-longitudinal community survey of 1488 women aged 14 to 24 in Germany, using a CIDI module based on DSM-IV algorithms, reported a 12-month prevalence of 5.8% (5.3% after exclusion rules), with a further 18.6% near the diagnostic threshold. Threshold PMDD was much rarer than premenstrual symptoms in general, although daily symptom ratings were not available and the impairment criterion was often unmet (Wittchen et al., 2002). Among women aged 36 to 44, a community cohort that screened 4164 women and completed prospective evaluation in 513 found PMDD in 33 of the 513 (6.4%). Only 513 of 976 eligible subjects agreed to the prospective phase, and one menstrual cycle was assessed (Cohen et al., 2002).
Screening 3,913 Swiss women between 15 and 54 with a self-report questionnaire, a population survey put the prevalence of premenstrual syndrome at 10.3% and of PMDD at 3.1% (Tschudin et al., 2010). A higher community figure comes from southern Brazil, where a cross-sectional population-based study of 727 women aged 18 to 24 found PMDD in 17.6%. The diagnosis there rested on the Mini International Neuropsychiatric Interview (M.I.N.I.-Plus) and on retrospective report, a caveat the authors share (de Carvalho et al., 2018).
Earlier reviews gave varied figures, some above those of the strict studies. One put PMDD at 3-8% of women of reproductive age and the broader group of clinically relevant cases at 13-18%, arguing that the five-symptom count is arbitrary and that epidemiological studies under-recognise the disorder, so that clinically relevant prevalence is probably higher (Halbreich et al., 2003). As many as 20% of women of reproductive age find their premenstrual symptoms distressing, a second review estimated, and in no fewer than 3-8% the symptoms impair functioning at work or in relationships (Rapkin & Winer, 2009). The DSM-5 work group's review put the figure at 2-5% of premenopausal women, noting that the two studies combining probability sampling, prospective daily ratings and documented impairment found 2% and that earlier estimates varied with study methods (Epperson et al., 2012).
The current position is that the disagreement is mainly one of method. When the diagnosis is confirmed prospectively, prevalence is a few percent, and studies that rely on provisional diagnosis report more (Reilly et al., 2024). The very high heterogeneity across all studies (I2 = 99%) means that no single figure should be treated as settled for every population (Reilly et al., 2024).
Onset and Course
One source on course is the German cohort of young women followed for 48 months (follow-up N = 1251). Fewer than 10% of women with PMDD at baseline showed complete remission, and the condition was described as stable over the follow-up. Cumulative lifetime incidence was 7.4% (Wittchen et al., 2002).
Age relates differently to symptom severity and to prevalence, depending on the sample. Among 332 treatment-seeking women with late luteal phase dysphoric disorder (mean age 33.1 years), severity was greater at ages 20 to 35 than at ages 36 to 44, while symptom duration did not predict severity significantly. The authors called for longitudinal study (Freeman et al., 1995). Among the Brazilian women aged 18 to 24, by contrast, PMDD was more common in the older women within that range (de Carvalho et al., 2018). When 12 studies of female students in Ethiopia were pooled, PMDD prevalence came to 54.5% (95% CI 40.8-67.6), with secondary-school samples broadly similar to university and college ones; the authors framed the review around the high and inconsistent rates that earlier Ethiopian studies had produced (Duko et al., 2021). That figure comes from student samples and should be read beside the confirmed-diagnosis estimates above.
An app-based survey of 238,114 Flo users across 140 countries, in four age groups from 18-27 to 48-55, found that most physical symptoms became more common with age, abdominal spasms less so. Neither mood swings nor anxiety varied significantly across age groups (p = 0.1569); in each group, between 61% and 64% of users reported mood symptoms. All of the data were self-reported, and none came from clinician ratings or from validated scales built for premenstrual symptoms (Hantsoo et al., 2022). A global survey of 7226 women aged 15 to 49 in 13 countries, using a 23-symptom questionnaire, described four age patterns of symptoms. The authors suggested that symptoms peaking late may reflect the hormonal transition of the later reproductive years. Some respondents came from Internet panels in Japan, Korea and Australia (Dennerstein et al., 2011).
Onset is not always followed by prompt recognition. In interviews with 17 UK women with a specialist diagnosis, the average delay before diagnosis was 20 years, often after misdiagnosis as depression or bipolar disorder. The sample was not representative of all women with PMDD, and the experience section gives the full account (Osborn et al., 2020). The DSM-5 work group's review says menopause brings an end to symptoms in the majority of cases; its treatment is covered under Somatic Treatments: Ovarian Suppression and Surgery (Epperson et al., 2012).
Burden and Impairment
Women at risk for PMDD reported lower health-related quality of life than US norms on six scales and on both summary measures of the SF-12v2, with the mental burden greater than the physical. Compared with people with chronic conditions, they scored worse than people with back pain on bodily pain and mental health, and worse than people with type 2 diabetes or hypertension on bodily pain. They scored the same as people with osteoarthritis or rheumatoid arthritis on all scales, and below people with depression on vitality, mental health and the mental summary, though equal on the other scales. The women were identified as being at risk rather than confirmed (Yang et al., 2008).
Work is also affected. In a two-month web-based prospective study, 1,477 women aged 15 to 45 started and 822 (56%) completed. Moderate-to-severe PMS or PMDD was associated with greater productivity impairment (adjusted odds ratio 3.12, 95% CI 1.75-5.57), more impaired days (5.6 against 1.1) and more absenteeism (14.2% against 6.0%) than mild or absent symptoms. Women whose premenstrual symptoms reached the moderate-to-severe range (PMS or PMDD) appeared to lose more productivity on the job and to miss more work, a pattern the authors read as a possible economic cost; productivity loss was gauged both with the Work Productivity and Activity Impairment questionnaire and day by day on the daily symptom record, and just 56% of the women who enrolled saw the study through (Heinemann et al., 2010).
Reviews describe the same picture at the level of the disorder. One reported PMDD impairment and lowered quality of life similar to dysthymic disorder and not much lower than in major depressive disorder, and a disability-adjusted life-year burden comparable to major recognised disorders (Halbreich et al., 2003). Another reported distress and impairment, with PMDD disability comparable to major depressive disorder (Rapkin & Winer, 2009). These statements come from reviews rather than from a single costing study, so the sources reviewed here give no definitive cost estimate.
The Differential Hormone-Sensitivity Model of Premenstrual Dysphoric Disorder
The differential hormone-sensitivity model holds that premenstrual dysphoric disorder (PMDD) arises from the way a woman's brain responds to ordinary cyclical steroid changes, not from abnormal hormone production. What follows covers the experiment that defined the model, the evidence that a hormonal change rather than an absolute level sets off symptoms, and the neurosteroid mechanism put forward to account for this. The account is currently supported, since one review concluded that the literature supports the hypothesis of impaired GABA-A receptor response to allopregnanolone fluctuation, although larger trials of GABA-modulating drugs are still needed (Hantsoo & Epperson, 2020).
Normal Hormones, Abnormal Response
In the defining experiment, 20 women with premenstrual syndrome first received either leuprolide or placebo; the 10 who improved went on to a double-blind crossover of estradiol and progesterone, while a comparison group of 15 women free of premenstrual syndrome followed a comparable protocol (Schmidt et al., 1998). Ovarian suppression with leuprolide reduced symptoms in the affected women relative to placebo. Add-back of estradiol or of progesterone then restored symptoms, whereas placebo hormone did not. In the women without premenstrual syndrome, the same hormones produced no mood change. The authors concluded that premenstrual syndrome reflects an abnormal response to normal hormonal change (Schmidt et al., 1998).
Figure 1
The Ovarian Cycle and the Premenstrual Symptom Window
Reviews have restated the account in similar terms. Steroids are said to destabilise mood in some women only, a pattern described as differential sensitivity (Rubinow & Schmidt, 2006). Changes in steroid level are held to produce affective dysregulation in susceptible women (Schiller et al., 2016). A seminar-style review judged that severe premenstrual syndrome and PMDD probably reflect heightened sensitivity to normal hormone fluctuation, not abnormal hormones. On its account, the symptoms are set off when gonadal hormone levels rise and fall (Yonkers et al., 2008).
Change, Not Level
A later add-back study with a single-blind placebo month enrolled 22 women with PMDD, aged 30 to 50 years; the 12 whose symptoms remitted on leuprolide went on to the placebo and add-back months (Schmidt et al., 2017). After stable suppression, symptoms returned in the first month of combined estradiol and progesterone, exceeding symptoms under leuprolide alone and under placebo. They did not return in months two and three, when hormone levels were steady, and symptoms in those months did not differ from the leuprolide or placebo conditions. Symptoms therefore tracked hormone change, not steady level. The placebo month was single-blind, with only the participants blind to the condition (Schmidt et al., 2017). The same idea of mood responding to steroid shifts is applied to postpartum and perimenopausal depression (Schiller et al., 2016); the relation is taken up under Types of Premenstrual Dysphoric Disorder.
Do symptoms follow hormone change or hormone level?
The ovarian-suppression design: hormones are switched off, then added back and held steady. Choose a group to see where symptoms appear.
Symptoms appear while hormones are cycling and in the first month of add-back, when levels change, and not once levels are held steady.
Buffering the perimenstrual fall has also been tried. In a double-blind crossover trial, 29 psychiatric outpatients with past-month suicidal ideation, none of the 27 with usable baseline ratings meeting C-PASS criteria for PMDD, were randomised and 28 analysed, receiving estradiol (0.1 mg/day) with progesterone (200 mg/day) or placebo across 14-day intervals (Eisenlohr-Moul et al., 2022b). The hormone condition reduced the perimenstrual rise in suicidal ideation and depressed mood, and it was not distinguished from placebo for anxiety, impulsivity or anger. The authors judged withdrawal a possibly causal contributor. The trial gave estradiol with progesterone against placebo, so the effect of each steroid alone could not be separated (Eisenlohr-Moul et al., 2022b). Its bearing on risk is taken up under Suicide and Self-Harm.
Allopregnanolone and the GABA-A Receptor
The mechanism most often proposed involves allopregnanolone, a progesterone metabolite that modulates the GABA-A receptor. According to one review, a paradoxical action of allopregnanolone at the GABA(A) receptor is the likely source of the negative mood experienced by women with PMDD (Andréen et al., 2009). The same idea is framed as a hypothesis whose mechanism might be shared with other conditions (Bäckström et al., 2014). One review proposed that PMDD pathophysiology is rooted in changes in GABA-A receptor sensitivity caused by rapid changes in allopregnanolone levels (Gao et al., 2023). Measured at particular points in the cycle, baseline neuroactive steroid levels did not separate women with PMDD from controls in the studies the review covered, though the review left open the possibility that women with PMDD differ from controls in how these hormones change across the menstrual cycle (Hantsoo & Epperson, 2020).
Human tests are few. A study gave an intravenous allopregnanolone challenge (0.05 mg/kg) to 10 women with PMDD and 10 controls, measuring saccadic eye velocity. Responses in the PMDD group were smaller in the follicular than the luteal phase, and the controls showed the opposite pattern, suggesting altered sensitivity (Timby et al., 2016). In a laboratory stress study of 24 women with PMDD and 12 controls, luteal allopregnanolone was higher and cortisol lower in the PMDD group, and a stress-induced allopregnanolone rise occurred in 83% of controls but 42% of the PMDD group (Girdler et al., 2001).
Blocking synthesis offers a further test. In double-blind placebo-controlled crossover trials with 16 women with PMDD and 16 controls, dutasteride at 2.5 mg/day eased symptoms relative to placebo, whereas 0.5 mg/day did not. Control women showed no mood effect. The authors described the support as preliminary (Martinez et al., 2016).
Mouse work gives a cellular parallel. Allopregnanolone (THP), which lowered anxiety in adult mice, had the opposite, anxiety-raising effect in pubertal female mice, a stage when α4 and δ subunit expression rose, and the authors implicated inhibition of α4β2δ receptors (Shen et al., 2007). The evidence comes from mice only, and from females only.
Standing
The model is supported as an account of who becomes symptomatic, within limits the evidence itself states. One review concluded that the literature supports the hypothesis and that larger trials of GABA-modulating drugs are needed (Hantsoo & Epperson, 2020). The add-back work rests on small samples and, in one case, single-blind design (Schmidt et al., 2017), and the challenge study gave allopregnanolone to 10 patients and 10 controls (Timby et al., 2016). A 2023 review judged GABA-A sensitivity probably the central mechanism but found few clinical and animal experiments and a specific mechanism that is still unclear (Gao et al., 2023). A 2022 review likewise called the etiology complex and said that further research is needed on how peripheral inflammatory molecules interact with brain neurotransmitter systems (Tiranini & Nappi, 2022). The cellular evidence is reported under The Biology of Premenstrual Dysphoric Disorder, and rival and complementary accounts follow in Serotonergic, Stress and Sociocultural Accounts. The underlying cause of the differential sensitivity is not established, and it remains open.
Serotonergic, Stress and Sociocultural Accounts
Several accounts of premenstrual dysphoric disorder (PMDD) sit alongside the hormone-sensitivity model described in The Differential Hormone-Sensitivity Model of Premenstrual Dysphoric Disorder. Some, such as the serotonergic account, complement it. Others, such as the stress and expectancy accounts, have been offered as explanations in their own right, and their standing differs: one is supported by imaging and treatment response, one is inconsistent, and one speaks mainly to general samples. A fourth, evolutionary account is a proposal whose own authors report confirming its predictions, while a critical review warns that the limitations of evolutionary work on the cycle have not yet been addressed.
Serotonin
Positron emission tomography (PET) gives the most direct evidence on serotonin. In a small preliminary study of eight women with premenstrual dysphoria, worsening irritability and depressed mood between the follicular and premenstrual phases tracked a lower change in trapping of a serotonin precursor (rank correlations of -0.83 and -0.81), whereas physical symptoms showed a weak relation or none (Eriksson et al., 2006). The authors judged that the result may partly support a serotonin role, and they noted the small sample and methodological shortcomings (Eriksson et al., 2006).
A larger longitudinal case-control PET study compared 30 women with PMDD and 29 controls across 118 scans. Midbrain serotonin transporter binding rose by a mean of 18% from the periovulatory to the premenstrual phase in the PMDD group and fell by a mean of 10% in controls. The midbrain increase correlated with depressive symptom severity across the cycle, which the authors read as pointing to cycle-specific serotonergic dynamics, possibly underlying depressed mood (Sacher et al., 2023).
A hormone-manipulation study bears on the mechanism but not on PMDD itself. Sixty-three healthy young women entered a double-blind trial in which each was randomly assigned to receive either a gonadotropin-releasing hormone agonist implant or a placebo, and 60 of them completed follow-up; compared with the placebo group, the agonist group developed more subclinical depressive symptoms, and among those given the agonist, greater depressive symptoms went with larger rises in neocortical serotonin transporter binding. Both estradiol decrease and transporter increase were positively related to the symptoms (Frokjaer et al., 2015). The sample was healthy volunteers with subclinical symptoms only, so the study implicates serotonin and estradiol in mood without showing the same chain in PMDD (Frokjaer et al., 2015).
Reviews place serotonin alongside hormonal sensitivity. One review reported that an aberrant response to hormonal fluctuation and serotonin deficits have both been implicated, while noting that causes are still being explored (Yonkers & Simoni, 2018). A second review held that reducing serotonin can produce symptoms resembling PMS, that whether a serotonergic deficit shows up hinges on the method used to estimate it, and that one neurotransmitter on its own probably cannot account for these syndromes (Rapkin & Akopians, 2012). The standing of the account is therefore that of a complement to hormone sensitivity, not a rival. Its main clinical support, the rapid response to serotonergic drugs, is taken up in How Treatments Work.
Stress and the HPA Axis
The stress account holds that the hypothalamic-pituitary-adrenal (HPA) axis and related systems respond abnormally to challenge in PMDD. A small case-control laboratory study of 12 women with PMDD and 12 controls used a speech stressor and the Paced Auditory Serial Addition Task. The PMDD group showed lower stroke volume, cardiac output and cortisol, and higher norepinephrine, total peripheral resistance and norepinephrine-to-cortisol ratio. These differences were present in both the follicular and luteal phases. The PMDD group also reported more sexual abuse history and more current life stress, and the authors suggested a possible chronic stress role in a subgroup of women (Girdler et al., 1998).
Studies of cortisol itself give a less consistent picture. A meta-analysis of 35 studies of 778 healthy menstruating women found cortisol slightly higher in the follicular than the luteal phase (Hedges' g = 0.13), with the difference significant in plasma and in morning samples and marginal in saliva (Hamidovic et al., 2020). That finding describes cycle-phase cortisol in healthy women, not PMDD. A review of 38 original research articles found little evidence that mean cortisol or cortisol reactivity differed between women with PMS or PMDD and controls, though the authors urged caution before accepting the null effects (Kiesner & Granger, 2016).
Taken together, the evidence on psychological stress responses in PMDD is inconsistent. A small case-control study found dysregulation in a subgroup, and a review found no consistent cortisol difference. The question remains open. Trauma and abuse history as risk factors are treated in Testing Cause and Consequence and in Comorbidity.
Expectancy, Recall and Sociocultural Accounts
A separate tradition holds that expectation and cultural belief shape how premenstrual change is reported. In an early experiment that manipulated belief independently of actual cycle phase, women told they were premenstrual reported more physical symptoms, such as water retention, than women told they were intermenstrual (Ruble, 1977). The author concluded that earlier conclusions may need reexamination, because self-report questionnaires may bias them (Ruble, 1977).
Recall bias supplies a second line of evidence. In a within-subject study of 49 women, retrospective reports of premenstrual changes exceeded prospective daily reports, and the belief that most women have PMS was linked to larger recall bias. The authors attributed this to stereotype-driven misperception (Marván & Cortés-Iniestra, 2001).
Individual differences add a third. In a laboratory study, women high in anxiety sensitivity reported more severe menstrual symptoms, more bodily preoccupation and more negative illness attitudes than women low in it, and showed greater skin conductance during rumination. The groups did not differ in menstrual attitudes or sex role socialization, and cycle phase predicted symptoms more weakly than anxiety sensitivity did (Sigmon et al., 2000). The authors discuss the implications of the results for the menstrual reactivity hypothesis (Sigmon et al., 2000).
A systematic review of 47 studies of non-help-seeking women, using prospective daily mood data, found no clear premenstrual-specific negative mood. Eighteen studies (38.3%) found no association with cycle phase, seven (14.9%) linked negative mood to the premenstrual phase only, and four (8.5%) to a non-premenstrual phase. Diverse methods precluded meta-analysis, and the authors concluded that belief in premenstrual negative mood needs challenging (Romans et al., 2012). The critique of the diagnosis built on such findings is set out in The Debate over the Diagnosis.
The current position separates two kinds of sample. The recall finding comes from a retrospective questionnaire (Marván & Cortés-Iniestra, 2001), and the review drew on non-help-seeking samples (Romans et al., 2012). Women with premenstrual syndrome in a double-blind crossover study, by contrast, improved when the ovaries were suppressed with leuprolide, and their symptoms returned when estradiol or progesterone was added back. Normal women showed no mood change on the same hormones, and placebo add-back did not bring symptoms back (Schmidt et al., 1998). The evidence therefore indicates that expectancy can inflate retrospective reports, but it does not account for a response to blinded hormone manipulation. How much expectation adds within confirmed cases remains open. The manipulation itself is covered in The Differential Hormone-Sensitivity Model of Premenstrual Dysphoric Disorder.
Evolutionary Proposals
One theory paper proposed, as a hypothesis, that premenstrual syndrome and PMDD are adaptive responses and not diseases, serving to end infertile pair bonds. In support, it pointed to findings that women with PMS report worse marriages during the luteal phase, while in the follicular phase their satisfaction with the relationship resembles that of women without PMS (Gillings, 2014).
A critical review of ovulation-focused cycle research argues that such studies have not shown that cycle-related behaviours have evolutionarily adaptive functions. Of the 50 published mate-preference papers its authors examined, not one adjusted for confounding by symptoms, and they contended that, for analytic purposes, how near a woman is to ovulation and how near she is to menstruation are inverses of one another (Kiesner et al., 2020). The authors recommended specific guidelines and more comprehensive and sophisticated theoretical structures (Kiesner et al., 2020). The evolutionary proposal is therefore best regarded as a hypothesis whose authors report confirming its predictions (Gillings, 2014), set against a critical review's warning that evolutionary accounts of cycle-related behaviour have significant limitations that have not yet been addressed (Kiesner et al., 2020).
Emotion, Attention and Cognition Across the Cycle
Emotional and cognitive measures in premenstrual dysphoric disorder (PMDD) have been studied with laboratory tasks, daily-life sampling and self-report scales. Two questions run through the work: whether a difference appears only in the late luteal phase (a state) or in every phase (a trait), and whether it reflects the hormone sensitivity described in the model section. The evidence for emotion is steadier than the evidence for cognition, and several of the samples are women with premenstrual syndrome (PMS) or premenstrual disorders broadly, not confirmed PMDD. That is flagged wherever it applies.
Emotion Processing and Recognition
The most direct test of how PMDD alters the reading of emotional faces used a case-control design with repeated measures across the cycle. Rubinow et al. gave 28 women with PMDD and 27 controls a facial discrimination task, with an age-discrimination task as a control (Rubinow et al., 2007). Controls' face judgements did not shift across the cycle, but women with PMDD were more negatively biased in the luteal than the follicular phase, misreading neutral faces as sad more often. By the authors' own account, the significance values they reached were only modest, and the results would not hold up once adjusted for the number of comparisons made (Rubinow et al., 2007).
The wider picture comes from a narrative review with a small meta-analysis of menstrual-cycle studies, mostly in healthy women. It concluded that differences on sexually dimorphic cognitive tasks are small and hard to replicate, whereas emotion-related changes are more consistent and track progesterone more than estradiol (Sundström Poromaa & Gingnell, 2014).
A 2025 systematic review put the cognitive side more cautiously. Drawing on 21 papers with 1,222 participants and 94 outcome measures, the review detected few cognitive-performance differences between women with PMDD and controls, and those it did detect were inconsistent; its authors judged that cognitive process, content and behaviour are likely to reveal more than measures of absolute ability (Henderson et al., 2025). No quantitative synthesis was possible because key data were thinly reported, and the reviewers also noted missing power analyses and inappropriate statistical methods as risks of bias. Neural responses to emotional stimuli are covered in Brain Networks and Imaging. The current position is that a luteal negative bias in face processing is plausible but rests on a few small studies and a single preliminary report in PMDD itself.
Attention to Negative Information
The attentional evidence comes from an emotional Stroop paradigm, in which interference from emotional content on a colour-naming task indexes the capture of attention. Eggert et al. tested 55 women with PMS and 55 controls on three emotional Stroop tasks across two cycle phases, with phase taken from two months of daily records and not from hormone assays (Eggert et al., 2017). The PMS group showed primarily a larger Stroop effect than controls for pictures and faces in the luteal phase, with a paradoxical Stroop facilitation effect for faces, and no difference for word stimuli (Eggert et al., 2017). The authors read this as a cognitive-emotional alteration consistent with PMS and asked for more study, noting that the sample's representativeness and the scope for causal interpretation were both limited. The sample is PMS, not confirmed PMDD.
A companion study in women with PMS was reported by Eggert et al. (Eggert et al., 2016). For that work, only its scope is described here.
The systematic review linked a negative attentional bias positively to the experience of PMDD, while finding performance differences limited overall (Henderson et al., 2025). Bias toward negative content therefore looks more consistent than general attentional performance, though the review noted missing power analyses and inappropriate statistical methods as risks of bias, and the one empirical study described here sampled women with PMS, not confirmed PMDD.
Rumination, Self-Focus and Emotion Regulation
Self-focused attention appears to rise under stress in premenstrual disorders. In a laboratory study of 52 women (24 with premenstrual disorders, 28 controls), the affected group showed higher state self-focus after laboratory stressors, higher trait self-focus and more maladaptive coping, though the change in negative affect did not differ significantly (Craner et al., 2015). The authors suggested that cycle changes may raise self-focused attention. The women were categorised by retrospective report, alongside 30-day prospective recording.
Daily-life designs add a time dimension. In a prospective diary cohort of 54 women with confirmed menstrually related mood disorders and no control group, emotion-related impulsivity was the only subscale robustly associated with premenstrual symptom severity (Dawson et al., 2018). Brooding did not predict overall premenstrual severity, but women high in brooding showed a steeper premenstrual rise in depression and eating symptoms and slower recovery after menstruation. The traits were measured once, not daily, and the effects were not unique to these disorders.
An ambulatory study of 59 women with natural cycles found that calmness was higher in the luteal and menstrual phases than in the follicular and ovulatory phases, and that other moods did not vary significantly by phase (Welz et al., 2016). Higher anxiety and trait rumination moderated the cycle-mood link, with irritability rising late in the cycle only at high levels. The sample was not selected for PMDD. In an ecological momentary assessment study of 61 women with PMDD and 61 controls, sampled eight times a day over two days per phase, women with PMDD had higher negative affect, lower positive affect and more rumination in the late luteal phase (Beddig et al., 2020). Rumination predicted later negative affect in the late luteal phase more strongly in PMDD, and negative affect predicted later rumination more strongly in PMDD than in controls (Beddig et al., 2020). The diagnosis lacked prospective daily ratings and the lagged tests were exploratory, so the direction of influence between the two remains tentative (Beddig et al., 2020).
On emotional regulation, a case-control study of 18 women with PMDD and 18 controls found poorer emotion regulation, higher behavioural impulsivity and lower socioemotional functioning in PMDD, all by self-report (Petersen et al., 2016). A study of 100 women with PMDD and 96 controls, diagnosed over three prospective cycles, found low emotional adjusting in the PMDD group in the premenstrual phase, with the group difference in premenstrual emotion regulation significant only among carriers of the G allele of an ESR1 polymorphism, and no association between PMDD and estrogen level (Yen et al., 2018). Premenstrual estrogen was inversely related to anxiety and stress within the PMDD group, which the authors read as an ESR1-dependent estrogen response. Taken together, these studies show poorer self-reported emotion regulation in PMDD, and in the genetic study the premenstrual group difference appeared only among carriers of the G allele of an ESR1 polymorphism, but the self-report instruments and single-study genetic finding leave the mechanism, and whether the difference is state-like or trait-like, open. Rumination and cognitive rumination as a treatment target are taken up with the treatments.
Inhibitory Control, Working Memory and Executive Function
Results on psychological inhibition and working memory disagree about whether deficits depend on phase. In a Go/NoGo task during functional imaging, 14 women with PMDD and 13 controls were compared in both phases. Women with PMDD showed reduced parietal activity in both phases, with no significant effect of phase (Bannbers et al., 2012). The neural detail is in Brain Networks and Imaging; the authors cautioned that the sample was limited and the NoGo trials few.
Behavioural studies split. Women with moderate to severe PMS (13) did worse than those with mild or no PMS (27) on N-back tasks, with poorer accuracy on the 0-back and more omission errors on the 0-back and 2-back, a pattern the authors described as subtle and persistent, present even in the follicular phase (Slyepchenko et al., 2017; see also Types of Premenstrual Dysphoric Disorder). A repeated-measures study of 105 women (51 with PMS or PMDD, 29 of whom met PMDD criteria) found longer stop-signal reaction times in every phase and lower 3-back accuracy (d = 0.35), with the working memory difference present only under the heaviest load (Gnaiger et al., 2026). Neither estradiol nor progesterone nor cycle phase predicted stop-signal performance, and the authors described the deficits as trait-like. The sample was mostly university students, and the authors noted that it is unclear whether the deficits are a cause or a result.
Other work finds the deficit confined to the late luteal phase. In a within-subject study with ten sessions, 14 women with PMDD and 15 controls differed in the luteal phase on word recall, digit recall and the Digit Symbol Substitution Test, with PMDD scoring lower, alongside more dysphoric mood and a greater desire for high-fat food (Reed et al., 2008). The authors proposed an altered serotonergic system. In 63 women with PMDD and 53 controls tested on the Simon task, the PMDD group performed worse in the late luteal phase (Lin et al., 2022). Reappraisal scores were lower in PMDD in both phases, and the study was cross-sectional with phases estimated and no ovulation test. Another study reported more inattention in PMDD than controls in both phases, worse in the luteal phase, by self-report; the sleep section covers it (Lin et al., 2021).
A narrative review found inconsistent effects of cycle phase on cognition and left open whether any disturbance in premenstrual disorders reflects mood symptoms or hormonal sensitivity (Le et al., 2020). The dispute between late-luteal-only and every-phase deficits is therefore unresolved. Samples are small, results mixed, and few designs separate a state that appears with the hormonal shift from a trait that precedes or outlasts it.
Testing Cause and Consequence
Experimental hormone manipulation is the strongest causal design the field has, and the section on the differential hormone-sensitivity model reports it. The designs gathered here are weaker. They are prospective cohorts, a nested case-control study and within-person repeated measures, and each asks whether something measured earlier goes before premenstrual symptoms or comes after them.
Trauma and anxiety history come first. A prospective community cohort followed 1488 women, aged 14 to 24 at the start, for 42 months. Traumatic events, a history of anxiety disorder and a higher daily-hassles score each predicted later PMDD, and subthreshold PMDD at baseline was the strongest predictor (Perkonigg et al., 2004). Incidence of threshold PMDD was 3.0%, and the authors note that the mechanisms underneath the link are unknown and need further investigation (Perkonigg et al., 2004).
Early abuse is the second line of evidence. In a nested case-control study within the Nurses' Health Study 2, 1,018 women with PMS were compared with 2,277 controls. Early emotional abuse and early physical abuse each predicted a higher risk of PMS, with an odds ratio of 2.6 (95% CI 1.7-3.9) for the highest emotional-abuse category against none. Sexual abuse showed a weaker association, and corporal-punishment items showed no relation to PMS (Bertone-Johnson et al., 2014a). Abuse was self-reported in 2001 and PMS rested on a self-reported physician diagnosis, so recall and residual confounding remain possible. The authors conclude that abuse is likely importantly related to PMS (Bertone-Johnson et al., 2014a).
Abuse history may also change how hormones relate to symptoms. In 66 women with prospectively confirmed menstrually related mood disorder, followed for one cycle with five blood-sample days, physical abuse history moderated the link from progesterone to mood and interpersonal symptoms. Women without that history showed no such link. Sexual abuse history likewise moderated the link from estradiol to anxiety. The sample came from a trial and only the baseline month was used, so the authors present the result as informing future stress-system research (Eisenlohr-Moul et al., 2016).
Consequences run in the other direction. Among 36 women followed up, scores on the Premenstrual Assessment Form's depressive subscale were linked with subsequent major depression (r = 0.35), an association that held over and above earlier depression and family history. The instrument was retrospective, and the section on related conditions returns to this finding (Graze et al., 1990).
Trait-like vulnerabilities form a third group. Among 54 women with prospectively confirmed menstrually related mood disorder, emotion-related impulsivity went with greater premenstrual severity, for instance a partial rho of .52 with anger and conflict. Brooding rumination was linked to steeper premenstrual rises in depression and eating symptoms and slower recovery after menses. That cohort had no control group, and the authors cautioned against reading the effects as unique to these disorders, which limits what they say about PMDD itself (Dawson et al., 2018); the cognition section covers them in detail. In one imaging study, women with PMDD showed more dorsolateral prefrontal activation than controls, and the authors suggested that dysfunction in this region may mark a risk substrate for the disorder (see Brain Networks and Imaging; Baller et al., 2013).
None of the studies reviewed here is a cognitive-bias modification trial, and none follows never-affected women prospectively to test cognitive vulnerability. The first would show whether changing a cognitive style changes symptoms. The second would show whether the style comes before the disorder or follows from living with it. Both questions remain open here.
Validity of Diaries, Laboratory Tasks and Cycle-Phase Measures
Findings about premenstrual dysphoric disorder (PMDD) are only as sound as the way the cycle is staged and the way symptoms are recorded. The instruments themselves are described in Symptoms, Diagnosis and Measurement; this section asks how far the methods behind the evidence can be trusted.
Inconsistent Cycle-Phase Methods
Cycle research has no shared operational definition of the cycle. A methods guideline for premenstrual disorders and the wider cycle literature notes that the menstrual cycle, its days and its phases are operationalised inconsistently, that this hinders cumulative knowledge, and that standardised tools should yield more meaningful and replicable results (Schmalenberger et al., 2021). The same paper adds that systematic reviews and meta-analyses of the area are limited.
Imaging work meets the same problem. A systematic review of 77 studies of 1,304 naturally cycling women linked fluctuating estrogen and progesterone to cortico-limbic reactivity and structure, and concluded that multimodal studies with careful staging are needed (Dubol et al., 2021).
Diary practice is uneven as well. In a systematic review of 75 studies of women meeting criteria for late luteal phase dysphoric disorder or PMDD, diaries differed widely in design, often only part of the cycle was analysed, and diagnostic procedures and criteria varied (Bosman et al., 2016). The reviewers judged daily ratings valuable but the diaries in need of improvement.
What Averaging and Ovulation-Focused Designs Can Hide
Group averages can conceal patterns that are not premenstrual. A daily-diary study of 213 female university students across two menstrual cycles found that a mid-cycle symptom peak pattern exists alongside premenstrual ones (Kiesner, 2011).
A prospective-study review of mood in women who were not seeking help points the same way. Of 47 English-language studies, 18 found no association with cycle phase, 18 found negative mood in the premenstrual phase plus another phase, 7 in the premenstrual phase only, and 4 in a non-premenstrual phase only. Diverse methods precluded a meta-analysis, and the authors found no clear evidence of a premenstrual-specific negative mood syndrome in the general population (Romans et al., 2012). How this bears on the diagnosis is taken up under The Debate over the Diagnosis.
Design flaws also affect studies built around ovulation. An audit of 50 published mate-preference papers found that none controlled for symptom confounds. The authors outlined significant limitations to internal validity and recommended specific guidelines (Kiesner et al., 2020). The critique of the theory behind such work belongs to the evolutionary account elsewhere in the article.
Ambulatory Assessment in Daily Life
Smartphone-based ambulatory assessment, a form of ecological momentary assessment, samples mood in daily life rather than by recall. In 59 naturally cycling women prompted ten times a day on eight days, two consecutive days per phase, calmness was higher in the luteal and menstrual phases than in the follicular and ovulatory ones, other moods did not vary reliably with phase, and anxiety and ruminative self-reflection moderated the cycle-mood link (Welz et al., 2016).
A comparable study followed 61 women with current PMDD and 61 controls, with eight diaries a day on two consecutive days in each of four phases and 87.3% of possible assessments completed. Negative affect and rumination rose, and positive affect fell, toward the end of the cycle in the PMDD group, and the effect of rumination on later negative affect was limited to the late luteal phase (Beddig et al., 2020). Its diagnoses were made without prospective daily ratings, a caveat that applies to the findings. The cognitive findings of both studies are covered under Emotion, Attention and Cognition Across the Cycle.
Laboratory Tasks
A laboratory session captures one phase per visit, so a single-session task cannot show how a person changes across the cycle. None of the studies reviewed here reports the test-retest reliability or the daily-life predictive validity of the laboratory paradigms used in PMDD research, so how well those tasks capture what women experience between visits remains open.
The Biology of Premenstrual Dysphoric Disorder
The biological evidence on premenstrual dysphoric disorder (PMDD) comes from three directions: family and molecular genetics, cell-level work on gene regulation, and measurement of inflammatory markers. Each is partial, and most findings still await replication. Ovarian-steroid and neurosteroid mechanisms are treated in the section on the differential hormone-sensitivity model, and serotonin and stress in the section on serotonergic, stress and sociocultural accounts; this section covers the remaining systems.
Heritability and Genetics
Twin studies supply the strongest genetic evidence, and they concern premenstrual symptoms broadly rather than the disorder alone. In an Australian sample of 720 female twin pairs (454 monozygotic, 266 dizygotic), additive genetic effects accounted for 44% of the total variance in a factor built from 17 premenstrual symptoms (Treloar et al., 2002). The authors judged that genetic influence was supported, while noting that a genetic liability to the condition could not be told apart from a genetic influence on how symptoms are reported retrospectively (Treloar et al., 2002).
A longitudinal study of 1,312 menstruating female twins, assessed twice six years apart, pointed the same way. It found that retrospectively reported premenstrual symptoms were substantially heritable, with a stable component, and that the best-fitting model showed no impact of family-environmental factors (Kendler et al., 1998). The authors flagged that retrospective reports of symptoms are unreliable. How far these genetic effects overlap with those for major depression is taken up under Related Conditions and Normal Premenstrual Change.
Molecular work is thinner. A case-control association study of 91 women with PMDD and 56 controls tested single-nucleotide polymorphisms in ESR1 and ESR2 and found that four in intron 4 of the estrogen receptor alpha gene (ESR1) were associated with the disorder (Huo et al., 2007). ESR2 variants and the COMT Val158Met polymorphism showed no association (Huo et al., 2007). The authors described this as a first genetic finding that is preliminary and needs replication. The associations would not survive correction for multiple testing, and the authors called the findings preliminary (Huo et al., 2007).
A genome-wide meta-analysis of two Nordic cohorts (the LifeGene and MoBa studies), covering 72,297 European women of whom 17,511 were cases, identified one locus: rs758170 in CACNA1C, associated with lower odds of premenstrual symptoms (odds ratio 0.93; p = 1.53 × 10⁻⁸) (Hysaj et al., 2026). The association was not significant in LifeGene alone, though its effect size was comparable to that in MoBa, and the authors called the result an initial insight that needs larger replication (Hysaj et al., 2026). Cases were identified by questionnaire (a modified Premenstrual Symptom Screening Tool) or by register-based clinical diagnosis, and the authors called for replication in external populations with larger samples (Hysaj et al., 2026). SNP-based heritability was estimated at 0.072, and the strongest genetic correlation was with major depression (Hysaj et al., 2026).
Taken together, heritability is reasonably supported for premenstrual symptoms; the identification of specific risk genes for PMDD remains preliminary.
The ESC/E(Z) Complex
The ESC/E(Z) complex is a gene-silencing complex that responds to ovarian steroids. Lymphoblastoid cell lines from 10 women with PMDD and 9 controls were compared by RNA sequencing, and the ESC/E(Z) complex, whose 13 genes were quantified, differed between the groups: messenger RNA tended to be higher and protein lower in the PMDD cells, with MTF2 and SIRT1 significantly higher at the mRNA level (both surviving correction) and MTF2, PHF19 and SIRT1 significantly lower at the protein level (Dubey et al., 2017).
The evidence is cell-line evidence from a small case-control sample. Only MTF2 and SIRT1 survived correction, individual gene differences were described as preliminary, the lymphoblastoid model is limited as a stand-in for neurons, and the mismatch between mRNA and protein was not investigated (Dubey et al., 2017). The authors proposed that dysregulation of this complex could contribute to PMDD; they did not show that it does (Dubey et al., 2017).
Inflammation
A systematic review of 11 studies (six case-control and five cross-sectional; 652 women with premenstrual syndrome and 678 controls) found limited evidence that inflammatory markers are raised in premenstrual syndrome (Granda et al., 2021). Antioxidant status was suggested to be lower in affected women, but data on oxidative stress were insufficient and inconsistent, and the reviewers called for larger studies (Granda et al., 2021).
One cross-sectional study of 277 women aged 18 to 30 measured cytokines in a mid-luteal fasting blood sample. Women with moderate-to-severe premenstrual syndrome (n = 37) had higher IL-4, IL-10, IL-12 and IFN-γ than controls (n = 67), and total symptom score was positively associated with IL-2, IL-4, IL-10 and IL-12 (Bertone-Johnson et al., 2014b). The authors read this as a possible inflammation link without proof of causation. The design was cross-sectional, so the temporal relation is unclear, and the authors listed a single blood sample as a limitation while noting that cytokine levels appear stable over time (Bertone-Johnson et al., 2014b).
A narrative review noted that many studies have examined whether peripheral inflammation is associated with premenstrual syndrome or PMDD, and described the results as controversial (Tiranini & Nappi, 2022). Whether inflammation contributes to premenstrual symptoms, or merely accompanies them, remains open.
How the Systems Fit Together
No single system accounts for the disorder. A narrative review concluded that single neurotransmitters are probably not sufficient to explain premenstrual syndrome and PMDD, and that evidence for a hormonal abnormality is not established (Rapkin & Akopians, 2012). The genetic, cell-level and inflammatory findings above are each preliminary and have not been integrated into one account. The neurosteroid account is set out in the section on the differential hormone-sensitivity model, and the serotonergic and stress accounts in the section on serotonergic, stress and sociocultural accounts.
Sleep and Circadian Rhythms
Sleep complaints are common premenstrually, and women with premenstrual dysphoric disorder (PMDD) report them more often than other women do. A narrative review concluded that cycle phase is relevant to sleep complaints. In women troubled by painful cramps or by premenstrual symptoms, the review observed, sleep quality tends to dip in the days before a period and while it lasts (Baker & Lee, 2018). According to that review, the luteal phase brings more spindle activity, less REM sleep and a flatter amplitude of the body-temperature rhythm than the follicular phase does. It treated a progesterone link to spindle activity as possible rather than shown (Baker & Lee, 2018). A second review found sleep disturbance greater in premenstrual mood disorders than in other women, with circadian disruption and melatonin secretion among its constructs (Meers & Nowakowski, 2020). Its conclusion was that links between sleep, circadian function and mood are growing but the mechanisms remain unclear, and specific risk mechanisms need further research (Meers & Nowakowski, 2020).
Laboratory Sleep Recordings
Subjective and recorded sleep do not always agree. In a laboratory study of nine women with premenstrual syndrome or PMDD and twelve asymptomatic controls, the women with premenstrual symptoms rated their sleep quality lower than controls did in the late luteal phase (P = 0.02). Polysomnography sleep composition did not differ by symptom expression (Baker et al., 2007). The authors concluded that poor perceived sleep marks severe PMS. The same recordings showed more theta activity and less delta activity in the symptomatic group, which the authors raised only as a possible trait marker (Baker et al., 2007).
A smaller polysomnography study followed seven women with PMDD who reported luteal-phase insomnia and five controls across the menstrual cycle. It found more slow-wave sleep and lower melatonin in the PMDD group. The authors read this as altered homeostatic sleep regulation, perhaps linked to melatonin (Shechter et al., 2012). Both studies are very small.
Biological Rhythms and Daytime Symptoms
A systematic review of 25 studies, with samples of 12 to 660 women, reported lower melatonin, higher nocturnal body temperature and poorer subjective sleep in PMS or PMDD than in controls (Nexha et al., 2024). Wrist actimetry did not differ, and subjective sleep quality was equal in one study. The review called these the most consistent abnormalities, found in some but not all of the rhythm parameters and in only some of the studies of each. Heterogeneity prevented meta-analysis, and results for objective sleep parameters, cortisol and thyroid-stimulating hormone were conflicting (Nexha et al., 2024).
Daytime consequences appear in questionnaire data. Of 100 women diagnosed with PMDD after a prospective investigation of three menstrual cycles, those with PMDD reported more insomnia, inattention and fatigue than 96 controls in both the premenstrual and follicular phases, and these symptoms were worse in the luteal than the follicular phase (Lin et al., 2021). The measures were self-report questionnaires (Lin et al., 2021).
Whether disturbed sleep and rhythms contribute to PMDD or follow from it remains open. Bright light as a treatment is covered under Lifestyle and Complementary Approaches.
Brain Networks and Imaging
Neuroimaging of premenstrual dysphoric disorder (PMDD) is a small literature. A systematic review of eighteen publications, covering 361 subjects, found structural, chemical and functional differences in the PMDD brain, but judged the characterisation sparse and somewhat inconsistent, and said replication is needed (Dubol et al., 2020). Among the contrasts it listed, PMDD showed higher cerebellar grey matter volume, higher cerebellar metabolism and higher amygdala activation than controls, together with lower fronto-cortical function. White matter integrity had not been investigated. The studies below show where that summary comes from, and where individual reports pull apart.
Amygdala and Emotion-Processing Regions
The amygdala is considered first here, and the findings are phase-dependent. In one fMRI study with an emotional faces task, women with PMDD showed higher bilateral amygdala reactivity than controls in the follicular phase, while the groups did not differ in the luteal phase (Gingnell et al., 2012). The expected luteal increase was not found, and the difference was present only at the first scan. An fMRI study using an emotional Go/NoGo task reported higher amygdala activation to negative than to neutral words in PMDD before menstruation, and lower ventral striatal activation to positive than to neutral words (Protopopescu et al., 2008). The authors of that study read their results as support for a fronto-limbic model and said that larger samples were needed (Protopopescu et al., 2008).
A later study of 29 women with PMDD and 27 controls found greater activity in brain regions that belong to emotion-processing networks in the late luteal phase (Stiernman et al., 2023). In PMDD the ratio of two progesterone-derived neurosteroids, isoallopregnanolone to allopregnanolone, was positively related to parahippocampal and amygdala activity, and in controls the relation ran the other way. The authors treated the neurosteroid role as tentative. Serum steroid levels may not reflect local brain levels, and the amygdala difference between groups was only a trend. The study's localisation was also inconsistent with earlier work. A broader review of 77 studies of naturally cycling women (n = 1304) linked fluctuations in estrogen and progesterone to cortico-limbic responses and called for multimodal studies with careful staging of the cycle (Dubol et al., 2021).
Prefrontal Cortex
The prefrontal cortex results run in both directions. A PET and fMRI study with a hormone manipulation found greater dorsolateral prefrontal activation in women with PMDD than in comparison women (15 and 15 in PET, 14 and 14 in fMRI) across all hormone conditions (Baller et al., 2013). Earlier onset was associated with greater activation, and greater activation with lower functioning. The authors saw in this a possible risk substrate of a trait-like kind, but because the design was correlational they drew no causal conclusion (Baller et al., 2013).
A cycle-phase fMRI study of 18 women with PMDD and 18 controls, using an emotion regulation task, found the opposite sign. Scanned in the late luteal phase during an emotion-regulation task, women with PMDD showed lower activity in the dorsolateral prefrontal cortex on the right, yet this dip appeared in every task condition rather than in the regulation contrast alone, so it cannot be read as specific to regulating emotion (Petersen et al., 2018). Amygdala activation did not differ between groups. By the authors' own account, the result contradicted what they had hypothesised, and with so few participants the study may have lacked statistical power (Petersen et al., 2018). The two reports differ in design, with hormone-controlled conditions in one and natural cycle phases in the other, but no study here tests whether that difference explains the opposing signs. The direction of dorsolateral prefrontal change in PMDD therefore remains open.
Connectivity, Structure and Inhibitory Chemistry
Network-level work adds little firm ground. In resting-state fMRI from 36 women (18 with PMDD and 18 controls), connectivity between the left executive control network and the middle temporal gyrus was stronger in PMDD (Petersen et al., 2019). Right executive control network and default mode network connectivity did not differ by group, and left amygdala connectivity showed a smaller follicular-luteal change in PMDD in the first session only; the stronger connection was not significantly related to daily symptom ratings. The authors suggested possibly altered left executive control network dynamics, and flagged the small sample and a first-scan cluster that did not survive correction.
Structural and inhibitory findings are thinner still. In 51 women with PMDD scanned in the late luteal phase, bilateral amygdala grey matter volume was negatively associated with depressive symptoms; across all regions of interest tested, correlation coefficients with symptom measures ranged from 0.27 to 0.43, and several of the region-of-interest findings did not survive correction for multiple testing (Dubol et al., 2022). The authors called this first evidence with only potential implications. There was no control group, several region-of-interest results lost significance after correction, whole-brain grey matter volume was unrelated to symptom severity, and causality could not be determined. On a Go/NoGo response-inhibition task, 14 women with PMDD showed lower parietal activity than 13 controls in both cycle phases, and menstrual phase did not change it. Left insula activity showed a group-by-phase interaction, and the authors cited the small sample as a limit (Bannbers et al., 2012).
None of the imaging studies reviewed here links rumination or self-focused attention to a neural correlate in PMDD.
Taken together, the studies point to emotion-related limbic and prefrontal differences in PMDD. The phase in which they appear and their direction vary across small studies.
Culture, Society and Disparities
Premenstrual dysphoric disorder (PMDD) has been counted in many countries, but the counts come from different designs, different instruments and different kinds of samples. This section sets out what the surveys from Asia, Africa and the United States show, what they cannot show, and which questions about social position the studies reviewed here leave unasked.
Prevalence Across Countries
Two population-based surveys and one clinic-based screening survey in East Asia give 12-month or point estimates of PMDD in the low single digits. A nationwide survey of 2,499 Korean women aged 18-64, using the Composite International Diagnostic Interview with a 12-month PMDD module, put 12-month prevalence at 2.4% (Hong et al., 2012). Women with PMDD in that sample were more likely than other women to have another psychiatric disorder (59.3% against 21.8%), and the diagnoses were made by lay interviewers (Hong et al., 2012). A population-based screening survey of Chinese women aged 18-45, in which women who screened positive for premenstrual syndrome kept two months of prospective daily ratings, found PMDD in 2.1% and premenstrual syndrome in 21.1% (Qiao et al., 2012). In Japan, a screening survey of clinic attendees aged 20-49 found moderate-to-severe premenstrual syndrome in 5.3% and PMDD in 1.2% (Takeda et al., 2006). Prevalence was lower than in Western women, and the authors suggested that race or ethnicity may affect how symptoms are expressed. The women were attending for uterine cancer screening, and few were being treated (Takeda et al., 2006).
Pooled estimates from India and Africa are higher but less certain. A meta-analysis of 25 Indian studies (8,542 women) gave 43% for premenstrual syndrome and 8% for PMDD, the PMDD figure excluding one study; with that study it rose to 14%. Heterogeneity was very high (I2 = 98%), all studies were cross-sectional, and few were community-based. State-level figures rested on few studies, such as 64.4% for premenstrual syndrome in Delhi against 15.3% in Kerala (Dutta & Sharma, 2021). PMDD prevalence was higher in low-quality studies than in high-quality ones, by 7.7%, as the paper itself puts it (Dutta & Sharma, 2021). A meta-analysis of 16 cross-sectional, English-language studies of 6,530 women in Africa pooled premenstrual syndrome at 46.98% (95% CI 28.9-65.06%), with 57.32% in Nigeria and 43.8% in Ethiopia and very high heterogeneity (I2 = 99.7%). Early menarche (before age 13) was a risk factor for premenstrual syndrome (Andualem et al., 2024). Because these pooled figures mostly describe premenstrual syndrome and rest on mixed instruments, they should not be set directly beside the PMDD estimates from the Korean and Chinese surveys. The effect of continent on pooled prevalence is treated under Prevalence, Course and Burden.
Symptom Patterns Across Countries and Ages
Two large cross-national surveys describe symptoms rather than diagnoses. In an app-based survey of 238,114 users in 140 countries, mood swings or anxiety were reported by 61-64% in every age group, with no significant difference by age, while most physical symptoms rose with age (the age finding is discussed under Prevalence, Course and Burden). Country-level mood-symptom rates ranged from 70.82% in Egypt to 25.99% in Togo (Hantsoo et al., 2022), but these were descriptive, with no statistical tests, and the data were aggregated self-reports without validated scales. The authors' caveats include that mobile access may select well-resourced users (Hantsoo et al., 2022). A survey of 7,226 women aged 15-49 across countries and territories in Europe, Asia, Latin America and Australia, using a 23-symptom questionnaire, found four age patterns of symptoms. It suggested that symptoms peaking late may reflect the hormonal transition. Smokers reported more premenstrual symptoms than nonsmokers, and women with higher parity reported fewer of some symptoms. The samples in Japan, Korea and Australia came from Internet panels (Dennerstein et al., 2011).
Acculturation, Race and Participation
Two national US surveys, pooled, supplied 3,856 premenopausal women of Black, Latina or Asian background; in this group, women born outside the US were less likely to meet PMDD criteria than US-born women (OR = 0.38; 95% CI 0.21-0.68), and the same held for those who were older than six on arrival, with an odds ratio of 0.33 (95% CI 0.18-0.62) (Pilver et al., 2011a). Likelihood rose with years of US residence, which the authors read as an apparent acculturation effect. The design was cross-sectional, with retrospective symptom reporting, a provisional diagnosis and English-speaking women only, so no causal claim follows (Pilver et al., 2011a).
Not every woman who agreed to join the US community probability sample stayed in the study to the end: 1,784 enrolled and 1,246 were analysed, and completion was more common among White than among non-White participants (p = 0.01). The authors noted this imbalance and too few cases to describe the demographics of women meeting criteria (Gehlert et al., 2009).
Access to Care and Social Position
In interviews with 32 US adults who identified as having PMDD, women described patient, provider and societal barriers that burdened the path to diagnosis and treatment, which the authors set out as a care continuum. Racial diversity was limited among the participants, the authors acknowledged, and they argued that the topic needs further study (Chan et al., 2023). The experience of seeking care is covered under The Experience of Premenstrual Dysphoric Disorder.
The studies reviewed here contain one social-determinant finding. In an online survey of 599 people reporting PMDD, low-to-moderate income predicted active suicidal ideation, and lower income predicted an attempt among those with ideation. Diagnosis was self-reported and recruitment came from online support groups (Eisenlohr-Moul et al., 2022a). This is treated further under Suicide and Self-Harm. None of the studies reviewed here examines socioeconomic pathways, discrimination or minority stress directly, so the pathways behind these associations are unknown. None of the studies reviewed here includes sexual or gender minorities, or transgender or nonbinary people who menstruate, so PMDD in those groups remains unexamined.
The Debate over the Diagnosis
Whether premenstrual dysphoric disorder (PMDD) belongs in a psychiatric manual has been disputed since the category's earliest form. The disputes differ in kind: some are historical and sociological, some philosophical, some an appraisal of the evidence. This section sets them side by side and ends with where the matter now stands. The criteria themselves are covered under Symptoms, Diagnosis and Measurement.
The Critiques
A review and historical analysis treated premenstrual syndrome (PMS) and PMDD as socially constructed labels (Chrisler & Caplan, 2002). A sociological case study of the American Psychiatric Association's 1986 DSM-III-R decision argued that the listing of late luteal phase dysphoric disorder was contested and not purely scientific (Figert, 1995). In that study the condition took different forms across three domains: science, health and mental health, and a women's domain (Figert, 1995).
Two further works are cited here for their scope only. One is a critic's account of how the psychiatric manual's categories are decided (Caplan, 1995). The other addresses gender bias in psychiatric nosology (Ussher, 2013).
A bioethical argument paper concluded that it is unethical to call PMDD a mental disorder, so that it should not be a listed disorder. It framed premenstrual anger and distress through the social construction of mental illness and as a culture-bound phenomenon. It did not deny women's premenstrual distress, which it treated as lived experience (Browne, 2015). A philosophical analysis took PMDD as a case study and argued that the revision process excluded patients, producing epistemic injustice. It concluded that more consultation is needed before medicalisation can be legitimate. It also noted that the patient narratives it drew on were collected after DSM-5 inclusion (Gagné-Julien, 2021).
A 2022 editorial described the diagnosis as contested and raised a worry about overdiagnosis (Schroll & Lauritsen, 2022). It argued that the definition is loose, that PMS and depression blur together, and that what is known about treatment is extrapolated from PMS. It set advocates' claims of treatment benefit against opponents' point that little is known. Patients, psychiatrists and drug manufacturers had all pushed hard for the addition, it noted (Schroll & Lauritsen, 2022).
The Case for Inclusion
The DSM-5 Mood Disorders Work Group, which convened experts to examine the literature, proposed that PMDD qualifies as a full DSM-5 category (Epperson et al., 2012). A review of 55 articles identified 38 concerns about inclusion and addressed the six reported most often; its search was restricted to English-language publications (Hartlage et al., 2014). It judged them largely rebutted and concluded that the evidence favours main-text placement.
A systematic review applied the Robins and Guze validity criteria and noted that the biological validity of the diagnosis remains inexplicit (Naik et al., 2023). It named both psychologising and medicalising bias among its constructs. It called for culturally validated assessment tools and for more biological validators (Naik et al., 2023).
The Present Position
DSM-5 placed PMDD in its main text as a depressive disorder (American Psychiatric Association, 2013), and DSM-5-TR kept it (American Psychiatric Association, 2022). ICD-11 lists it among genitourinary diseases, as the section What Premenstrual Dysphoric Disorder Is explains. A qualitative study of 17 UK women with specialist-diagnosed PMDD noted that PMDD is classed as a psychiatric condition in DSM-5 and as a disease of the genitourinary system in ICD-11 (Osborn et al., 2020).
Whether PMDD is best seen as a mental disorder, a gynaecological condition or neither remains open. The two classifications disagree.
The concern that the diagnosis could be misused against women is reported directly in a 2022 editorial, where some argued it might be used against women (Schroll & Lauritsen, 2022), and indirectly in the critics' works above. They argue that PMS is a socially constructed label (Chrisler & Caplan, 2002) and that PMDD is one too (Chrisler & Caplan, 2002), that neither the DSM nor the ICD should list PMDD at all (Browne, 2015), and that patients' own narratives were gathered only once the diagnosis was already in the manual (Gagné-Julien, 2021). Hartlage et al. (2014) concluded that neither the historical nor the legal record backs the claim that PMS has been turned against women by society (Hartlage et al., 2014), so the concern remains disputed.
Comorbidity
Premenstrual dysphoric disorder often co-occurs with other conditions in clinical and survey samples. The evidence below covers psychiatric co-occurrence, trauma, and the narrower findings for bipolar disorder, eating disorders and ADHD, followed by physical illness and substance use. Most of it is cross-sectional or self-reported, so it describes who tends to carry both conditions and says little about which came first.
Other Psychiatric Disorders
Of 78 women interviewed with late luteal phase dysphoric disorder (the diagnosis that preceded PMDD), 78% had had an axis I disorder at some point in life, compared with 10% who had an axis II disorder (Pearlstein et al., 1990). Within that sample, 29% of the women who had borne children reported an earlier postpartum depression. A later review reported that PMDD can co-occur with other axis I conditions, mood and anxiety disorders most of all, and interpreted the evidence with attention to how study methods differed (Kim et al., 2004).
Co-occurrence does not make PMDD a variant of those conditions. A separate review judged it a distinct entity rather than a subtype of depression or of an anxiety disorder, while acknowledging that depression-like or anxiety-like subtypes were not excluded and that similarities with panic disorder remained to be studied (Landén & Eriksson, 2003). It also reported that symptom relief on serotonin reuptake inhibitors comes faster in PMDD than in depression or anxiety. The reviews therefore agree on overlap and on distinctness, and the panic disorder question stayed open in that review. The wider argument about where PMDD sits among mood disorders is taken up in The Debate over the Diagnosis.
In a nationwide Korean survey of 2,499 women aged 18 to 64, women meeting criteria for PMDD had a higher rate of any psychiatric disorder than women without it (59.3% against 21.8%), and also more insomnia and more suicidality (Hong et al., 2012). Lay interviewers administered the diagnoses. Suicidal thoughts and behaviour have their own section, Suicide and Self-Harm.
Trauma and Posttraumatic Stress
In a national US sample of 3,968 women aged 18 to 40, trauma and PTSD were independently tied to PMDD in a graded pattern. Compared with women who had no trauma, the odds of PMDD were 8.14 times higher for those with both trauma and PTSD and 2.84 times higher for those whose trauma had not led to PTSD; within the trauma-exposed group, PTSD remained independently linked to PMDD, though features of the trauma itself explained part of that link (Pilver et al., 2011b). The analysis was cross-sectional and drew on secondary data, and trauma characteristics partly accounted for the PTSD link.
A descriptive study of 100 women with PMDD in an Australian clinic database found early-life trauma common across emotional abuse, physical abuse, sexual abuse and neglect, with every trauma type more prevalent than in the general Australian population (Kulkarni et al., 2022). Prevalence was similar across four childhood and adolescent age bands. The design was descriptive only.
Only a prospective design can say whether trauma comes first. In a community cohort of 1,488 women aged 14 to 24, followed for 42 months, traumatic events, a history of anxiety disorder and a higher daily-hassles score each predicted later PMDD, and subthreshold PMDD at baseline was the strongest predictor (Perkonigg et al., 2004). The authors noted that the underlying mechanisms are unknown. The prospective evidence on risk factors is weighed further in Testing Cause and Consequence.
Bipolar Disorder, Eating Disorders and ADHD
Reviewing five studies, a systematic review reported that the limited literature suggests comorbidity running both ways, with bipolar disorder more frequent in women who had PMDD than in the general population and PMDD more frequent in women who had bipolar disorder, and noted that none of the findings relied on prospective symptom monitoring (Sharma et al., 2022). Estimates ran from 10% to 15% for bipolar disorder among women with PMDD, and from 27% to 76% for PMDD among women with bipolar disorder. The review stressed that few studies exist and none monitored symptoms prospectively, and it called for prospective work to clarify the relationship. How premenstrual exacerbation of bipolar disorder fits the typology is set out in Types of Premenstrual Dysphoric Disorder.
In a US national survey of 8,694 women, PMDD and premenstrual syndrome were both associated with bulimia nervosa, with odds ratios of 7.2 and 2.5 respectively (Nobles et al., 2016). Associations with binge-eating disorder were not significant. The authors concluded that PMS and PMDD may be important comorbidities of bulimia nervosa, and noted that onset and duration were unclear.
Among 209 consecutive women with ADHD, symptoms of PMDD and postpartum depression were prevalent at high rates compared with the general population, and climacteric scores were high (Dorani et al., 2021). Sleep characteristics and current comorbidity did not differ between women with and without PMDD or postpartum depression. The authors described the study as the first of its kind and said it suggests a marked burden of hormone-related mood symptoms in this group.
Physical Illness and Substance Use
The Korean survey also listed physical illness, underweight and alcohol disorder among the factors positively associated with PMDD, alongside major depressive disorder, PTSD, social phobia, specific phobia and somatoform disorder (Hong et al., 2012). Age was controlled in the associations with alcohol disorder and the psychiatric disorders.
For alcohol, the evidence concerns premenstrual syndrome rather than PMDD. A systematic review and meta-analysis of 19 studies found a moderate link between alcohol consumption and PMS risk (Fernández et al., 2018). Any drinking carried a pooled odds ratio of 1.45 (95% CI 1.17 to 1.79), and heavy drinking a larger one of 1.79 (95% CI 1.39 to 2.32). The estimate was not significant among studies that used a validated measure of exposure, or outside the United States. Heterogeneity was substantial and unexplained, alcohol was assessed at the same time as PMS, and reverse causation was judged plausible. No cohort studies were found, and the authors advised future work to avoid cross-sectional designs. The threshold of intake at which risk rises remained unclear.
None of the studies reviewed here addresses comorbidity of PMDD with endometriosis, migraine or chronic pain, so those links are not assessed.
Self-Reported Comorbidity in Patients
Seventy percent of the 599 respondents to an online survey, all of whom said their PMDD had been diagnosed from two months of prospective daily ratings, reported at least one other psychiatric diagnosis over their lifetime (Eisenlohr-Moul et al., 2022a). The diagnoses were self-reported and recruitment came through online support groups, so the figure describes a self-selected sample. That study is treated in full under Suicide and Self-Harm.
Taken together, the surveys point the same way, but the direction of effect is unsettled for nearly every pairing. Prospective evidence exists only for trauma, anxiety history, daily hassles and subthreshold PMDD, and for bipolar disorder, eating disorders, ADHD and alcohol the question of which condition comes first remains open.
Suicide and Self-Harm
Premenstrual dysphoric disorder (PMDD) is associated with suicidal ideation, suicide plans and suicide attempts across several independent bodies of evidence. Nearly all of that evidence is cross-sectional or retrospective, so it shows a link and does not show that the disorder causes suicidal behaviour. This section sets out the associations, what is known about timing across the cycle, the candidate mechanisms, and what follows for assessment and prevention.
Evidence Linking PMDD to Suicidality
A systematic review of ten studies, covering 10,951 women, found that PMDD was strongly associated with suicidal thoughts, plans and attempts (Osborn et al., 2021). In the reviewers' judgment, women with PMDD ought to be regarded as a group at high risk of suicidality, and they recommended that any woman presenting with suicidality be screened as a matter of routine. They also listed limits: diagnoses were provisional, causality could not be inferred, and the work covered non-fatal suicidality only (Osborn et al., 2021). Some contrasts in the same review were null. Women with PMDD who attempted suicide did not differ from other attempters in impulsivity, in the lethality of the attempt, or in luteal-phase timing, and one adolescent study found ideation lower with PMDD than with moderate or severe premenstrual syndrome (PMS), though higher than with no or mild symptoms (Osborn et al., 2021).
A systematic review and meta-analysis of 13 studies, ten of them pooled, reached a consistent conclusion. Across the pooled studies, PMDD carried elevated odds of both suicidal ideation and suicide attempts compared with controls, and the reviewers concluded that premenstrual disorders may raise the risk of suicidality (Prasad et al., 2021). PMS was associated with ideation, but its association with attempt was not significant (Prasad et al., 2021). The authors flagged several caveats. All but one study was cross-sectional, measures were nonstandardised self-reports, PMS and PMDD diagnoses were provisional, and the larger studies dominated the pooled results. Findings on suicidal plans were preliminary, and the evidence was judged inadequate for definite conclusions (Prasad et al., 2021).
A secondary analysis of the Collaborative Psychiatric Epidemiology Survey, covering 3,965 US women aged 18 to 40, found PMDD independently associated with suicidal ideation (OR 2.22), plans (OR 2.27) and attempts (OR 2.10) (Pilver et al., 2013). Moderate or severe PMS was associated with ideation only (OR 1.49), and plans and attempts were not significantly elevated (Pilver et al., 2013). Adjustment greatly attenuated the unadjusted association, and the authors concluded that clinicians should assess suicidality in PMDD (Pilver et al., 2013).
Samples With Confirmed or Self-Reported PMDD
The strongest diagnostic evidence comes from women whose PMDD was confirmed by prospective daily ratings. A baseline analysis of two randomised trials enrolled 110 such women, and 43 of them (39.1%) reported current suicidal ideation (Wikman et al., 2022). Ideation was linked to more luteal depressive symptoms and to prior psychological treatment, and inversely to self-rated health. Current suicidal ideation was more likely among women who had already had psychological treatment for their PMDD and among those with more depressive symptoms late in the luteal phase, whereas better self-rated health went with lower odds (Wikman et al., 2022). The caveats are material. The sample was limited, ideation came from a single item on a self-rating scale, fleeting thoughts may have inflated the prevalence, the odds ratios were unadjusted, and the trial excluded current psychiatric comorbidity. The authors concluded that women with PMDD are a high-risk group and that screening is needed (Wikman et al., 2022).
A global online survey of 2,542 respondents with self-reported PMDD symptoms who answered the suicidality questions included 599 reporting a prospectively confirmed PMDD diagnosis, and it measured self-injurious thoughts and behaviours with the Columbia Suicide Severity Rating Scale. Among the 599 respondents reporting a prospectively confirmed diagnosis, lifetime rates were high: 72% reported active suicidal ideation, 49% planning, 42% intent, 40% preparing for an attempt, 34% an attempt, and 51% non-suicidal self-injury (Eisenlohr-Moul et al., 2022a). Rates of suicidal thoughts and behaviours were high among those reporting a prospectively confirmed diagnosis (Eisenlohr-Moul et al., 2022a). Nulliparity, low-to-moderate income, major depression and posttraumatic stress disorder predicted active ideation. Among those with ideation, older age, nulliparity, lower income, PTSD and borderline personality disorder predicted an attempt (Eisenlohr-Moul et al., 2022a). The diagnosis and the lifetime comorbid diagnoses were self-reported and recruitment was through online support groups, and the authors called for prospective research and for screening (Eisenlohr-Moul et al., 2022a).
Timing Across the Cycle
A systematic review and meta-analysis of five studies of 425 female suicide deaths, mostly autopsy or retrospective data, compared the phase of the cycle at death. Deaths were most frequent in the secretory phase and least frequent in the menstrual phase, with the menstrual phase judged lowest in risk (Alnashwan et al., 2023). Menstrual-phase deaths were more common among younger women than middle-aged women (Alnashwan et al., 2023). This review concerns fatal attempts by cycle phase and says nothing about PMDD. Its authors named three limitations: a very small sample, most studies from India, and contributing factors that were not assessed; publication bias was not assessed because only five studies were included (Alnashwan et al., 2023). In the review by Osborn and colleagues, luteal-phase timing did not distinguish PMDD attempters from other attempters (Osborn et al., 2021). Neither result settles whether suicidal behaviour clusters in a particular phase in PMDD, and the question remains open.
Candidate Mechanisms
A review organised around the Research Domain Criteria proposed that cycle-related mechanisms may produce acute suicide risk in the perimenstrual phase in hormone-sensitive women (Owens & Eisenlohr-Moul, 2018). Early life adversity, proximal stress and markers of impulsivity were listed as predictors of hormone sensitivity, and COMT Val was linked to loss of inhibitory control in the perimenstrual phase. Women with PMDD showed perimenstrual increases in sadness, guilt and shame that healthy women did not (Owens & Eisenlohr-Moul, 2018). The review noted that no longitudinal studies of suicidality across the cycle existed, that methods were rudimentary with single hormone measures, that self-report was overused, and that findings on perimenstrual inhibitory control were not entirely consistent (Owens & Eisenlohr-Moul, 2018).
The only experimental evidence is a double-blind crossover trial in 28 analysed psychiatric outpatients with past-month suicidal ideation. Relative to placebo, the estradiol-plus-progesterone condition blunted the perimenstrual rise in suicidal ideation and suicide planning, and likewise in hopelessness, rejection sensitivity, perceived burdensomeness and perceived stress; anxiety, impulsivity and anger or irritability showed no significant condition-by-phase interaction (Eisenlohr-Moul et al., 2022b). The authors concluded that hormone withdrawal is possibly a causal contributor. The trial was powered for medium effects only, could not separate estradiol from progesterone, did not select participants for perimenstrual exacerbation, and had no suicide attempt outcome (Eisenlohr-Moul et al., 2022b). The wider hormone-sensitivity account appears in The Differential Hormone-Sensitivity Model of Premenstrual Dysphoric Disorder.
Assessment and Prevention
The reviews and the survey analysis make related practical recommendations. Osborn and colleagues encouraged routine screening of women who present with suicidality, and Pilver and colleagues advised that clinicians assess suicidality (Osborn et al., 2021; Pilver et al., 2013). Wikman and colleagues and the online-survey authors also called for screening (Wikman et al., 2022; Eisenlohr-Moul et al., 2022a). None of the studies reviewed here is a PMDD-specific suicide prevention trial. The hormone-buffering crossover trial described above is the only intervention study here that touches perimenstrual suicidality, and it enrolled psychiatric outpatients rather than a PMDD sample (Eisenlohr-Moul et al., 2022b). Whether screening or any specific intervention lowers suicidal behaviour in PMDD remains untested in the evidence reviewed here.
Anyone in immediate danger should contact local emergency services; in the United States the 988 Suicide and Crisis Lifeline is available by call or text, and the International Association for Suicide Prevention keeps a directory of crisis centres in other countries.
Related Conditions and Normal Premenstrual Change
Timing is the main way to tell premenstrual dysphoric disorder (PMDD) apart from the conditions it resembles. A complaint that persists through the whole cycle, or that peaks at some other phase, is not PMDD. Timing is established by rating symptoms every day as they happen, not by recall. The subsections below take the main boundaries in turn: ordinary premenstrual change, major depression, borderline personality, premenstrual exacerbation, and medical and psychiatric conditions that fluctuate with the cycle.
Normal Premenstrual Change
Some premenstrual change is normal and not a sign of illness. An expert consensus report from the International Society for Premenstrual Disorders (ISPMD) cited 80-95% for physiological premenstrual symptoms as an example of how widely published prevalence estimates vary. It gave 30-40% for premenstrual syndrome and 3-8% for PMDD as examples, citing Pearlstein (2007), of how differences in interpretation produce marked variation in estimated prevalence (O'Brien et al., 2011). Types of Premenstrual Dysphoric Disorder sets out these categories and their figures. The group found no objective test that can sort a woman into one level or another, so self-ratings are still needed. It also noted that such ratings depend on how each woman sees her own symptoms (O'Brien et al., 2011). A later ISPMD consensus review called for prospective ratings across two consecutive cycles and listed the Daily Record of Severity of Problems among the instruments (Nevatte et al., 2013).
Daily records also challenge the common belief that low mood belongs to the week before menstruation. A systematic review gathered 47 English-language prospective studies of women who were not seeking help. In 18 of them (38.3%), cycle phase showed no link with negative mood. Another 18 linked negative mood to the premenstrual phase together with some other phase. Only 7 (14.9%) found a pattern confined to the premenstrual phase, and 4 (8.5%) placed it in a phase other than the premenstrual one (Romans et al., 2012). The reviewers concluded that there is no clear evidence of a negative mood specific to the premenstrual phase in this population, and that the belief should be challenged. The studies varied too much in sampling, instruments and phase definitions for a meta-analysis (Romans et al., 2012). This evidence comes from women in general, not from women with PMDD. It does not show that PMDD is rare or unreal. It shows that cyclical low mood cannot be assumed from expectation, which is why the diagnosis depends on prospective records.
Major Depression
The oldest boundary question is whether PMDD is a form of depression. A review judged it a distinct entity. In its reading, PMDD is not a variant of depression and not a subtype of an anxiety disorder. It also noted that serotonin reuptake inhibitors act with a short onset in PMDD, which it took to suggest a mechanism other than their antidepressant and anti-anxiety effects (Landén & Eriksson, 2003). The same review did not rule out subgroups that look like depression or anxiety, and it said that the similarities with panic disorder needed more study.
Twin and follow-up studies point to partial overlap rather than identity. A longitudinal study assessed 1,312 menstruating female twins twice, six years apart. Because retrospective reports of premenstrual symptoms are unreliable, it used a model that corrects for measurement error to estimate the stable component of premenstrual symptoms. That component was substantially heritable, and family environment made no contribution to it. Risk factors for lifetime major depression overlapped with it only modestly (Kendler et al., 1998). A smaller study ran the other way. It followed 36 women who had volunteered for menstrual cycle research. Even with family history and previous depression controlled, higher depressive-subscale scores on the Premenstrual Assessment Form went with later onset of major depressive disorder (r = 0.35). The Premenstrual Change Index also predicted it but added no further predictive power (Graze et al., 1990). The Premenstrual Assessment Form was a retrospective instrument, whereas the Premenstrual Change Index was derived from prospective daily self-ratings. Taken together, this evidence supports a partial overlap. Premenstrual symptoms share some risk with major depression, and in one small sample they predicted it, but a separate heritable component remains. Whether PMDD has depressive subtypes is still an open question.
Borderline Personality and Affective Instability
The rapid mood shifts of borderline personality disorder can look like premenstrual dysphoria, and the cycle may make them worse. A daily-diary study followed fifteen unmedicated females with borderline personality disorder for 35 days. It timed the cycle with urine luteinizing hormone and salivary progesterone and scored symptoms with the Carolina Premenstrual Assessment Scoring System. Multilevel models showed that most symptoms were higher in the midluteal and perimenstrual phases than in the follicular and ovulatory phases (Eisenlohr-Moul et al., 2018). Depressive symptoms followed an unexpected, delayed course. They were higher in the perimenstrual and follicular phases than in the ovulatory and midluteal phases. No participant met PMDD criteria. In post-hoc analyses, higher progesterone relative to each woman's own average went with lower levels of most symptoms. The authors concluded that perimenstrual emotional worsening may be elevated in this disorder and called for longitudinal and hormonal experiments (Eisenlohr-Moul et al., 2018). With fifteen participants, the result points to further research rather than settling the question. The practical point is the same as for depression: only daily ratings across the cycle can separate cycle-linked worsening from instability that is always present.
Premenstrual Exacerbation
The ISPMD classification lists premenstrual exacerbation as a variant of premenstrual disorder. Independent comorbidities and misattributed symptoms are kept outside both its core and variant categories (O'Brien et al., 2011). PMDD has a symptom-free period that opens after menses begin and closes before ovulation (Pinkerton et al., 2010). Types of Premenstrual Dysphoric Disorder treats premenstrual exacerbation as a presentation in its own right.
Medical Conditions That Mimic Premenstrual Dysphoric Disorder
Many medical and psychiatric conditions worsen across the menstrual cycle, according to a review of cycle-related exacerbation of disease (Pinkerton et al., 2010). The review does not show how often these conditions are mistaken for PMDD. Among the medical conditions it covers are migraine, asthma and catamenial epilepsy, a form of epilepsy whose seizures follow the cycle. On the psychiatric side, it examines cyclical change in mood disorders, including major depression, atypical depression and bipolar disorder. It also covers anxiety disorders, schizophrenia, obsessive compulsive disorder and bulimia.
The evidence for cyclical worsening is uneven. The review reports effects in some studies but not all. Two studies found no significant rise in panic attacks before menstruation. No study of anorexia had been published. The review also states that the precise cause of cyclical exacerbation is not clearly understood (Pinkerton et al., 2010). Its diagnostic advice uses the same timing rule as the subsections above. The review describes PMDD as followed by a symptom-free period after bleeding has started and before ovulation, and states that prospective daily ratings for at least two consecutive cycles are essential to confirm a preliminary diagnosis (Pinkerton et al., 2010). The studies reviewed here give no systematic workup for thyroid disease, anaemia or endometriosis. They do not say how these conditions should be ruled out before PMDD is diagnosed.
Treatment Evidence
The evidence for treating premenstrual dysphoric disorder (PMDD) is strongest for serotonergic antidepressants and weaker, or more qualified, for every other option. Many trials enrolled women with premenstrual syndrome (PMS) as well as PMDD, so each estimate below is tied to the population its source studied. This section sets out efficacy, certainty and caveats; how the treatments are thought to work is covered under How Treatments Work, and the hormonal options at length under Somatic Treatments: Ovarian Suppression and Surgery. Table 2 at the end of the section summarises the standing of each treatment.
Selective Serotonin Reuptake Inhibitors
Selective serotonin reuptake inhibitors (SSRIs) have the largest number of randomised trials among the treatments reviewed here. The 2024 Cochrane review included 34 randomised trials and found moderate-certainty evidence, from 12 studies, that SSRIs eased overall self-rated PMS or PMDD symptoms more than placebo did, with a standardised mean difference of -0.57 (95% confidence interval from -0.72 to -0.42) (Jespersen et al., 2024). Heterogeneity across studies was moderate for overall symptoms (I2 = 51%). Three cautions travel with that estimate: the authors flagged poor reporting of study methods, suspected publication bias in the response-rate outcome, and a pharmaceutical-funding share of 68% that they advised interpreting cautiously (Jespersen et al., 2024).
Adverse events were more common on SSRIs than on placebo. The review gave odds ratios of 3.30 for nausea, 1.99 for insomnia, 5.38 for tremor, 3.28 for asthenia and 3.26 for somnolence, the last resting on low-certainty evidence (Jespersen et al., 2024). Earlier syntheses pointed the same way on efficacy. A 2013 Cochrane review of 31 trials found SSRIs superior to placebo, with a moderate effect on end-of-treatment scores and a small one on change scores, and rated the evidence quality low to moderate (Marjoribanks et al., 2013). A 2008 meta-analysis of 29 trials (2,964 women) reported an odds ratio of 0.40 favouring SSRIs, no SSRI better than another, and an effect smaller than earlier reports had suggested (Shah et al., 2008).
The individual trials behind these pooled estimates are mostly older. In a randomised, double-blind, placebo-controlled trial across seven Canadian clinics, 405 women were enrolled and 313 randomised, and both 20 mg and 60 mg of fluoxetine daily beat placebo on tension, irritability and dysphoria over six cycles. The higher dose brought more side effects, and the authors judged 20 mg the best balance; only 180 of the 313 completed (Steiner et al., 1995). Sertraline (50 to 150 mg/d, flexible dosing) outperformed both placebo and the tricyclic desipramine in 189 women over three months, with responders at 65%, 36% and 29% respectively, while desipramine did not differ from placebo (Freeman et al., 1999). Luteal-phase escitalopram in 151 women reduced symptoms in a dose-dependent way: 20 mg/d beat 10 mg/d, and 80% of women on 20 mg/d reached an 80% or greater reduction in irritability, against 30% on placebo. Physical complaints such as breast tenderness and food craving, along with low energy, improved only modestly, with no significant advantage over placebo, which itself produced a large response (Eriksson et al., 2008). Over three menstrual cycles, a trial comparing continuous paroxetine, luteal-phase paroxetine and placebo, with 55 to 56 women per group, found that paroxetine taken every day reduced premenstrual symptoms with a response rate of 85%, and the authors identified irritability as a key target symptom (Landén et al., 2007).
A 2026 network meta-analysis offers the nearest thing to a head-to-head comparison of treatment classes. Of 16 studies in the review, five were pooled; continuous paroxetine was favoured over other antidepressants across symptom domains, and the 24/4 drospirenone and ethinyl estradiol pill over other combined oral contraceptives for physical and emotional symptoms. The authors called for direct comparative trials of the two classes, and only five studies entered the network (Berni et al., 2026).
One harm deserves separate mention. One systematic review gathered 19 studies on sexual dysfunction that lingers after an SSRI is stopped: 11 case reports, six observational studies and two retrospective interventional studies. It found no reliable prevalence estimates and could not establish a cause-effect relationship, though it could not rule out persistence either (Tarchi et al., 2023). This review concerns SSRI exposure in general and describes no premenstrual sample, so it bears on PMDD only as a general caution about the drug class.
Continuous, Luteal-Phase and Symptom-Onset Dosing
Unlike depression, PMDD symptoms recur only in the luteal phase, so treatment can be restricted to those days. Luteal-phase sertraline (50 to 100 mg) was effective in 281 women with DSM-IV PMDD over three cycles: 50% responded against 26% on placebo, and symptom change and quality of life favoured sertraline. About 8% of women on sertraline and under 1% on placebo discontinued because of adverse events (Halbreich et al., 2002). Intermittent paroxetine matched continuous paroxetine for irritability, affect lability and mood swings, though its effect was somewhat weaker for depressed mood and somatic symptoms (Landén et al., 2007). The expert consensus view agrees in outline: intermittent and continuous SSRI use were equivalent in overall efficacy, with intermittent dosing inferior for somatic symptoms, and evidence for as-required use was limited (Nevatte et al., 2013).
Symptom-onset dosing, in which the drug starts when symptoms begin, gave a mixed result. In 252 women over six cycles, sertraline at 50 to 100 mg/d did not beat placebo on the primary Premenstrual Tension Scale outcome (P = .06). Its advantage showed in responder rate (67.0% against 52.4%), in the anger/irritability and total DRSP scores, and on the Inventory of Depressive Symptomatology as rated by clinicians. Symptomatic days and withdrawal symptoms did not differ from placebo. The authors concluded that benefit was uncertain and depended on the scale (Yonkers et al., 2015).
Two syntheses address whether intermittent dosing matches continuous dosing, and they disagree. A 2023 meta-analysis of eight randomised trials (460 women, 212 on intermittent and 248 on continuous dosing) found no difference in response rate (odds ratio 1.0, 95% CI 0.23 to 4.31; I2 = 71%), dropout rate or symptom change (standardised mean difference 0.04, 95% CI -0.27 to 0.35). Subgroups of PMDD and of severe PMS showed the same null result. The authors cautioned that every included study carried moderate or high risk of bias, that response-rate heterogeneity was substantial, and that funnel asymmetry for symptom scores (Egger's p = 0.040; adjusted SMD -0.130) suggested small studies with large effects. Since taking the drug for only part of the cycle avoids the potential for withdrawal symptoms, the reviewers argued that intermittent dosing should be considered more commonly (Reilly et al., 2023). Here the Cochrane subgroup analysis pointed the opposite way, favouring continuous over luteal-phase dosing (SMD -0.69, 95% CI -0.88 to -0.51, against -0.39, 95% CI -0.58 to -0.21), a gap significant at P = 0.03 (Jespersen et al., 2024). The 2008 meta-analysis also favoured continuous dosing (Shah et al., 2008), whereas the 2013 Cochrane review found no clear difference and noted few direct luteal-versus-continuous comparisons (Marjoribanks et al., 2013).
The current position is therefore split. Luteal-phase dosing works against placebo; whether it matches continuous dosing is unsettled, with the 2023 meta-analysis and the 2024 Cochrane review disagreeing and each limited by the quality of its trials (Reilly et al., 2023; Jespersen et al., 2024).
Drospirenone-Containing Oral Contraceptives
The combined pill with drospirenone, a progestogen, is the best-studied hormonal alternative to an SSRI. In a multicentre double-blind trial of 450 women with PMDD symptoms, a 24/4 regimen of drospirenone 3 mg with ethinyl estradiol 20 microg reduced the total Daily Record of Severity of Problems score more than placebo (adjusted mean difference -7.5, 95% CI -11.2 to -3.8), with mood, physical and behavioural subscales all favouring the pill. The response rate was 48% against 36%, a number-needed-to-treat of 8 (Yonkers et al., 2005).
Cochrane reviews are more guarded. A 2012 review of five trials (1,920 women) found that drospirenone pills may help severe symptoms. Symptom severity fell more than on placebo (mean difference -7.92, 95% CI -11.16 to -4.67), and so did productivity, social and relationship impairment, but adverse events rose (total adverse events OR 2.36; nausea OR 3.15; intermenstrual bleeding OR 4.92; breast pain OR 2.67). The authors noted a large placebo response and no evidence beyond three cycles, in less severe symptoms, or against other contraceptives (Lopez et al., 2012). A 2023 update of five trials in 858 women, mostly with PMDD, gave a standardised mean difference of -0.41 (95% CI -0.59 to -0.24) and concluded that benefit is possible but adverse effects are more frequent. It rated the evidence as very low to moderate quality, with serious risk of bias, inconsistency and imprecision, and noted that placebo also had a significant effect (Ma & Song, 2023).
Contraceptive pills have effects outside the premenstrual period, and two registry studies of pill users generally, not women with PMDD, frame the risks. In a Danish national cohort of 1,296,120 women followed for 8,010,290 women-years, combined-pill users had a raised risk of venous thromboembolism that varied by progestogen: drospirenone users had a rate ratio of 2.1 (95% CI 1.6 to 2.8) relative to levonorgestrel users. Smoking and body mass index were not available, and only 67% of events were confirmed (Lidegaard et al., 2011). A second Danish cohort of 1,061,997 women aged 15 to 34 (mean follow-up 6.4 years) linked hormonal contraception with later antidepressant use (relative risk 1.23, 95% CI 1.22 to 1.25 for combined oral contraceptives) and with a depression diagnosis, with higher relative risks in adolescents (1.8 for combined pills). The authors treated depression as a potential adverse effect, and the finding is an association from registry data (Skovlund et al., 2016).
A community cohort supplies a counterweight on mood. Among 658 pill users in a sample of 976 premenopausal women, the pill rarely changed premenstrual mood: 16.3% reported deterioration and 12.3% improvement. A history of depression was the only significant predictor of deterioration, whereas dysmenorrhoea and early-onset premenstrual mood disturbance predicted improvement (Joffe et al., 2003).
Psychological Treatments
Psychological treatment has a thinner and more qualified record. A meta-analysis of nine randomised trials in women with PMS, five of which tested cognitive behavioral therapy, found that it outperformed control on anxiety, depression, behavioural change and interference with daily living. The authors judged it possibly beneficial but rated the evidence low in quality, with design weaknesses and possible reporting bias; monitoring alone had limited support and the results suggested that education was ineffective (Busse et al., 2009). A meta-analysis of 22 controlled trials in PMS and PMDD found small to medium gains for both cognitive-behavioural interventions (d+ 0.24 to 0.70) and serotonergic antidepressants (d+ 0.29 to 0.58). Its authors called the efficacy unsatisfactory and thought a combination worth testing, and follow-up effects were available only for the cognitive-behavioural studies (Kleinstäuber et al., 2012). An earlier systematic review of seven published reports, three of them randomised trials, found little significant evidence and wide variation in methods (Lustyk et al., 2009).
Direct comparisons give the clearest picture. In a three-arm pragmatic trial in women with PMDD (60 completers), ten sessions of cognitive-behavioural therapy and fluoxetine 20 mg daily produced equal numbers of remaining cases after treatment, fluoxetine worked faster, cognitive-behavioural therapy held better at follow-up, and combining them added no benefit (Hunter et al., 2002). A randomised trial in Australia compared four 90-minute sessions of couple-based and one-to-one cognitive-behavioural therapy with a wait list in 83 women with premenstrual disorders (63 completers). Both formats lowered premenstrual symptoms and distress relative to wait list, and the formats did not differ on symptoms or distress. The abstract reported an advantage for the couple format on active behavioural coping. The trial was not publicly registered before enrolment (Ussher & Perz, 2017). Internet-delivered versions are covered under Emerging Treatments.
Guidelines and Treatment Order
Guidance converges on SSRIs first and hormonal options next. An expert consensus from the International Society for Premenstrual Disorders (a London meeting in 2011) found SSRIs superior to desipramine, bupropion and maprotiline, which did not differ from placebo (Nevatte et al., 2013). It called anxiolytics less well studied and their use controversial because of the risk of drug dependence (Nevatte et al., 2013). The same society's 19-member group later collected 66 proposed auditable standards for the diagnosis and treatment of premenstrual disorders and ranked them in order of priority, so that clinical care can be audited (Ismaili et al., 2016). The Royal College of Obstetricians and Gynaecologists issued Green-top Guideline No. 48 on the management of premenstrual syndrome (Royal College of Obstetricians and Gynaecologists, 2017).
A scoping review of 113 articles published between 2000 and 2022 ranked SSRIs and combined oral contraceptives as the best-supported treatments, with GnRH analogues and surgery as options for refractory cases. It called for individualised, interdisciplinary care and warned of a paucity of high-quality data and strong placebo responses (Carlini et al., 2022). A clinical review likewise noted limited research evidence for hormonal treatment and a large placebo effect in the drospirenone pill trials (Hantsoo & Epperson, 2015).
The 2023 American College of Obstetricians and Gynecologists (ACOG) guideline for premenstrual disorders used a modified GRADE framework, with Ungraded Good Practice Points for matters the evidence could not settle. It noted that inadequate evidence prevented some recommendations and that advice for adolescents was extrapolated from adult data (Ireland & Truehart, 2023).
Other Medications
Several other agents have been tested, with results that range from null to promising. A Cochrane review of progesterone for PMS included two trials (280 women) and judged its effect unproven: the evidence was inconclusive, neither showing the drug effective nor ineffective. One trial favoured progesterone over placebo once ineligible women were excluded; in the smaller study, oral and vaginal progesterone did not differ from placebo. Both trials had defects, the smaller study reported its outcomes incompletely, the studies could not be combined, and no subgroup of responders was identified (Ford et al., 2012).
Venlafaxine, a serotonin and norepinephrine reuptake inhibitor, beat placebo in 164 women with PMDD in a flexible-dose (50 to 200 mg/day), four-cycle, double-blind trial, on symptom scores, on more than 50% improvement and on remission (Freeman et al., 2001). Its authors noted that intermittent dosing was untested, that long-term maintenance efficacy was unknown, and that adverse events were mild and transient (Freeman et al., 2001). A multicentre placebo-controlled trial of a levonorgestrel (90 mcg) and ethinyl estradiol (20 mcg) pill in 367 women with PMDD gave a mixed result: the drug improved Daily Record of Severity of Problems scores more than placebo in the first cycle (-30.52 versus -22.47, p < .001) and the worst five days in the last cycle (p = .016), and more women responded (52% versus 40%, p = .025), but other primary endpoints were not significant (Halbreich et al., 2012).
Table 2
Treatments for Premenstrual Dysphoric Disorder and Their Standing
| Treatment | Evidence | Standing |
|---|---|---|
| SSRIs, continuous dosing | Cochrane review of 34 trials, 2024 | Probably effective, moderate certainty |
| SSRIs, luteal-phase dosing | Trials and a 2023 meta-analysis | Supported; comparison with continuous dosing unsettled |
| Drospirenone-containing pill | Cochrane reviews, 2012 and 2023 | Possible benefit, very low to moderate certainty |
| Venlafaxine | One randomised trial, 164 women | Beat placebo; intermittent dosing and long-term effect untested |
| Progesterone | Cochrane review of two trials, 2012 | Inconclusive; effect unproven |
| Cognitive behavioural therapy | Meta-analyses | Possibly beneficial; low-quality evidence |
| GnRH analogues with add-back | Meta-analysis and Cochrane review, 2025 | Agonists alone effective for global symptoms (high certainty); with add-back, low certainty; short-term use only |
| Hysterectomy with bilateral oophorectomy | Retrospective case series | Last resort |
| Sepranolone | Phase II trials | Primary endpoint not met |
| Ulipristal acetate | One randomised trial, 95 women | Early; replication needed |
| Dutasteride | Two small crossover trials reported together | Early; preliminary support at high dose only |
Note. Evidence labels follow the cited reviews and trials discussed in this section and in Somatic Treatments: Ovarian Suppression and Surgery and Emerging Treatments. Several syntheses combine PMS and PMDD samples. SSRI = selective serotonin reuptake inhibitor; GnRH = gonadotropin-releasing hormone.
How Treatments Work
Why a treatment helps is a separate question from whether it does (see Treatment Evidence), and for premenstrual dysphoric disorder (PMDD) the evidence on mechanism is thinner than the evidence on benefit. The field's signature puzzle is the speed of serotonergic drugs. In depression these agents take weeks to act; in PMDD they appear to act within days.
Why Serotonergic Drugs Act Quickly
An open-label study of 24 women with PMDD gave fluoxetine (20 mg daily) to twelve and left twelve untreated. In the treated group, sadness, anxiety and mood swings on an hourly visual analogue scale rose above baseline, so the response reached beyond irritability, and its time course matched the time course of the fall in symptoms at menses onset. The authors suggested that the two may share a state-change mechanism (Steinberg et al., 2012). Luteal-phase clomipramine, taken at 25 to 75 mg over three cycles, also beat placebo for irritability, depressed mood and global improvement in 29 nondepressed women. Symptoms fell by more than 70% on the drug and by about 45% on placebo, so the placebo group improved markedly too (Sundblad et al., 1993).
One proposal concerns neurosteroid synthesis. In purified rat and human enzymes, fluoxetine, paroxetine and sertraline raised the affinity of 3α-hydroxysteroid dehydrogenase III for its substrate, while imipramine had no such effect, a result the authors said may partly explain SSRI relief in the luteal phase. This was an in vitro finding only. Its authors noted that plasma steroid may not reflect brain steroid and that firm conclusions cannot be drawn (Griffin & Mellon, 1999).
Human data are sparse and open-label. In a controlled laboratory study of 36 women with PMDD, the luteal rise in anxiety-potentiated startle was seen when untreated and was reduced after luteal sertraline, but only among the 12 responders. In the 14 non-responders it did not change, and the effect in the whole PMDD group was not significant. The analysis of responders was exploratory, there was no placebo control, and the primary hypotheses were not supported (Hantsoo et al., 2021). The neurosteroid account therefore remains a hypothesis. The Biology of Premenstrual Dysphoric Disorder section sets it beside the other biological findings.
How Cognitive Behavioural Therapy Is Thought to Work
In a randomised pragmatic trial, 108 women were allocated to ten sessions of cognitive behavioural therapy (CBT), to fluoxetine, or to both. CBT and fluoxetine improved symptoms about equally after treatment. Fluoxetine acted faster, CBT held its gains better at one-year follow-up, and combining them added no benefit (Hunter et al., 2002). The proposed mechanisms concern appraisal and coping. In interviews with sixty self-defined sufferers of premenstrual syndrome, the condition emerged as a negotiated process rather than a fixed one, and the authors concluded that reframing, coping and self-monitoring may reduce distress (Ussher & Perz, 2013). In an internet-delivered CBT trial with 174 women, the treatment beat a waitlist on impairment, symptom intensity and disability, and the gains held at six months. Active coping was associated with greater improvement, while support-seeking coping and perceived stress were associated with less, and the authors concluded that treatment should address coping and stress (Weise et al., 2019).
None of the studies reviewed here reports a formal mediation analysis showing that a change in coping or appraisal produces the symptom change. Among the studies reviewed here, that test has not been done, and it is the field's gap.
Hormonal Treatments
In a double-blind crossover study, leuprolide, which suppresses the ovaries, relieved symptoms in the 10 women with premenstrual syndrome who received it, compared with 10 who received placebo. Adding back estradiol or progesterone brought symptoms back in them but caused no mood change in 15 women without the condition, a pattern the authors read as an abnormal response to normal hormones (Schmidt et al., 1998). A review reached a compatible conclusion: the disorder probably reflects heightened sensitivity rather than abnormal hormone levels, and gonadotropin-releasing hormone agonists suppress ovulation and relieve symptoms (Yonkers et al., 2008). The Differential Hormone-Sensitivity Model of Premenstrual Dysphoric Disorder and Somatic Treatments: Ovarian Suppression and Surgery sections take this up.
For the drospirenone and ethinyl estradiol pill, the studies reviewed here report benefit, not mechanism. Scored on the DRSP, 450 women with PMDD symptoms improved more with the 24/4 regimen than with placebo (Yonkers et al., 2005). A 2012 Cochrane review of five trials and 1920 women found that drospirenone pills may help severe symptoms, with a large placebo effect and unknown effects beyond three cycles (Lopez et al., 2012). None of the studies reviewed here tests how these pills act in PMDD.
Somatic Treatments: Ovarian Suppression and Surgery
Somatic treatments for premenstrual dysphoric disorder (PMDD) that act on the ovary sit at the far end of the treatment ladder. They suppress the ovarian cycle with gonadotropin-releasing hormone (GnRH) analogues or remove the ovaries by surgery. The drospirenone pill is covered under Treatment Evidence.
GnRH Analogues and Add-Back Therapy
A meta-analysis of placebo-controlled trials in women with premenstrual syndrome (PMS) and PMDD found GnRH analogues better than placebo overall (SMD −1.19, 95% CI −1.88 to −0.51). In the pooled trials, giving hormonal add-back alongside the analogue did not appear to weaken its benefit (Wyatt et al., 2004); the later Cochrane review found the evidence insufficient to establish that add-back reduces side effects without decreasing the global efficacy of the agonists (Naheed et al., 2025). Add-back therapy is the replacement of ovarian hormones given alongside the analogue, and the meta-analysis found no significant difference in effect between physical and behavioural symptoms (Wyatt et al., 2004).
The 2025 Cochrane review pooled 11 randomised trials with 275 women. GnRH agonists beat placebo for global symptoms (SMD −1.23, 95% CI −1.76 to −0.71; high certainty), but women on the agonist were more likely to withdraw because of adverse events (Naheed et al., 2025). Menopausal side effects may be more frequent with GnRH agonists than with placebo, but the estimate is imprecise, its confidence interval spanning 1 (RR 1.93; 95% CI from 0.83 to 4.48), and the evidence for it is of low certainty (Naheed et al., 2025). The reviewers concluded that the relief is short-term and that long-term safety remains unconfirmed (Naheed et al., 2025). The review located no randomised trial of a GnRH antagonist, and none of the included trials reported quality of life or long-term outcomes for bone (Naheed et al., 2025).
The evidence on add-back itself is thinner. Agonist plus add-back may improve global symptoms compared with placebo (low certainty, one trial), while oestrogen plus cyclical progestogen add-back may worsen global symptoms compared with placebo (low certainty, one trial) (Naheed et al., 2025). Tibolone add-back could not be told apart from placebo, and low and standard add-back doses did not differ significantly. The review rated the trials as imprecise and at high risk of bias (Naheed et al., 2025).
The regimen matters. In a randomised double-blind cross-over trial of 27 women with PMDD on a GnRH agonist, 1.5 mg estradiol with 400 mg progesterone produced the most symptom recurrence. That combination recurred more than 0.5 mg estradiol with progesterone and more than estradiol alone. The authors concluded that long-cycle add-back with less progestagen is probably best (Segebladh et al., 2009).
Surgery
In a retrospective interview series of 47 women with severe PMS, total hysterectomy with bilateral salpingo-oophorectomy followed by hormone replacement therapy gave complete resolution of cyclical symptoms in 93.6%, and 96% were satisfied or very satisfied. The women had a median age of 42 years and about 3.8 years of postoperative hormone therapy. The authors called it an effective permanent cure (Cronje et al., 2004). The design is retrospective and uncontrolled, so the satisfaction figure is not a trial estimate. The authors also noted that few such reports exist (Cronje et al., 2004).
Place in Guidance
A scoping review of 113 articles found selective serotonin reuptake inhibitors and combined oral contraceptives best supported, and described GnRH analogues and surgery as options for refractory cases (Carlini et al., 2022). The American College of Obstetricians and Gynecologists issued graded treatment recommendations for premenstrual disorders, and it noted that inadequate evidence prevented some of them (Ireland & Truehart, 2023). The Royal College of Obstetricians and Gynaecologists addresses the management of premenstrual syndrome in Green-top Guideline No. 48 (Royal College of Obstetricians and Gynaecologists, 2017).
Lifestyle and Complementary Approaches
Most of the evidence on lifestyle and complementary options comes from premenstrual syndrome (PMS) rather than premenstrual dysphoric disorder (PMDD), and almost all of it is of low quality. The adjuncts below are therefore best read as leads for better trials, not as established treatments.
A systematic review of 15 randomised trials (717 women) pooled seven trials (265 women) and found that exercise reduced global PMS symptoms more than non-exercise comparators (SMD = -1.08; 95% CI -1.88 to -0.29), with similar gains for psychological, physical and behavioural symptoms (Pearce et al., 2020). The interval is wide and heterogeneity was high (I² = 87%). Eighty-seven percent of the trials were at high risk of bias, 12 of the 15 were run in Iran, none followed women after the intervention ended, and moderate publication bias was possible. The authors concluded that exercise may help PMS and that uncertainty remains (Pearce et al., 2020).
Calcium has been studied in PMS too. A systematic review of 14 studies, 8 interventional and 6 observational, found that serum calcium was lower in women with PMS than in controls in four studies, and that calcium beat placebo in 7 of the 8 interventions. The studies were small, short and drawn only from the United States and Iran, and they were too heterogeneous to pool. The review judged calcium possibly beneficial and called for more trials, including dose-response trials (Arab et al., 2020).
Vitex agnus-castus, the chaste tree, showed a large pooled benefit over placebo for total PMS symptoms across 14 quantitative trials (Hedges g = -1.21; 95% CI -1.53 to -0.88). Heterogeneity was extremely high (I² = 91%), the risk of bias was high and publication bias was suggested, so the authors called the result explorative and drew no definitive conclusion (Verkaik et al., 2017).
Vitamin B6 was better than placebo for overall premenstrual symptoms and for depressive symptoms in a review of nine placebo-controlled trials with 940 patients. Higher doses did no better than lower ones, and most trials were of low quality and low power. The review considered B6 likely beneficial but found the evidence insufficient for a confident recommendation (Wyatt et al., 1999).
Bright light is the one adjunct tested in the disorder itself. Testing bright light in six women with a condition then named for the late luteal phase (LLPDD), the forerunner of PMDD, an early trial found a significant reduction in depression ratings after evening bright light but not after morning light (Parry et al., 1989). A later meta-analysis of four crossover trials (55 participants) pooled its three higher-quality trials to a small, uncertain effect on PMDD depressive symptoms (effect size -0.20; 95% CI -0.48 to 0.07, which includes zero). Bright light was neither recommended nor ruled out by the reviewers, and of the four trials, the single fully unblinded one produced a far larger effect than the remaining three (Krasnik et al., 2005).
A psychological adjunct was tested in a trial of mindfulness-based cognitive therapy. Sixty students with PMS and depressive symptoms were assigned to eight weekly group sessions or to no intervention. At the end of the study the treated group had lower PMS, depression and anxiety scores than the control group, which received no intervention (Panahi & Faramarzi, 2016). The sample was small, the outcomes were self-reported, participants knew their allocation, and the treated group had more contact. In the authors' view, women with PMS symptoms found the therapy acceptable, and it might help them (Panahi & Faramarzi, 2016).
On current evidence the position is unresolved. Exercise, calcium, Vitex, B6 and mindfulness-based therapy were studied in PMS, and only the light trials addressed PMDD, where the effect is small and uncertain.
Emerging Treatments
Several newer approaches to premenstrual dysphoric disorder (PMDD) target the neurosteroid allopregnanolone and its action at the GABA-A receptor, and one tests a delivery format for cognitive-behavioural therapy. None of the drug approaches has yet reached the standing of the established treatments covered under Treatment Evidence. A review of early clinical work judged that the interplay of allopregnanolone and GABAergic transmission is a plausible contributor to how symptoms arise, and noted that the approved treatments remain suboptimal (Sikes-Keilp & Rubinow, 2023). The same review covers dutasteride, isoallopregnanolone and ulipristal acetate, and it rests on early clinical trials only.
Sepranolone
Sepranolone, also called isoallopregnanolone, acts as an antagonist of the steroids that modulate the GABA-A receptor. Its largest trial is a randomized, double-blind, placebo-controlled study of 206 women with PMDD at 12 European centers, given 10 mg or 16 mg over three consecutive menstrual cycles. The prespecified primary endpoint, the Sum21 score from the Daily Record of Severity of Problems, showed no significant difference between drug and placebo (Bäckström et al., 2021). Secondary results leaned toward benefit. Sepranolone beat placebo on distress (p = 0.037), while its advantage on impairment was only a trend. A post hoc analysis of the 9 premenstrual days favoured the 10 mg dose on Sum21 (p = 0.008) and on the share of women with minimal symptoms (p = 0.020). The authors reported a large treatment effect of all three treatments with no significant difference to placebo, and the post hoc analysis used the per protocol population only (Bäckström et al., 2021).
The earlier trial was explorative. It enrolled 126 women with PMDD, of whom 106 completed, and found sepranolone better than placebo on the total Daily Record score (p=0.041), while negative mood was only borderline (p=0.051) (Bixo et al., 2017). A post hoc subgroup of women with pure PMDD showed a 75% against 47% symptom reduction, and the authors called the drug a promising potential treatment while stressing that the study was explorative (Bixo et al., 2017). Its limits included 27 participants who missed the intended medication and 19 who showed follicular-phase symptoms. Sepranolone therefore has one explorative signal and one trial whose primary endpoint was null.
Ulipristal Acetate
Ulipristal acetate is a selective progesterone receptor modulator. In a double-blind multicenter randomized trial of 95 women with PMDD, 5 mg a day for three 28-day cycles improved total Daily Record scores more than placebo (41% against 22%; mean difference -18%, 95% CI -29 to -8) (Comasco et al., 2021). The drug also showed treatment effects on the depressive and anger/irritability subscales and a significantly higher remission rate (20 women, 50.0%, against eight, 21.1%), but not on the physical subscale (Comasco et al., 2021). The authors concluded that it could help if the result is replicated, so it stands as a proof-of-concept trial awaiting replication.
5-Alpha-Reductase Blockade
High-dose dutasteride, which inhibits 5-alpha-reductase, eased symptoms against placebo in one of two small crossover trials reported together, whereas the low dose did not (Martinez et al., 2016). The authors described this as preliminary support only. The trial and its link to the allopregnanolone rise are set out in The Differential Hormone-Sensitivity Model of Premenstrual Dysphoric Disorder.
Internet-Delivered Cognitive-Behavioural Therapy
The emerging nonpharmacological option is internet-delivered CBT. In a waitlist-controlled trial of 174 women with PMDD (86 and 88 per arm), the 8-week programme beat the waitlist on functional impairment, symptom intensity, symptom disability and everyday-life impact, and the gains held at 6 months (Weise et al., 2019). Among women receiving the programme, those who coped actively, and those who leaned less on seeking support, gained more on symptom intensity and on how far the condition intruded on daily life, while less perceived stress went with greater gains on functional impairment (Weise et al., 2019). The authors judged the format highly effective.
Where This Leaves the Field
For the drugs, the position is open. Sepranolone has a null primary endpoint, ulipristal acetate awaits replication and dutasteride has preliminary support from a small trial, so none of the drug approaches is established.
Worked Example
A screening questionnaire and a prospective diary can look at the same women and return very different counts of premenstrual dysphoric disorder (PMDD). This example follows one validation study through the arithmetic, then scales the published prevalence estimates to a round population to show what the gap means in practice.
One Sample, Two Instruments
Henz et al. studied women aged 20 to 45 years who had premenstrual complaints, in a cross-sectional validation study (Henz et al., 2018). The Premenstrual Symptoms Screening Tool (PSST) was answered by 282 eligible women, and 127 of them went on to fill in the Daily Record of Severity of Problems (DRSP) as well. Those 127 women are the sample for the comparison below (Henz et al., 2018).
The two instruments disagreed sharply about PMDD. The PSST classified 34.6% of the 127 women as having it, whereas the DRSP classified 3.9%. Agreement between them on the PMS/PMDD diagnosis was poor, with a kappa of 0.12 (Henz et al., 2018).
The counts follow from the percentages. This arithmetic is worked from the study's percentages; the study did not report it as counts. Of 127 women, 34.6% is about 44 women, and 3.9% is about 5 women. If the five prospectively rated women are taken to lie among the 44 flagged by the screen, roughly 39 of the 44 did not meet PMDD on prospective rating. That overlap is an assumption of the sketch, since the study reports only the two totals.
The disagreement was not uniform across categories. For premenstrual syndrome the direction reversed, with the DRSP identifying more women than the PSST (74.8% against 41.7%). For women with no clinically relevant premenstrual problem, the two instruments gave similar counts (Henz et al., 2018). The discrepancy is therefore concentrated in the PMDD category, where the retrospective screen found far more cases than the daily record.
From Sample to Population
The next step is illustrative arithmetic. It comes from no single study. It applies the pooled prevalences of a meta-analysis of 44 studies and 50,659 participants to a hypothetical 10,000 women (Reilly et al., 2024). That analysis reported a pooled prevalence of 7.7% under provisional diagnosis and 3.2% under confirmed diagnosis, and its authors concluded that provisional diagnosis probably inflates prevalence. Community-based samples with a confirmed diagnosis gave 1.6%, lower than the pooled 3.2% (Reilly et al., 2024).
In 10,000 women the three figures translate as follows.
| Basis of the estimate | Pooled prevalence | Women per 10,000 (approx.) | |---|---|---| | Provisional diagnosis | 7.7% | 770 | | Confirmed diagnosis | 3.2% | 320 | | Community-based samples, confirmed diagnosis | 1.6% | 160 |
Provisional diagnosis therefore yields more than twice the confirmed figure, the same direction of inflation seen when the PSST was set against the DRSP. The meta-analysis carries its own caveats. Heterogeneity across studies was high, and only a small number of included studies used the full DSM criteria in community settings (Reilly et al., 2024).
Figure 2
Premenstrual Dysphoric Disorder Identified by a Retrospective Screen and by Prospective Daily Ratings
What the Gap Shows
The two sets of numbers point the same way. A retrospective screen asks a woman to recall her symptoms, and the PSST was not collected over time (Henz et al., 2018). A daily record gathers ratings across the cycle. Where the screen flags many women and the record confirms few, the screen is measuring something broader than the disorder. This is why the PSST should be read as a screen only, with confirmation from the DRSP (Henz et al., 2018).
The screen still has a role. Its developers presented it as an effective and quick way to identify women with severe premenstrual syndrome or PMDD, and as a starting point rather than a diagnosis. They contrasted its speed with two cycles of prospective charting (Steiner et al., 2003). Its sensitivity in the validation sample was 79%, with a specificity of 33.3%, for the combined PMS/PMDD diagnosis (Henz et al., 2018). Those figures fit the pattern above, in which few cases are missed and many false positives are flagged.
One limit applies to the whole example. Most eligible women did not complete the diary: only 127 of the 282 who answered the PSST (45%) completed two cycles of the DRSP (Henz et al., 2018). Women who finished both instruments may differ from those who did not, so the 34.6% and 3.9% describe the completers and should not be read as rates for all 282. The population table likewise rests on pooled estimates with wide confidence intervals (Reilly et al., 2024).
Discussion
The studies reviewed here give a narrower and firmer picture of premenstrual dysphoric disorder (PMDD) than either the folk idea of a universal premenstrual change or the strongest critiques of the diagnosis. A few points are well supported by the evidence reviewed here, several remain contested, and for each contested point a particular kind of study would move it forward.
What Is Settled
A prospectively confirmed disorder exists in a small minority of women. Pooled prevalence was 3.2% for confirmed diagnosis, 1.6% for confirmed diagnosis in community samples, and 7.7% for provisional diagnosis, though heterogeneity was very high across all studies and low in the community-sample estimate (Reilly et al., 2024); Prevalence, Course and Burden gives the detail. In a study of 22 women with PMDD, of whom 12 had remission under ovarian suppression and went on to add-back, symptoms followed the change in hormone levels rather than a steady level: after stable suppression, combined estradiol and progesterone brought symptoms back in the first month of add-back and not in the two months that followed (Schmidt et al., 2017). That study was small and only the participants were blind, so the model is supported within the limits set out in The Differential Hormone-Sensitivity Model of Premenstrual Dysphoric Disorder. On moderate-certainty evidence, SSRIs probably ease symptoms more than placebo does, though the review suspected publication bias and noted that drug-company money funded 68% of the studies it pooled (Jespersen et al., 2024); for severe cases, ovarian suppression brings short-term relief, as Somatic Treatments: Ovarian Suppression and Surgery describes.
What Is Contested
Why only some women respond to normal hormonal change in this way is not known. The neurosteroid account is a proposal, and the cell-line work on the ESC/E(Z) gene-silencing complex came from lymphoblastoid cell lines of women with PMDD and controls, whose authors proposed that its dysregulation could contribute (Dubey et al., 2017). The imaging literature is sparse and somewhat inconsistent, and its own reviewers asked for replication (Dubol et al., 2020).
Whether the cognitive changes are a state or a trait is unresolved. Le and colleagues' narrative review found a lack of consistent findings on cognition across the cycle, while noting associations between the luteal phase and poorer performance on emotion-related cognition (Le et al., 2020); see Emotion, Attention and Cognition Across the Cycle.
The dosing question is also open. A 2023 meta-analysis found no statistically significant difference between intermittent and continuous SSRI dosing in response rate or symptom change, with every included study at moderate or high risk of bias (Reilly et al., 2023). The later Cochrane review found a larger effect with continuous dosing in a subgroup analysis that it rated moderate-certainty (Jespersen et al., 2024), while the 2023 meta-analysis found no significant difference, with every included study at moderate or high risk of bias, so the matter is not settled.
The status of the diagnosis is contested in a different way. A review of 55 articles judged the six objections to inclusion that it addressed largely rebutted (Hartlage et al., 2014), while a bioethical argument held that calling PMDD a mental disorder is unethical, without denying that the distress is real (Browne, 2015). The manuals kept the category, and the argument over what kind of condition it is remains open, as The Debate over the Diagnosis explains.
What Would Settle Each Question
Each dispute points to a design. The state-versus-trait question needs larger within-person studies that test the same women across prospectively confirmed and hormonally staged phases, with tasks whose reliability is known. The cause of the sensitivity needs the cellular, genetic and imaging findings replicated in larger samples before they are joined into one account. The dosing question needs head-to-head trials of luteal-phase against continuous dosing at low risk of bias, and the choice between drug classes needs trials that compare an SSRI directly with a contraceptive pill, which no trial reviewed here has done.
Current Directions
Several lines of work are reshaping the field, and most of them are early. Each is summarised here with a pointer to the section that reports it in full.
Genetics has reached large samples. A meta-analysis of two Nordic cohorts covering 72,297 European women (17,511 cases) found one locus in CACNA1C, rs758170, associated with premenstrual symptoms in the combined analysis (OR = 0.93), although the association was not significant in the LifeGene cohort alone (Hysaj et al., 2026). The signal was not significant in the smaller LifeGene cohort, the authors list the lack of replication as a limitation, and they call the result an initial insight that needs larger replication, so the finding is provisional. The genetic correlations are reported under The Biology of Premenstrual Dysphoric Disorder.
Imaging of the serotonin transporter now follows patients across the cycle. In a longitudinal PET study of 30 women with the disorder and 29 controls, midbrain transporter binding rose premenstrually in patients (a mean increase of 18%) and fell in controls (a mean decrease of 10%) (Sacher et al., 2023). The authors interpret this as cycle-specific serotonergic dynamics that may underlie depressed mood. The account is set out in Serotonergic, Stress and Sociocultural Accounts.
Neurosteroid-targeted drugs have a mixed record. A narrative review judged the interplay of allopregnanolone and GABA plausible as a source of symptoms, while noting that the clinical trials are early and the approved treatments suboptimal (Sikes-Keilp & Rubinow, 2023). In the 206-patient sepranolone trial, the prespecified primary endpoint showed no difference from placebo. Distress favoured the drug, impairment showed a trend only, and the benefit at 10 mg came from a post hoc analysis (Bäckström et al., 2021). A broader review links GABA sensitivity to allopregnanolone with a pathogenesis it describes as complex, with the role of inflammation still to be clarified (Tiranini & Nappi, 2022). The question remains open; Emerging Treatments gives the trial record.
Hormone buffering is being used as a causal test. In a crossover trial of 28 analysed psychiatric outpatients with recent suicidal ideation, estradiol plus progesterone reduced the perimenstrual rise in ideation and in suicide planning compared with placebo. The authors judge hormone withdrawal a possible causal contributor (Eisenlohr-Moul et al., 2022b). The trial was powered for medium effects only, could not separate the two hormones and had no attempt outcome. See Testing Cause and Consequence and Suicide and Self-Harm.
Method is a further direction. Inconsistent operationalisation of the cycle hinders cumulative knowledge, and standardised tools are argued to give more meaningful, replicable results (Schmalenberger et al., 2021). Validity of Diaries, Laboratory Tasks and Cycle-Phase Measures covers the measurement problems.
On cognition, a repeated-measures study of 105 women tested at three cycle phases found stop-signal deficits in the 51 with premenstrual syndrome or the disorder at every phase, plus a working-memory deficit only under high cognitive load, and no significant correlation between performance and gonadal hormone levels (Gnaiger et al., 2026). The authors read this as persistent, trait-like deficits, although whether they are a cause or a result is unclear and the sample was mostly university students. See Emotion, Attention and Cognition Across the Cycle.
Finally, a perspective article argues that the cycle should be treated as a vital sign in psychiatry, with routine enquiry about it, because phase relates to symptoms across diagnoses. It describes the evidence that cycle stage affects mental health symptoms across diagnoses as growing (Marwick et al., 2025).
Common Misconceptions
- PMDD is just bad PMS, and nearly every woman has it.
- Mild premenstrual change is common, but the disorder is not. A consensus report from the International Society for Premenstrual Disorders noted that published prevalence estimates vary widely with how symptoms are interpreted, giving 80 to 95% for physiological premenstrual symptoms, 30 to 40% for premenstrual syndrome and 3 to 8% for PMDD as examples (O'Brien et al., 2011), and once diagnosis is confirmed by prospective ratings the pooled prevalence is about 3.2% (Reilly et al., 2024).
- Women with PMDD have abnormal hormone levels.
- In one hormone-manipulation experiment, the authors concluded that premenstrual syndrome reflects an abnormal response to normal hormonal change. Leuprolide relieved symptoms in women with premenstrual syndrome, and estradiol or progesterone add-back restored them in the ten whose symptoms had improved on leuprolide, while the same hormones did not change mood in women without it (Schmidt et al., 1998). A review likewise judged that premenstrual syndrome does not seem to reflect abnormal concentrations of sex steroids, the difference from controls probably being greater sensitivity to their fluctuations (Yonkers et al., 2008).
- Remembering several bad premenstrual weeks is enough to make the diagnosis.
- Recall is a poor guide. Retrospective reports predicted the diagnosis from scored daily ratings badly (Eisenlohr-Moul et al., 2017), and in a within-subject comparison retrospective reports of premenstrual change exceeded prospective ones, more so among women who believed most women have premenstrual syndrome (Marván & Cortés-Iniestra, 2001).
- Antidepressants help only if they are taken every day.
- Treatment can be limited to the luteal phase. Luteal-phase sertraline produced a response in 50% of women with PMDD against 26% on placebo (Halbreich et al., 2002), and a meta-analysis found no statistically significant difference in response between intermittent and continuous dosing, though its included studies carried moderate or high risk of bias (Reilly et al., 2023). Whether luteal dosing fully matches continuous dosing is still unsettled.
Glossary
- Allopregnanolone.
- A metabolite of progesterone that modulates the GABA-A receptor. In one account of PMDD it is proposed to have a paradoxical negative effect on mood in sensitive women, a mechanism that is still not established.
- Carolina Premenstrual Assessment Scoring System.
- An algorithm, known as C-PASS, that converts the daily entries made on the DRSP into a diagnostic decision; it scores ratings rather than collecting any of its own. In its first validation its diagnoses matched those of expert clinicians in 98% of 200 women.
- Daily Record of Severity of Problems.
- A diary, abbreviated DRSP, that a woman completes herself each day across the cycle. It is one of the daily-rating instruments used to confirm PMDD.
- Differential hormone sensitivity.
- The proposal, from a hormone-manipulation experiment in women with premenstrual syndrome, that symptoms reflect an abnormal response to normal hormonal change. One test of it is a small hormone-manipulation experiment in which estradiol or progesterone add-back restored symptoms in 10 women with premenstrual syndrome but not in 15 women without it.
- Drospirenone.
- A progestogen used in some combined oral contraceptive pills. Pills containing it with ethinyl estradiol reduced premenstrual symptoms more than placebo in trials, on evidence rated very low to moderate in quality and with more adverse effects.
- Ecological momentary assessment.
- Repeated sampling of mood or behaviour in daily life, often by smartphone prompts several times a day, in place of later recall. In PMDD research it has tracked negative affect and rumination across cycle phases.
- Follicular phase.
- The part of the menstrual cycle from the start of menstruation to ovulation. In PMDD the symptoms subside a few days after menstruation starts, and the diagnosis requires a symptom-free stretch between then and ovulation.
- GABA-A receptor.
- A receptor for the inhibitory neurotransmitter GABA whose activity neurosteroids such as allopregnanolone modulate. Altered sensitivity of this receptor to allopregnanolone is one proposed mechanism for PMDD, with evidence that remains limited.
- Gonadotropin-releasing hormone agonist.
- A drug, such as leuprolide, that suppresses the ovarian cycle. It relieved global premenstrual symptoms more than placebo in trials and gives short-term relief only; hormone add-back can be given alongside it, though the evidence on add-back is imprecise.
- Late luteal phase dysphoric disorder.
- The name under which the condition was first listed, in the DSM-III-R appendix of categories needing further study. It was the forerunner of the later PMDD category.
- Luteal phase.
- The part of the menstrual cycle between ovulation and the next menstruation. PMDD symptoms arise late in that phase and start to ease a few days after bleeding begins.
- Luteal-phase dosing.
- Taking a medication, usually an SSRI, only during the luteal phase rather than every day. It beats placebo, and whether it works as well as continuous dosing is unsettled.
- Ovarian suppression.
- Stopping the ovarian cycle, usually with a gonadotropin-releasing hormone agonist. It is both a short-term treatment for severe cases and an experimental tool, since symptoms that remit under suppression and return with hormone add-back point to hormone sensitivity.
- Premenstrual exacerbation.
- The premenstrual worsening of a disorder that is present across the whole cycle, such as depression. The International Society for Premenstrual Disorders classes it as a variant of premenstrual disorder, distinct from core PMDD.
- Premenstrual Symptoms Screening Tool.
- A retrospective questionnaire, abbreviated PSST, that asks how severe premenstrual symptoms are and how much they interfere with daily life. Built as a quick screen, it was described by its authors as effective but only a first step before fuller assessment, and in one sample it identified many more women with PMDD than the daily record did.
- Premenstrual syndrome.
- A milder and more common presentation of premenstrual physical and mood symptoms, abbreviated PMS. Its boundary with PMDD lies in severity and impairment, and some criteria for it require no impact on functioning.
- Prospective daily rating.
- Recording symptoms each day as they occur, across at least two cycles, rather than recalling them later. It is the standard against which recalled premenstrual change is checked.
- Provisional diagnosis.
- A PMDD diagnosis made before two cycles of prospective ratings confirm it. Provisional diagnosis gives a higher pooled prevalence than confirmed diagnosis and probably inflates it.
- Rumination.
- Repetitive, self-focused thinking about distress and its causes. In women with PMDD it rose in the late luteal phase and predicted later negative affect in daily-life sampling, though the direction of influence is still tentative.
- Selective serotonin reuptake inhibitor.
- A class of antidepressant, abbreviated SSRI, that includes fluoxetine, sertraline, paroxetine and escitalopram. A scoping review ranked SSRIs and combined oral contraceptives as the best-supported treatments for PMDD, although the Cochrane review of drospirenone pills rated its evidence very low to moderate in quality; SSRIs reduce symptoms more than placebo on moderate-certainty evidence.
Key Researchers
Torbjörn Bäckström
Professor emeritus of obstetrics and gynecology at Umeå University who studied allopregnanolone and the GABA-A receptor in premenstrual dysphoric disorder and led the sepranolone trials. ORCID - Faculty Page
Erika Comasco
Researcher in neuropsychopharmacology in the Department of Women's and Children's Health at Uppsala University who reviewed neuroimaging of premenstrual dysphoric disorder and led a randomised trial of ulipristal acetate. ORCID - Faculty Page
Katharina Dalton
(1916–2004). British physician who, with Raymond Greene, named the premenstrual syndrome in 1953. Wikipedia
Tory A. Eisenlohr-Moul
Clinical psychologist and professor of adult psychiatry at the University of Chicago who developed the Carolina Premenstrual Assessment Scoring System and studied perimenstrual suicidality. ORCID - Faculty Page
C. Neill Epperson
Professor and chair of psychiatry at the University of Colorado School of Medicine who led the DSM-5 work-group review of premenstrual dysphoric disorder. ORCID - Faculty Page
Elias Eriksson
Professor in the Department of Pharmacology at the Sahlgrenska Academy, University of Gothenburg, who tested luteal-phase serotonin reuptake inhibitors in premenstrual dysphoria. ORCID - Faculty Page
Liisa Hantsoo
Psychologist at the Johns Hopkins University School of Medicine, in its Reproductive Mental Health Center, who reviewed dysregulated sensitivity to allopregnanolone in premenstrual dysphoric disorder. ORCID - Faculty Page
P. M. Shaughn O'Brien
Emeritus professor of obstetrics and gynaecology at Keele University who led the International Society for Premenstrual Disorders consensus on diagnosis and trial design. Faculty Page
David R. Rubinow
Distinguished professor of psychiatry at the University of North Carolina at Chapel Hill School of Medicine, formerly of the National Institute of Mental Health, who co-led the ovarian-suppression and hormone add-back studies. Faculty Page
Peter J. Schmidt
Chief of the Section on Behavioral Endocrinology at the National Institute of Mental Health who led the ovarian-suppression and hormone add-back experiments in premenstrual dysphoric disorder. Faculty Page
Meir Steiner
Professor emeritus of psychiatry and behavioural neurosciences at McMaster University who developed the Premenstrual Symptoms Screening Tool and led a large fluoxetine trial. ORCID
Inger Sundström-Poromaa
Professor of obstetrics and gynaecology at Uppsala University who studied emotion processing, amygdala reactivity and cognition across the menstrual cycle in premenstrual dysphoric disorder. ORCID - Faculty Page
Jane M. Ussher
Professor of women's health psychology at Western Sydney University who studied how women negotiate premenstrual distress and tested couple-based cognitive behavioural therapy. ORCID - Faculty Page
Kimberly A. Yonkers
Chair and professor of psychiatry at UMass Chan Medical School who led trials of sertraline dosing and of a drospirenone-containing oral contraceptive in premenstrual dysphoric disorder. ORCID - Faculty Page
Frequently Asked Questions
What is premenstrual dysphoric disorder, and how does it differ from premenstrual syndrome?
PMDD is a severe cyclical disorder of mood, irritability and tension in the days before menstruation, while premenstrual syndrome is a milder and far more common presentation. A consensus report noted that published prevalence estimates vary widely with how symptoms are interpreted, citing 30 to 40% for premenstrual syndrome and 3 to 8% for PMDD as examples (O'Brien et al., 2011).
How is PMDD diagnosed, and how common is it?
A confirmed diagnosis depends on symptoms rated every day as they happen, across the cycle, rather than on recall. In a meta-analysis of 44 studies, pooled prevalence was 3.2% for confirmed diagnosis and 7.7% for provisional diagnosis, and the authors concluded that provisional diagnosis probably inflates prevalence (Reilly et al., 2024).
What causes PMDD?
One account holds that affected women are unusually sensitive to normal hormonal change, possibly including allopregnanolone acting at the GABA-A receptor, rather than having abnormal hormone levels. Reviewing the evidence, Hantsoo and Epperson judged it consistent with the idea that, in PMDD, GABA-A receptors respond abnormally as allopregnanolone rises and falls over the menstrual cycle, while noting that larger trials are still needed (Hantsoo & Epperson, 2020).
Does PMDD affect attention, memory or thinking?
The evidence is mixed. A 2025 systematic review of 21 papers found only limited and inconsistent differences in cognitive performance between women with PMDD and controls, while a negative attentional bias was associated with the PMDD experience (Henderson et al., 2025).
Does PMDD raise the risk of suicide?
Studies link PMDD with suicidal thoughts and behaviour, though nearly all of them are cross-sectional and cannot show cause. A meta-analysis found higher odds of both suicidal ideation and suicide attempt in women with PMDD than in controls (Prasad et al., 2021). Anyone in immediate danger should contact local emergency services; in the United States the 988 Suicide and Crisis Lifeline is available by call or text.
Can a contraceptive pill help?
Pills combining drospirenone with ethinyl estradiol may help. A 2023 Cochrane review of five trials, mostly in women with PMDD, found that the pills may improve symptoms more than placebo, but rated the evidence very low to moderate in quality, found that they may cause more adverse effects, and noted that placebo also had a significant effect and that benefit beyond three cycles is unknown (Ma & Song, 2023).
Do exercise and other lifestyle measures help?
Exercise reduced global symptoms more than comparison conditions in a pooled analysis, but the trials concerned premenstrual syndrome rather than PMDD. A systematic review of 15 randomised trials, seven of which were pooled, found that exercise reduced global symptoms more than comparison conditions, with substantial heterogeneity and most trials (87%) at high risk of bias (Pearce et al., 2020).
What options remain if first-line treatment does not help?
In one scoping review, SSRIs and combined oral contraceptives had the strongest evidence, and gonadotropin-releasing hormone analogues and surgery showed efficacy for refractory cases. A scoping review of 113 articles reached that ranking, noting that the quality and methods of the studies varied (Carlini et al., 2022).
References
ACOG Committee on Clinical Practice Guidelines-Gynecology (Yonkers, K. A., Ireland, L. D., & Truehart, A. I., listed contributors). (2023). Management of premenstrual disorders: ACOG Clinical Practice Guideline No. 7. Obstetrics & Gynecology, 142(6), 1516-1533. https://doi.org/10.1097/AOG.0000000000005426
Alnashwan, Y. A., Rashid, A. M., Javaid, S. S., Kharoshah, M. A., Arun, M., Dsouza, H. L., Atreya, A., & Menezes, R. G. (2023). Incidence and comparison of suicide in various phases of the menstrual cycle: A systematic review and meta-analysis. Acta Informatica Medica, 31(1), 76-83. https://doi.org/10.5455/aim.2023.31.76-83
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Association Publishing. https://doi.org/10.1176/appi.books.9780890425787
Andréen, L., Nyberg, S., Turkmen, S., van Wingen, G., Fernández, G., & Bäckström, T. (2009). Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology, 34(8), 1121-1132. https://doi.org/10.1016/j.psyneuen.2009.02.003
Andualem, F., Melkam, M., Takelle, G. M., Nakie, G., Tinsae, T., Fentahun, S., Rtbey, G., Seid, J., Gedef, G. M., Bitew, D. A., & Godana, T. N. (2024). Prevalence of premenstrual syndrome and its associated factors in Africa: a systematic review and meta-analysis. Frontiers in Psychiatry, 15, 1338304. https://doi.org/10.3389/fpsyt.2024.1338304
Arab, A., Rafie, N., Askari, G., & Taghiabadi, M. (2020). Beneficial role of calcium in premenstrual syndrome: A systematic review of current literature. International Journal of Preventive Medicine, 11, 156. https://doi.org/10.4103/ijpvm.ijpvm_243_19
Bäckström, T., Bixo, M., Johansson, M., Nyberg, S., Ossewaarde, L., Ragagnin, G., Savic, I., Strömberg, J., Timby, E., van Broekhoven, F., & van Wingen, G. (2014). Allopregnanolone and mood disorders. Progress in Neurobiology, 113, 88-94. https://doi.org/10.1016/j.pneurobio.2013.07.005
Bäckström, T., Ekberg, K., Hirschberg, A. L., Bixo, M., Epperson, C. N., Briggs, P., Panay, N., & O'Brien, S. (2021). A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology, 133, 105426. https://doi.org/10.1016/j.psyneuen.2021.105426
Baker, F. C., & Lee, K. A. (2018). Menstrual cycle effects on sleep. Sleep Medicine Clinics, 13(3), 283-294. https://doi.org/10.1016/j.jsmc.2018.04.002
Baker, F. C., Kahan, T. L., Trinder, J., & Colrain, I. M. (2007). Sleep quality and the sleep electroencephalogram in women with severe premenstrual syndrome. Sleep, 30(10), 1283-1291. https://doi.org/10.1093/sleep/30.10.1283
Baller, E. B., Wei, S. M., Kohn, P. D., Rubinow, D. R., Alarcón, G., Schmidt, P. J., & Berman, K. F. (2013). Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: A multimodal neuroimaging study. American Journal of Psychiatry, 170(3), 305-314. https://doi.org/10.1176/appi.ajp.2012.12030385
Bannbers, E., Gingnell, M., Engman, J., Morell, A., Comasco, E., Kask, K., Garavan, H., Wikström, J., & Sundström Poromaa, I. (2012). The effect of premenstrual dysphoric disorder and menstrual cycle phase on brain activity during response inhibition. Journal of Affective Disorders, 142(1-3), 347-350. https://doi.org/10.1016/j.jad.2012.04.006
Beddig, T., Reinhard, I., Ebner-Priemer, U., & Kuehner, C. (2020). Reciprocal effects between cognitive and affective states in women with Premenstrual Dysphoric Disorder: An Ecological Momentary Assessment study. Behaviour Research and Therapy, 131, 103613. https://doi.org/10.1016/j.brat.2020.103613
Berni, L. C., Nunes, L. R., & de Oliveira, R. C. S. (2026). Comparison of premenstrual dysphoric disorder treatment with antidepressants and combined oral contraceptives: a systematic review with network meta-analysis. Journal of Psychiatric Research, 194, 99-115. https://doi.org/10.1016/j.jpsychires.2025.12.046
Bertone-Johnson, E. R., Ronnenberg, A. G., Houghton, S. C., Nobles, C., Zagarins, S. E., Takashima-Uebelhoer, B. B., Faraj, J. L., & Whitcomb, B. W. (2014). Association of inflammation markers with menstrual symptom severity and premenstrual syndrome in young women. Human Reproduction, 29(9), 1987-1994. https://doi.org/10.1093/humrep/deu170
Bertone-Johnson, E. R., Whitcomb, B. W., Missmer, S. A., Manson, J. E., Hankinson, S. E., & Rich-Edwards, J. W. (2014). Early life emotional, physical, and sexual abuse and the development of premenstrual syndrome: A longitudinal study. Journal of Women's Health, 23(9), 729-739. https://doi.org/10.1089/jwh.2013.4674
Bixo, M., Ekberg, K., Poromaa, I. S., Hirschberg, A. L., Jonasson, A. F., Andréen, L., Timby, E., Wulff, M., Ehrenborg, A., & Bäckström, T. (2017). Treatment of premenstrual dysphoric disorder with the GABA(A) receptor modulating steroid antagonist Sepranolone (UC1010): A randomized controlled trial. Psychoneuroendocrinology, 80, 46-55. https://doi.org/10.1016/j.psyneuen.2017.02.031
Bloch, M., Schmidt, P. J., Danaceau, M., Murphy, J., Nieman, L., & Rubinow, D. R. (2000). Effects of gonadal steroids in women with a history of postpartum depression. American Journal of Psychiatry, 157(6), 924-930. https://doi.org/10.1176/appi.ajp.157.6.924
Bosman, R. C., Jung, S. E., Miloserdov, K., Schoevers, R. A., & aan het Rot, M. (2016). Daily symptom ratings for studying premenstrual dysphoric disorder: A review. Journal of Affective Disorders, 189, 43-53. https://doi.org/10.1016/j.jad.2015.08.063
Brown, D., Smith, D. M., Osborn, E., & Wittkowski, A. (2024). The experiences and psychological impact of living with premenstrual disorders: a systematic review and thematic synthesis. Frontiers in Psychiatry, 15, 1440690. https://doi.org/10.3389/fpsyt.2024.1440690
Browne, T. K. (2015). Is premenstrual dysphoric disorder really a disorder? Journal of Bioethical Inquiry, 12(2), 313-330. https://doi.org/10.1007/s11673-014-9567-7
Busse, J. W., Montori, V. M., Krasnik, C., Patelis-Siotis, I., & Guyatt, G. H. (2009). Psychological intervention for premenstrual syndrome: A meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics, 78(1), 6-15. https://doi.org/10.1159/000162296
Buttner, M. M., Mott, S. L., Pearlstein, T., Stuart, S., Zlotnick, C., & O'Hara, M. W. (2013). Examination of premenstrual symptoms as a risk factor for depression in postpartum women. Archives of Women's Mental Health, 16(3), 219-225. https://doi.org/10.1007/s00737-012-0323-x
Caplan, P. J. (1995). They say you're crazy: How the world's most powerful psychiatrists decide who's normal. Addison-Wesley.
Carlini, S. V., Lanza di Scalea, T., McNally, S. T., Lester, J., & Deligiannidis, K. M. (2022). Management of premenstrual dysphoric disorder: A scoping review. International Journal of Women's Health, 14, 1783-1801. https://doi.org/10.2147/IJWH.S297062
Cary, E., & Simpson, P. (2024). Premenstrual disorders and PMDD - a review. Best Practice & Research Clinical Endocrinology & Metabolism, 38(1), 101858. https://doi.org/10.1016/j.beem.2023.101858
Chan, K., Rubtsova, A. A., & Clark, C. J. (2023). Exploring diagnosis and treatment of premenstrual dysphoric disorder in the U.S. healthcare system: A qualitative investigation. BMC Women's Health, 23, 272. https://doi.org/10.1186/s12905-023-02334-y
Chrisler, J. C., & Caplan, P. (2002). The strange case of Dr. Jekyll and Ms. Hyde: How PMS became a cultural phenomenon and a psychiatric disorder. Annual Review of Sex Research, 13(1), 274-306. https://doi.org/10.1080/10532528.2002.10559807
Cohen, L. S., Soares, C. N., Otto, M. W., Sweeney, B. H., Liberman, R. F., & Harlow, B. L. (2002). Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women: The Harvard Study of Moods and Cycles. Journal of Affective Disorders, 70(2), 125-132. https://doi.org/10.1016/S0165-0327(01)00458-X
Comasco, E., Kopp Kallner, H., Bixo, M., Hirschberg, A. L., Nyback, S., de Grauw, H., Epperson, C. N., & Sundström-Poromaa, I. (2021). Ulipristal acetate for treatment of premenstrual dysphoric disorder: A proof-of-concept randomized controlled trial. American Journal of Psychiatry, 178(3), 256-265. https://doi.org/10.1176/appi.ajp.2020.20030286
Craner, J. R., Sigmon, S. T., & Martinson, A. A. (2015). Self-focused attention in response to laboratory stressors among women with premenstrual disorders. Archives of Women's Mental Health, 18(4), 595-606. https://doi.org/10.1007/s00737-015-0505-4
Cronje, W. H., Vashisht, A., & Studd, J. W. W. (2004). Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Human Reproduction, 19(9), 2152-2155. https://doi.org/10.1093/humrep/deh354
Dawson, D. N., Eisenlohr-Moul, T. A., Paulson, J. L., Peters, J. R., Rubinow, D. R., & Girdler, S. S. (2018). Emotion-related impulsivity and rumination predict the perimenstrual severity and trajectory of symptoms in women with a menstrually related mood disorder. Journal of Clinical Psychology, 74(4), 579-593. https://doi.org/10.1002/jclp.22522
de Carvalho, A. B., Cardoso, T. A., Mondin, T. C., da Silva, R. A., Souza, L. D. M., Magalhães, P. V. S., & Jansen, K. (2018). Prevalence and factors associated with premenstrual dysphoric disorder: A community sample of young adult women. Psychiatry Research, 268, 42-45. https://doi.org/10.1016/j.psychres.2018.06.005
Dennerstein, L., Lehert, P., & Heinemann, K. (2011). Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. Menopause International, 17(3), 96-101. https://doi.org/10.1258/mi.2011.011028
Dias, R. S., Lafer, B., Russo, C., Del Debbio, A., Nierenberg, A. A., Sachs, G. S., & Joffe, H. (2011). Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: Findings from STEP-BD. American Journal of Psychiatry, 168(4), 386-394. https://doi.org/10.1176/appi.ajp.2010.09121816
Dorani, F., Bijlenga, D., Beekman, A. T. F., van Someren, E. J. W., & Kooij, J. J. S. (2021). Prevalence of hormone-related mood disorder symptoms in women with ADHD. Journal of Psychiatric Research, 133, 10-15. https://doi.org/10.1016/j.jpsychires.2020.12.005
Dubey, N., Hoffman, J. F., Schuebel, K., Yuan, Q., Martinez, P. E., Nieman, L. K., Rubinow, D. R., Schmidt, P. J., & Goldman, D. (2017). The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Molecular Psychiatry, 22(8), 1172-1184. https://doi.org/10.1038/mp.2016.229
Dubol, M., Epperson, C. N., Lanzenberger, R., Sundström-Poromaa, I., & Comasco, E. (2020). Neuroimaging premenstrual dysphoric disorder: A systematic and critical review. Frontiers in Neuroendocrinology, 57, 100838. https://doi.org/10.1016/j.yfrne.2020.100838
Dubol, M., Epperson, C. N., Sacher, J., Pletzer, B., Derntl, B., Lanzenberger, R., Sundström-Poromaa, I., & Comasco, E. (2021). Neuroimaging the menstrual cycle: A multimodal systematic review. Frontiers in Neuroendocrinology, 60, 100878. https://doi.org/10.1016/j.yfrne.2020.100878
Dubol, M., Wikström, J., Lanzenberger, R., Epperson, C. N., Sundström-Poromaa, I., & Comasco, E. (2022). Grey matter correlates of affective and somatic symptoms of premenstrual dysphoric disorder. Scientific Reports, 12, 5996. https://doi.org/10.1038/s41598-022-07109-3
Duko, B., Mekuriaw, B., Molla, A., & Ayano, G. (2021). The prevalence of premenstrual dysphoric disorder among adolescents in Ethiopia: a systematic review and meta-analysis. Irish Journal of Medical Science, 190(1), 419-427. https://doi.org/10.1007/s11845-020-02275-7
Dutta, A., & Sharma, A. (2021). Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in India: A systematic review and meta-analysis. Health Promotion Perspectives, 11(2), 161-170. https://doi.org/10.34172/hpp.2021.20
Eggert, L., Kleinstäuber, M., Hiller, W., & Witthöft, M. (2017). Emotional interference and attentional processing in premenstrual syndrome. Journal of Behavior Therapy and Experimental Psychiatry, 54, 77-87. https://doi.org/10.1016/j.jbtep.2016.07.002
Eggert, L., Witthöft, M., Hiller, W., & Kleinstäuber, M. (2016). Emotion regulation in women with premenstrual syndrome (PMS): Explicit and implicit assessments. Cognitive Therapy and Research, 40(6), 747-763. https://doi.org/10.1007/s10608-016-9788-7
Eisenlohr-Moul, T. A., Bowers, S. M., Prinstein, M. J., Schmalenberger, K. M., Walsh, E. C., Young, S. L., Rubinow, D. R., & Girdler, S. S. (2022). Effects of acute estradiol and progesterone on perimenstrual exacerbation of suicidal ideation and related symptoms: A crossover randomized controlled trial. Translational Psychiatry, 12(1), 528. https://doi.org/10.1038/s41398-022-02294-1
Eisenlohr-Moul, T. A., Girdler, S. S., Schmalenberger, K. M., Dawson, D. N., Surana, P., Johnson, J. L., & Rubinow, D. R. (2017). Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS). American Journal of Psychiatry, 174(1), 51-59. https://doi.org/10.1176/appi.ajp.2016.15121510
Eisenlohr-Moul, T. A., Rubinow, D. R., Schiller, C. E., Johnson, J. L., Leserman, J., & Girdler, S. S. (2016). Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder. Psychoneuroendocrinology, 67, 142-152. https://doi.org/10.1016/j.psyneuen.2016.01.026
Eisenlohr-Moul, T. A., Schmalenberger, K. M., Owens, S. A., Peters, J. R., Dawson, D. N., & Girdler, S. S. (2018). Perimenstrual exacerbation of symptoms in borderline personality disorder: Evidence from multilevel models and the Carolina Premenstrual Assessment Scoring System. Psychological Medicine, 48(12), 2085-2095. https://doi.org/10.1017/S0033291718001253
Eisenlohr-Moul, T., Divine, M., Schmalenberger, K., Murphy, L., Buchert, B., Wagner-Schuman, M., Kania, A., Raja, S., Miller, A. B., Barone, J., & Ross, J. (2022). Prevalence of lifetime self-injurious thoughts and behaviors in a global sample of 599 patients reporting prospectively confirmed diagnosis with premenstrual dysphoric disorder. BMC Psychiatry, 22, 199. https://doi.org/10.1186/s12888-022-03851-0
Endicott, J., Nee, J., & Harrison, W. (2006). Daily Record of Severity of Problems (DRSP): Reliability and validity. Archives of Women's Mental Health, 9(1), 41-49. https://doi.org/10.1007/s00737-005-0103-y
Epperson, C. N., Steiner, M., Hartlage, S. A., Eriksson, E., Schmidt, P. J., Jones, I., & Yonkers, K. A. (2012). Premenstrual dysphoric disorder: Evidence for a new category for DSM-5. American Journal of Psychiatry, 169(5), 465-475. https://doi.org/10.1176/appi.ajp.2012.11081302
Eriksson, E., Ekman, A., Sinclair, S., Sörvik, K., Ysander, C., Mattson, U.-B., & Nissbrandt, H. (2008). Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 28(2), 195-202. https://doi.org/10.1097/JCP.0b013e3181678a28
Eriksson, O., Wall, A., Marteinsdottir, I., Agren, H., Hartvig, P., Blomqvist, G., Långström, B., & Naessén, T. (2006). Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Research: Neuroimaging, 146(2), 107-116. https://doi.org/10.1016/j.pscychresns.2005.02.012
Fernández, M. D. M., Saulyte, J., Inskip, H. M., & Takkouche, B. (2018). Premenstrual syndrome and alcohol consumption: a systematic review and meta-analysis. BMJ Open, 8(3), e019490. https://doi.org/10.1136/bmjopen-2017-019490
Figert, A. E. (1995). The three faces of PMS: The professional, gendered, and scientific structuring of a psychiatric disorder. Social Problems, 42(1), 56-73. https://doi.org/10.2307/3097005
First, M. B., Yousif, L. H., Clarke, D. E., Wang, P. S., Gogtay, N., & Appelbaum, P. S. (2022). DSM-5-TR: Overview of what's new and what's changed. World Psychiatry, 21(2), 218-219. https://doi.org/10.1002/wps.20989
Ford, O., Lethaby, A., Roberts, H., & Mol, B. W. J. (2012). Progesterone for premenstrual syndrome. Cochrane Database of Systematic Reviews, (3), CD003415. https://doi.org/10.1002/14651858.CD003415.pub4
Frank, R. T. (1931). The hormonal causes of premenstrual tension. Archives of Neurology and Psychiatry, 26(5), 1053-1057. https://doi.org/10.1001/archneurpsyc.1931.02230110151009
Freeman, E. W. (2003). Premenstrual syndrome and premenstrual dysphoric disorder: Definitions and diagnosis. Psychoneuroendocrinology, 28(Suppl 3), 25-37. https://doi.org/10.1016/s0306-4530(03)00099-4
Freeman, E. W., Rickels, K., Schweizer, E., & Ting, T. (1995). Relationships between age and symptom severity among women seeking medical treatment for premenstrual symptoms. Psychological Medicine, 25(2), 309-315. https://doi.org/10.1017/s0033291700036205
Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (1999). Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: A randomized controlled trial. Archives of General Psychiatry, 56(10), 932-939. https://doi.org/10.1001/archpsyc.56.10.932
Freeman, E. W., Rickels, K., Yonkers, K. A., Kunz, N. R., McPherson, M., & Upton, G. V. (2001). Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstetrics and Gynecology, 98(5 Pt 1), 737-744. https://doi.org/10.1016/s0029-7844(01)01530-7
Freeman, E. W., Sammel, M. D., Rinaudo, P. J., & Sheng, L. (2004). Premenstrual syndrome as a predictor of menopausal symptoms. Obstetrics and Gynecology, 103(5, Pt 1), 960-966. https://doi.org/10.1097/01.aog.0000124804.81095.7f
Frokjaer, V. G., Pinborg, A., Holst, K. K., Overgaard, A., Henningsson, S., Heede, M., Larsen, E. C., Jensen, P. S., Agn, M., Nielsen, A. P., Stenbaek, D. S., da Cunha-Bang, S., Lehel, S., Siebner, H. R., Mikkelsen, J. D., Svarer, C., & Knudsen, G. M. (2015). Role of serotonin transporter changes in depressive responses to sex-steroid hormone manipulation: A positron emission tomography study. Biological Psychiatry, 78(8), 534-543. https://doi.org/10.1016/j.biopsych.2015.04.015
Gagné-Julien, A.-M. (2021). Wrongful medicalization and epistemic injustice in psychiatry: The case of premenstrual dysphoric disorder. European Journal of Analytic Philosophy, 17(2), 5-36. https://doi.org/10.31820/ejap.17.3.3
Gao, Q., Sun, W., Wang, Y. R., Li, Z. F., Zhao, F., Geng, X. W., Xu, K. Y., Chen, D., Liu, K., Xing, Y., Liu, W., & Wei, S. (2023). Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder: Toward precise targets for translational medicine and drug development. Frontiers in Psychiatry, 14, 1140796. https://doi.org/10.3389/fpsyt.2023.1140796
Gehlert, S., Song, I. H., Chang, C.-H., & Hartlage, S. A. (2009). The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychological Medicine, 39(1), 129-136. https://doi.org/10.1017/S003329170800322X
Gillings, M. R. (2014). Were there evolutionary advantages to premenstrual syndrome? Evolutionary Applications, 7(8), 897-904. https://doi.org/10.1111/eva.12190
Gingnell, M., Morell, A., Bannbers, E., Wikström, J., & Sundström Poromaa, I. (2012). Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder. Hormones and Behavior, 62(4), 400-406. https://doi.org/10.1016/j.yhbeh.2012.07.005
Girdler, S. S., Pedersen, C. A., Straneva, P. A., Leserman, J., Stanwyck, C. L., Benjamin, S., & Light, K. C. (1998). Dysregulation of cardiovascular and neuroendocrine responses to stress in premenstrual dysphoric disorder. Psychiatry Research, 81(2), 163-178. https://doi.org/10.1016/s0165-1781(98)00074-2
Girdler, S. S., Straneva, P. A., Light, K. C., Pedersen, C. A., & Morrow, A. L. (2001). Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biological Psychiatry, 49(9), 788-797. https://doi.org/10.1016/s0006-3223(00)01044-1
Gnaiger, A. M., Werlein, P., Gruschwitz, P., Siebers, M., Panzik, A., Comasco, E., Hidalgo-Lopez, E., & Pletzer, B. (2026). Impairment of executive functions in premenstrual syndrome: State or trait? Biological Psychiatry Global Open Science, 6(4), 100730. https://doi.org/10.1016/j.bpsgos.2026.100730
Gordon, J. L., Girdler, S. S., Meltzer-Brody, S. E., Stika, C. S., Thurston, R. C., Clark, C. T., Prairie, B. A., Moses-Kolko, E., Joffe, H., & Wisner, K. L. (2015). Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: A novel heuristic model. American Journal of Psychiatry, 172(3), 227-236. https://doi.org/10.1176/appi.ajp.2014.14070918
Granda, D., Szmidt, M. K., & Kaluza, J. (2021). Is premenstrual syndrome associated with inflammation, oxidative stress and antioxidant status? A systematic review of case-control and cross-sectional studies. Antioxidants, 10(4), 604. https://doi.org/10.3390/antiox10040604
Graze, K. K., Nee, J., & Endicott, J. (1990). Premenstrual depression predicts future major depressive disorder. Acta Psychiatrica Scandinavica, 81(2), 201-205. https://doi.org/10.1111/j.1600-0447.1990.tb06479.x
Greene, R., & Dalton, K. (1953). The premenstrual syndrome. British Medical Journal, 1(4818), 1007-1014. https://doi.org/10.1136/bmj.1.4818.1007
Griffin, L. D., & Mellon, S. H. (1999). Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proceedings of the National Academy of Sciences of the United States of America, 96(23), 13512-13517. https://doi.org/10.1073/pnas.96.23.13512
Halbreich, U., Backstrom, T., Eriksson, E., O'Brien, S., Calil, H., Ceskova, E., Dennerstein, L., Douki, S., Freeman, E., Genazzani, A., Heuser, I., Kadri, N., Rapkin, A., Steiner, M., Wittchen, H.-U., & Yonkers, K. (2007). Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecological Endocrinology, 23(3), 123-130. https://doi.org/10.1080/09513590601167969
Halbreich, U., Bergeron, R., Yonkers, K. A., Freeman, E., Stout, A. L., & Cohen, L. (2002). Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstetrics & Gynecology, 100(6), 1219-1229. https://doi.org/10.1016/s0029-7844(02)02326-8
Halbreich, U., Borenstein, J., Pearlstein, T., & Kahn, L. S. (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology, 28(Suppl 3), 1-23. https://doi.org/10.1016/s0306-4530(03)00098-2
Halbreich, U., Freeman, E. W., Rapkin, A. J., Cohen, L. S., Grubb, G. S., Bergeron, R., Smith, L., Mirkin, S., & Constantine, G. D. (2012). Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception, 85(1), 19-27. https://doi.org/10.1016/j.contraception.2011.05.008
Hamidovic, A., Karapetyan, K., Serdarevic, F., Choi, S. H., Eisenlohr-Moul, T., & Pinna, G. (2020). Higher circulating cortisol in the follicular vs. luteal phase of the menstrual cycle: A meta-analysis. Frontiers in Endocrinology, 11, 311. https://doi.org/10.3389/fendo.2020.00311
Hantsoo, L., & Epperson, C. N. (2015). Premenstrual dysphoric disorder: Epidemiology and treatment. Current Psychiatry Reports, 17(11), 87. https://doi.org/10.1007/s11920-015-0628-3
Hantsoo, L., & Epperson, C. N. (2020). Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiology of Stress, 12, 100213. https://doi.org/10.1016/j.ynstr.2020.100213
Hantsoo, L., Grillon, C., Sammel, M., Johnson, R., Marks, J., & Epperson, C. N. (2021). Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder. Psychopharmacology, 238(10), 2985-2997. https://doi.org/10.1007/s00213-021-05916-6
Hantsoo, L., Rangaswamy, S., Voegtline, K., Salimgaraev, R., Zhaunova, L., & Payne, J. L. (2022). Premenstrual symptoms across the lifespan in an international sample: Data from a mobile application. Archives of Women's Mental Health, 25(5), 903-910. https://doi.org/10.1007/s00737-022-01261-5
Hardy, C., & Hardie, J. (2017). Exploring premenstrual dysphoric disorder (PMDD) in the work context: A qualitative study. Journal of Psychosomatic Obstetrics and Gynaecology, 38(4), 292-300. https://doi.org/10.1080/0167482X.2017.1286473
Hartlage, S. A., Brandenburg, D. L., & Kravitz, H. M. (2004). Premenstrual exacerbation of depressive disorders in a community-based sample in the United States. Psychosomatic Medicine, 66(5), 698-706. https://doi.org/10.1097/01.psy.0000138131.92408.b9
Hartlage, S. A., Breaux, C. A., & Yonkers, K. A. (2014). Addressing concerns about the inclusion of premenstrual dysphoric disorder in DSM-5. The Journal of Clinical Psychiatry, 75(1), 70-76. https://doi.org/10.4088/JCP.13cs08368
Hartlage, S. A., Freels, S., Gotman, N., & Yonkers, K. (2012). Criteria for premenstrual dysphoric disorder: Secondary analyses of relevant data sets. Archives of General Psychiatry, 69(3), 300-305. https://doi.org/10.1001/archgenpsychiatry.2011.1368
Heinemann, L. A. J., Minh, T. D., Filonenko, A., & Uhl-Hochgräber, K. (2010). Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. Women's Health Issues, 20(1), 58-65. https://doi.org/10.1016/j.whi.2009.09.005
Henderson, A., Gardani, M., Dyker, G., & Matthews, L. (2025). Cognition and behaviour across the menstrual cycle in individuals with premenstrual dysphoric disorder - A systematic review. Journal of Affective Disorders, 371, 134-146. https://doi.org/10.1016/j.jad.2024.11.033
Henz, A., Ferreira, C. F., Oderich, C. L., Gallon, C. W., Castro, J. R. S., Conzatti, M., Fleck, M. P. A., & Wender, M. C. O. (2018). Premenstrual syndrome diagnosis: A comparative study between the Daily Record of Severity of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST). Revista Brasileira de Ginecologia e Obstetrícia, 40(1), 20-25. https://doi.org/10.1055/s-0037-1608672
Hong, J. P., Park, S., Wang, H. R., Chang, S. M., Sohn, J. H., Jeon, H. J., Lee, H. W., Cho, S. J., Kim, B. S., Bae, J. N., & Cho, M. J. (2012). Prevalence, correlates, comorbidities, and suicidal tendencies of premenstrual dysphoric disorder in a nationwide sample of Korean women. Social Psychiatry and Psychiatric Epidemiology, 47(12), 1937-1945. https://doi.org/10.1007/s00127-012-0509-6
Hunter, M. S., Ussher, J. M., Browne, S. J., Cariss, M., Jelley, R., & Katz, M. (2002). A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. Journal of Psychosomatic Obstetrics & Gynecology, 23(3), 193-199. https://doi.org/10.3109/01674820209074672
Huo, L., Straub, R. E., Roca, C., Schmidt, P. J., Shi, K., Vakkalanka, R., Weinberger, D. R., & Rubinow, D. R. (2007). Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biological Psychiatry, 62(8), 925-933. https://doi.org/10.1016/j.biopsych.2006.12.019
Hysaj, E., Jaholkowski, P., Shadrin, A. A., Bergstedt, J., Lu, Y., Bertone-Johnson, E., Bulik, C. M., Landén, M., Sandin, S., Kowalec, K., Hägg, S., Di Florio, A., Goldman, D., Schmidt, P. J., Valdimarsdóttir, U. A., Andreassen, O. A., & Lu, D. (2026). A genome-wide association study of premenstrual symptoms in two Nordic populations. Biological Psychiatry Global Open Science, 6(5), 100784. https://doi.org/10.1016/j.bpsgos.2026.100784
Ismaili, E., Walsh, S., O'Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., ... Yonkers, K. (2016). Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): Auditable standards for diagnosis and management of premenstrual disorder. Archives of Women's Mental Health, 19(6), 953-958. https://doi.org/10.1007/s00737-016-0631-7
Jespersen, C., Lauritsen, M. P., Frokjaer, V. G., & Schroll, J. B. (2024). Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database of Systematic Reviews, 8(8), CD001396. https://doi.org/10.1002/14651858.CD001396.pub4
Joffe, H., Cohen, L. S., & Harlow, B. L. (2003). Impact of oral contraceptive pill use on premenstrual mood: Predictors of improvement and deterioration. American Journal of Obstetrics and Gynecology, 189(6), 1523-1530. https://doi.org/10.1016/s0002-9378(03)00927-x
Kaiser, G., Janda, C., Kleinstäuber, M., & Weise, C. (2018). Clusters of premenstrual symptoms in women with PMDD: Appearance, stability and association with impairment. Journal of Psychosomatic Research, 115, 38-43. https://doi.org/10.1016/j.jpsychores.2018.10.004
Kendler, K. S., Karkowski, L. M., Corey, L. A., & Neale, M. C. (1998). Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. American Journal of Psychiatry, 155(9), 1234-1240. https://doi.org/10.1176/ajp.155.9.1234
Kepple, A. L., Lee, E. E., Haq, N., Rubinow, D. R., & Schmidt, P. J. (2016). History of postpartum depression in a clinic-based sample of women with premenstrual dysphoric disorder. Journal of Clinical Psychiatry, 77(4), e415-e420. https://doi.org/10.4088/jcp.15m09779
Kiesner, J., & Granger, D. A. (2016). A lack of consistent evidence for cortisol dysregulation in premenstrual syndrome/premenstrual dysphoric disorder. Psychoneuroendocrinology, 65, 149-164. https://doi.org/10.1016/j.psyneuen.2015.12.009
Kiesner, J. (2011). One woman's low is another woman's high: Paradoxical effects of the menstrual cycle. Psychoneuroendocrinology, 36(1), 68-76. https://doi.org/10.1016/j.psyneuen.2010.06.007
Kiesner, J., Eisenlohr-Moul, T., & Mendle, J. (2020). Evolution, the menstrual cycle, and theoretical overreach. Perspectives on Psychological Science, 15(4), 1113-1130. https://doi.org/10.1177/1745691620906440
Kim, D. R., Gyulai, L., Freeman, E. W., Morrison, M. F., Baldassano, C., & Dubé, B. (2004). Premenstrual dysphoric disorder and psychiatric co-morbidity. Archives of Women's Mental Health, 7(1), 37-47. https://doi.org/10.1007/s00737-003-0027-3
Kleinstäuber, M., Witthöft, M., & Hiller, W. (2012). Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: A meta-analysis. Journal of Clinical Psychology in Medical Settings, 19(3), 308-319. https://doi.org/10.1007/s10880-012-9299-y
Krasnik, C., Montori, V. M., Guyatt, G. H., Heels-Ansdell, D., & Busse, J. W. (2005). The effect of bright light therapy on depression associated with premenstrual dysphoric disorder. American Journal of Obstetrics and Gynecology, 193(3), 658-661. https://doi.org/10.1016/j.ajog.2005.01.055
Kuehner, C., & Nayman, S. (2021). Premenstrual exacerbations of mood disorders: Findings and knowledge gaps. Current Psychiatry Reports, 23(11), 78. https://doi.org/10.1007/s11920-021-01286-0
Kulkarni, J., Leyden, O., Gavrilidis, E., Thew, C., & Thomas, E. H. X. (2022). The prevalence of early life trauma in premenstrual dysphoric disorder (PMDD). Psychiatry Research, 308, 114381. https://doi.org/10.1016/j.psychres.2021.114381
Landén, M., & Eriksson, E. (2003). How does premenstrual dysphoric disorder relate to depression and anxiety disorders? Depression and Anxiety, 17(3), 122-129. https://doi.org/10.1002/da.10089
Landén, M., Nissbrandt, H., Allgulander, C., Sörvik, K., Ysander, C., & Eriksson, E. (2007). Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology, 32(1), 153-161. https://doi.org/10.1038/sj.npp.1301216
Le, J., Thomas, N., & Gurvich, C. (2020). Cognition, the menstrual cycle, and premenstrual disorders: A review. Brain Sciences, 10(4), 198. https://doi.org/10.3390/brainsci10040198
Lidegaard, Ø., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Løkkegaard, E. (2011). Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ, 343, d6423. https://doi.org/10.1136/bmj.d6423
Lin, J., Nunez, C., Susser, L., & Gershengoren, L. (2024). Understanding premenstrual exacerbation: navigating the intersection of the menstrual cycle and psychiatric illnesses. Frontiers in Psychiatry, 15, 1410813. https://doi.org/10.3389/fpsyt.2024.1410813
Lin, P.-C., Ko, C.-H., & Yen, J.-Y. (2022). Early and late luteal executive function, cognitive and somatic symptoms, and emotional regulation of women with premenstrual dysphoric disorder. Journal of Personalized Medicine, 12(5), 819. https://doi.org/10.3390/jpm12050819
Lin, P.-C., Ko, C.-H., Lin, Y.-J., & Yen, J.-Y. (2021). Insomnia, inattention and fatigue symptoms of women with premenstrual dysphoric disorder. International Journal of Environmental Research and Public Health, 18(12), 6192. https://doi.org/10.3390/ijerph18126192
Lopez, L. M., Kaptein, A. A., & Helmerhorst, F. M. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews, (2), CD006586. https://doi.org/10.1002/14651858.CD006586.pub4
Lustyk, M. K. B., Gerrish, W. G., Shaver, S., & Keys, S. L. (2009). Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: A systematic review. Archives of Women's Mental Health, 12(2), 85-96. https://doi.org/10.1007/s00737-009-0052-y
Ma, S., & Song, S. J. (2023). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews, 2023(6), CD006586. https://doi.org/10.1002/14651858.CD006586.pub5
Marjoribanks, J., Brown, J., O'Brien, P. M. S., & Wyatt, K. (2013). Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews, 2013(6), CD001396. https://doi.org/10.1002/14651858.CD001396.pub3
Martinez, P. E., Rubinow, D. R., Nieman, L. K., Koziol, D. E., Morrow, A. L., Schiller, C. E., Cintron, D., Thompson, K. D., Khine, K. K., & Schmidt, P. J. (2016). 5α-Reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology, 41(4), 1093-1102. https://doi.org/10.1038/npp.2015.246
Marván, M. L., & Cortés-Iniestra, S. (2001). Women's beliefs about the prevalence of premenstrual syndrome and biases in recall of premenstrual changes. Health Psychology, 20(4), 276-280. https://doi.org/10.1037//0278-6133.20.4.276
Marwick, K. F., Reilly, T. J., Allan, S., & Golightly, E. (2025). The menstrual cycle: an overlooked vital sign in psychiatry? BMJ Mental Health, 28(1), e301463. https://doi.org/10.1136/bmjment-2024-301463
Meers, J. M., & Nowakowski, S. (2020). Sleep, premenstrual mood disorder, and women's health. Current Opinion in Psychology, 34, 43-49. https://doi.org/10.1016/j.copsyc.2019.09.003
Naheed, B., Kuiper, J. H., O'Mahony, F., & O'Brien, P. M. (2025). Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS). Cochrane Database of Systematic Reviews, 2025(6), CD011330. https://doi.org/10.1002/14651858.CD011330.pub2
Naik, S. S., Nidhi, Y., Kumar, K., & Grover, S. (2023). Diagnostic validity of premenstrual dysphoric disorder: revisited. Frontiers in Global Women's Health, 4, 1181583. https://doi.org/10.3389/fgwh.2023.1181583
Nevatte, T., O'Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C. N., Eriksson, E., Freeman, E. W., Halbreich, U., Ismail, K., Panay, N., Pearlstein, T., Rapkin, A., Reid, R., Rubinow, D., Schmidt, P., Steiner, M., Studd, J., Sundström-Poromaa, I., & Yonkers, K. (2013). ISPMD consensus on the management of premenstrual disorders. Archives of Women's Mental Health, 16(4), 279-291. https://doi.org/10.1007/s00737-013-0346-y
Nexha, A., Caropreso, L., de Azevedo Cardoso, T., Suh, J. S., Tonon, A. C., & Frey, B. N. (2024). Biological rhythms in premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. BMC Women's Health, 24(1), 551. https://doi.org/10.1186/s12905-024-03395-3
Nobles, C. J., Thomas, J. J., Valentine, S. E., Gerber, M. W., Vaewsorn, A. S., & Marques, L. (2016). Association of premenstrual syndrome and premenstrual dysphoric disorder with bulimia nervosa and binge-eating disorder in a nationally representative epidemiological sample. International Journal of Eating Disorders, 49(7), 641-650. https://doi.org/10.1002/eat.22539
Nolan, L. N., & Hughes, L. (2022). Premenstrual exacerbation of mental health disorders: A systematic review of prospective studies. Archives of Women's Mental Health, 25(5), 831-852. https://doi.org/10.1007/s00737-022-01246-4
O'Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C. N., Eriksson, E., Freeman, E., Halbreich, U., Ismail, K. M. K., Panay, N., Pearlstein, T., Rapkin, A., Reid, R., Schmidt, P., Steiner, M., Studd, J., & Yonkers, K. (2011). Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: The ISPMD Montreal consensus. Archives of Women's Mental Health, 14(1), 13-21. https://doi.org/10.1007/s00737-010-0201-3
Osborn, E., Brooks, J., O'Brien, P. M. S., & Wittkowski, A. (2021). Suicidality in women with premenstrual dysphoric disorder: A systematic literature review. Archives of Women's Mental Health, 24(2), 173-184. https://doi.org/10.1007/s00737-020-01054-8
Osborn, E., Wittkowski, A., Brooks, J., Briggs, P. E., & O'Brien, P. M. S. (2020). Women's experiences of receiving a diagnosis of premenstrual dysphoric disorder: A qualitative investigation. BMC Women's Health, 20, Article 242. https://doi.org/10.1186/s12905-020-01100-8
Owens, S. A., & Eisenlohr-Moul, T. (2018). Suicide risk and the menstrual cycle: A review of candidate RDoC mechanisms. Current Psychiatry Reports, 20(11), 106. https://doi.org/10.1007/s11920-018-0962-3
Panahi, F., & Faramarzi, M. (2016). The effects of mindfulness-based cognitive therapy on depression and anxiety in women with premenstrual syndrome. Depression Research and Treatment, 2016, 9816481. https://doi.org/10.1155/2016/9816481
Parry, B. L., Berga, S. L., Mostofi, N., Sependa, P. A., Kripke, D. F., & Gillin, J. C. (1989). Morning versus evening bright light treatment of late luteal phase dysphoric disorder. American Journal of Psychiatry, 146(9), 1215-1217. https://doi.org/10.1176/ajp.146.9.1215
Payne, J. L., Palmer, J. T., & Joffe, H. (2009). A reproductive subtype of depression: Conceptualizing models and moving toward etiology. Harvard Review of Psychiatry, 17(2), 72-86. https://doi.org/10.1080/10673220902899706
Pearce, E., Jolly, K., Jones, L. L., Matthewman, G., Zanganeh, M., & Daley, A. (2020). Exercise for premenstrual syndrome: A systematic review and meta-analysis of randomised controlled trials. BJGP Open, 4(3), bjgpopen20X101032. https://doi.org/10.3399/bjgpopen20x101032
Pearlstein, T. B., Frank, E., Rivera-Tovar, A., Thoft, J. S., Jacobs, E., & Mieczkowski, T. A. (1990). Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. Journal of Affective Disorders, 20(2), 129-134. https://doi.org/10.1016/0165-0327(90)90126-s
Perkonigg, A., Yonkers, K. A., Pfister, H., Lieb, R., & Wittchen, H. U. (2004). Risk factors for premenstrual dysphoric disorder in a community sample of young women: The role of traumatic events and posttraumatic stress disorder. Journal of Clinical Psychiatry, 65(10), 1314-1322. https://doi.org/10.4088/jcp.v65n1004
Petersen, N., Ghahremani, D. G., Rapkin, A. J., Berman, S. M., Liang, L., & London, E. D. (2018). Brain activation during emotion regulation in women with premenstrual dysphoric disorder. Psychological Medicine, 48(11), 1795-1802. https://doi.org/10.1017/S0033291717003270
Petersen, N., Ghahremani, D. G., Rapkin, A. J., Berman, S. M., Wijker, N., Liang, L., & London, E. D. (2019). Resting-state functional connectivity in women with PMDD. Translational Psychiatry, 9(1), 339. https://doi.org/10.1038/s41398-019-0670-8
Petersen, N., London, E. D., Liang, L., Ghahremani, D. G., Gerards, R., Goldman, L., & Rapkin, A. J. (2016). Emotion regulation in women with premenstrual dysphoric disorder. Archives of Women's Mental Health, 19(5), 891-898. https://doi.org/10.1007/s00737-016-0634-4
Pilver, C. E., Kasl, S., Desai, R., & Levy, B. R. (2011). Exposure to American culture is associated with premenstrual dysphoric disorder among ethnic minority women. Journal of Affective Disorders, 130(1-2), 334-341. https://doi.org/10.1016/j.jad.2010.10.013
Pilver, C. E., Levy, B. R., Libby, D. J., & Desai, R. A. (2011). Posttraumatic stress disorder and trauma characteristics are correlates of premenstrual dysphoric disorder. Archives of Women's Mental Health, 14(5), 383-393. https://doi.org/10.1007/s00737-011-0232-4
Pilver, C. E., Libby, D. J., & Hoff, R. A. (2013). Premenstrual dysphoric disorder as a correlate of suicidal ideation, plans, and attempts among a nationally representative sample. Social Psychiatry and Psychiatric Epidemiology, 48(3), 437-446. https://doi.org/10.1007/s00127-012-0548-z
Pinkerton, J. V., Guico-Pabia, C. J., & Taylor, H. S. (2010). Menstrual cycle-related exacerbation of disease. American Journal of Obstetrics and Gynecology, 202(3), 221-231. https://doi.org/10.1016/j.ajog.2009.07.061
Pope, C. J., Oinonen, K., Mazmanian, D., & Stone, S. (2017). The hormonal sensitivity hypothesis: A review and new findings. Medical Hypotheses, 102, 69-77. https://doi.org/10.1016/j.mehy.2017.03.012
Prasad, D., Wollenhaupt-Aguiar, B., Kidd, K. N., de Azevedo Cardoso, T., & Frey, B. N. (2021). Suicidal risk in women with premenstrual syndrome and premenstrual dysphoric disorder: A systematic review and meta-analysis. Journal of Women's Health, 30(12), 1693-1707. https://doi.org/10.1089/jwh.2021.0185
Protopopescu, X., Tuescher, O., Pan, H., Epstein, J., Root, J., Chang, L., Altemus, M., Polanecsky, M., McEwen, B., Stern, E., & Silbersweig, D. (2008). Toward a functional neuroanatomy of premenstrual dysphoric disorder. Journal of Affective Disorders, 108(1-2), 87-94. https://doi.org/10.1016/j.jad.2007.09.015
Qiao, M., Zhang, H., Liu, H., Luo, S., Wang, T., Zhang, J., & Ji, L. (2012). Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample in China. European Journal of Obstetrics & Gynecology and Reproductive Biology, 162(1), 83-86. https://doi.org/10.1016/j.ejogrb.2012.01.017
Rapkin, A. J., & Akopians, A. L. (2012). Pathophysiology of premenstrual syndrome and premenstrual dysphoric disorder. Menopause International, 18(2), 52-59. https://doi.org/10.1258/mi.2012.012014
Rapkin, A. J., & Winer, S. A. (2009). Premenstrual syndrome and premenstrual dysphoric disorder: Quality of life and burden of illness. Expert Review of Pharmacoeconomics & Outcomes Research, 9(2), 157-170. https://doi.org/10.1586/erp.09.14
Reed, G. M., First, M. B., Kogan, C. S., et al. (2019). Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry, 18(1), 3-19. https://doi.org/10.1002/wps.20611
Reed, S. C., Levin, F. R., & Evans, S. M. (2008). Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder). Hormones and Behavior, 54(1), 185-193. https://doi.org/10.1016/j.yhbeh.2008.02.018
Reilly, T. J., Patel, S., Unachukwu, I. C., Knox, C.-L., Wilson, C. A., Craig, M. C., Schmalenberger, K. M., Eisenlohr-Moul, T. A., & Cullen, A. E. (2024). The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis. Journal of Affective Disorders, 349, 534-540. https://doi.org/10.1016/j.jad.2024.01.066
Reilly, T. J., Wallman, P., Clark, I., Knox, C. L., Craig, M. C., & Taylor, D. (2023). Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials. Journal of Psychopharmacology, 37(3), 261-267. https://doi.org/10.1177/02698811221099645
Richards, M., Rubinow, D. R., Daly, R. C., & Schmidt, P. J. (2006). Premenstrual symptoms and perimenopausal depression. American Journal of Psychiatry, 163(1), 133-137. https://doi.org/10.1176/appi.ajp.163.1.133
Roberts, B., Eisenlohr-Moul, T., & Martel, M. M. (2018). Reproductive steroids and ADHD symptoms across the menstrual cycle. Psychoneuroendocrinology, 88, 105-114. https://doi.org/10.1016/j.psyneuen.2017.11.015
Romans, S., Clarkson, R., Einstein, G., Petrovic, M., & Stewart, D. (2012). Mood and the menstrual cycle: A review of prospective data studies. Gender Medicine, 9(5), 361-384. https://doi.org/10.1016/j.genm.2012.07.003
Royal College of Obstetricians and Gynaecologists. (2017). Management of premenstrual syndrome: Green-top Guideline No. 48. BJOG, 124(3), e73-e105. https://doi.org/10.1111/1471-0528.14260
Rubinow, D. R., & Schmidt, P. J. (2006). Gonadal steroid regulation of mood: The lessons of premenstrual syndrome. Frontiers in Neuroendocrinology, 27(2), 210-216. https://doi.org/10.1016/j.yfrne.2006.02.003
Rubinow, D. R., Roy-Byrne, P., Hoban, M. C., Gold, P. W., & Post, R. M. (1984). Prospective assessment of menstrually related mood disorders. American Journal of Psychiatry, 141(5), 684-686. https://doi.org/10.1176/ajp.141.5.684
Rubinow, D. R., Smith, M. J., Schenkel, L. A., Schmidt, P. J., & Dancer, K. (2007). Facial emotion discrimination across the menstrual cycle in women with premenstrual dysphoric disorder (PMDD) and controls. Journal of Affective Disorders, 104(1-3), 37-44. https://doi.org/10.1016/j.jad.2007.01.031
Ruble, D. N. (1977). Premenstrual symptoms: A reinterpretation. Science, 197(4300), 291-292. https://doi.org/10.1126/science.560058
Sacher, J., Zsido, R. G., Barth, C., et al. (2023). Increase in serotonin transporter binding in patients with premenstrual dysphoric disorder across the menstrual cycle: A case-control longitudinal neuroreceptor ligand positron emission tomography imaging study. Biological Psychiatry, 93(12), 1081-1088. https://doi.org/10.1016/j.biopsych.2022.12.023
Schiller, C. E., Johnson, S. L., Abate, A. C., Schmidt, P. J., & Rubinow, D. R. (2016). Reproductive steroid regulation of mood and behavior. Comprehensive Physiology, 6(3), 1135-1160. https://doi.org/10.1002/cphy.c150014
Schmalenberger, K. M., Tauseef, H. A., Barone, J. C., Owens, S. A., Lieberman, L., Jarczok, M. N., Girdler, S. S., Kiesner, J., Ditzen, B., & Eisenlohr-Moul, T. A. (2021). How to study the menstrual cycle: Practical tools and recommendations. Psychoneuroendocrinology, 123, 104895. https://doi.org/10.1016/j.psyneuen.2020.104895
Schmidt, P. J., Ben Dor, R., Martinez, P. E., Guerrieri, G. M., Harsh, V., Thompson, K., Koziol, D. E., Nieman, L. K., & Rubinow, D. R. (2015). Effects of estradiol withdrawal on mood in women with past perimenopausal depression: A randomized clinical trial. JAMA Psychiatry, 72(7), 714-726. https://doi.org/10.1001/jamapsychiatry.2015.0111
Schmidt, P. J., Martinez, P. E., Nieman, L. K., Koziol, D. E., Thompson, K. D., Schenkel, L., Wakim, P. G., & Rubinow, D. R. (2017). Premenstrual dysphoric disorder symptoms following ovarian suppression: Triggered by change in ovarian steroid levels but not continuous stable levels. American Journal of Psychiatry, 174(10), 980-989. https://doi.org/10.1176/appi.ajp.2017.16101113
Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine, 338(4), 209-216. https://doi.org/10.1056/NEJM199801223380401
Schroll, J. B., & Lauritsen, M. P. (2022). Premenstrual dysphoric disorder: A controversial new diagnosis. Acta Obstetricia et Gynecologica Scandinavica, 101(5), 482-483. https://doi.org/10.1111/aogs.14360
Segebladh, B., Borgström, A., Nyberg, S., Bixo, M., & Sundström-Poromaa, I. (2009). Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. American Journal of Obstetrics and Gynecology, 201(2), 139.e1-139.e8. https://doi.org/10.1016/j.ajog.2009.03.016
Shah, N. R., Jones, J. B., Aperi, J., Shemtov, R., Karne, A., & Borenstein, J. (2008). Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: A meta-analysis. Obstetrics & Gynecology, 111(5), 1175-1182. https://doi.org/10.1097/aog.0b013e31816fd73b
Sharma, V., Mazmanian, D., & Eccles, H. (2022). Relationship of premenstrual dysphoric disorder with bipolar disorder: A systematic review. The Journal of Clinical Psychiatry, 83(6), 22r14416. https://doi.org/10.4088/jcp.22r14416
Shechter, A., Lespérance, P., Ng Ying Kin, N. M. K., & Boivin, D. B. (2012). Nocturnal polysomnographic sleep across the menstrual cycle in premenstrual dysphoric disorder. Sleep Medicine, 13(8), 1071-1078. https://doi.org/10.1016/j.sleep.2012.05.012
Shen, H., Gong, Q. H., Aoki, C., Yuan, M., Ruderman, Y., Dattilo, M., Williams, K., & Smith, S. S. (2007). Reversal of neurosteroid effects at α4β2δ GABAA receptors triggers anxiety at puberty. Nature Neuroscience, 10(4), 469-477. https://doi.org/10.1038/nn1868
Sigmon, S. T., Dorhofer, D. M., Rohan, K. J., & Boulard, N. E. (2000). The impact of anxiety sensitivity, bodily expectations, and cultural beliefs on menstrual symptom reporting: A test of the menstrual reactivity hypothesis. Journal of Anxiety Disorders, 14(6), 615-633. https://doi.org/10.1016/s0887-6185(00)00054-2
Sikes-Keilp, C., & Rubinow, D. R. (2023). GABA-ergic modulators: New therapeutic approaches to premenstrual dysphoric disorder. CNS Drugs, 37(8), 679-693. https://doi.org/10.1007/s40263-023-01030-7
Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154-1162. https://doi.org/10.1001/jamapsychiatry.2016.2387
Slyepchenko, A., Lokuge, S., Nicholls, B., Steiner, M., Hall, G. B. C., Soares, C. N., & Frey, B. N. (2017). Subtle persistent working memory and selective attention deficits in women with premenstrual syndrome. Psychiatry Research, 249, 354-362. https://doi.org/10.1016/j.psychres.2017.01.031
Spitzer, R. L., Severino, S. K., Williams, J. B. W., & Parry, B. L. (1989). Late luteal phase dysphoric disorder and DSM-III-R. American Journal of Psychiatry, 146(7), 892-897. https://doi.org/10.1176/ajp.146.7.892
Steinberg, E. M., Cardoso, G. M. P., Martinez, P. E., Rubinow, D. R., & Schmidt, P. J. (2012). Rapid response to fluoxetine in women with premenstrual dysphoric disorder. Depression and Anxiety, 29(6), 531-540. https://doi.org/10.1002/da.21959
Steiner, M., Macdougall, M., & Brown, E. (2003). The premenstrual symptoms screening tool (PSST) for clinicians. Archives of Women's Mental Health, 6(3), 203-209. https://doi.org/10.1007/s00737-003-0018-4
Steiner, M., Steinberg, S., Stewart, D., Carter, D., Berger, C., Reid, R., Grover, D., & Streiner, D. (1995). Fluoxetine in the treatment of premenstrual dysphoria. New England Journal of Medicine, 332(23), 1529-1534. https://doi.org/10.1056/NEJM199506083322301
Stiernman, L., Dubol, M., Comasco, E., Sundström-Poromaa, I., Boraxbekk, C.-J., Johansson, M., & Bixo, M. (2023). Emotion-induced brain activation across the menstrual cycle in individuals with premenstrual dysphoric disorder and associations to serum levels of progesterone-derived neurosteroids. Translational Psychiatry, 13, 124. https://doi.org/10.1038/s41398-023-02424-3
Sundblad, C., Hedberg, M. A., & Eriksson, E. (1993). Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo-controlled trial. Neuropsychopharmacology, 9(2), 133-145. https://doi.org/10.1038/npp.1993.52
Sundström Poromaa, I., & Gingnell, M. (2014). Menstrual cycle influence on cognitive function and emotion processing: From a reproductive perspective. Frontiers in Neuroscience, 8, 380. https://doi.org/10.3389/fnins.2014.00380
Takeda, T., Tasaka, K., Sakata, M., & Murata, Y. (2006). Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women. Archives of Women's Mental Health, 9(4), 209-212. https://doi.org/10.1007/s00737-006-0137-9
Tarchi, L., Merola, G. P., Baccaredda-Boy, O., Arganini, F., Cassioli, E., Rossi, E., Maggi, M., Baldwin, D. S., Ricca, V., & Castellini, G. (2023). Selective serotonin reuptake inhibitors, post-treatment sexual dysfunction and persistent genital arousal disorder: A systematic review. Pharmacoepidemiology and Drug Safety, 32(10), 1053-1067. https://doi.org/10.1002/pds.5653
Timby, E., Bäckström, T., Nyberg, S., Stenlund, H., Wihlbäck, A.-C. N., & Bixo, M. (2016). Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls, a pilot study. Psychopharmacology, 233(11), 2109-2117. https://doi.org/10.1007/s00213-016-4258-1
Tiranini, L., & Nappi, R. E. (2022). Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Faculty Reviews, 11, 11. https://doi.org/10.12703/r/11-11
Treloar, S. A., Heath, A. C., & Martin, N. G. (2002). Genetic and environmental influences on premenstrual symptoms in an Australian twin sample. Psychological Medicine, 32(1), 25-38. https://doi.org/10.1017/S0033291701004901
Tschudin, S., Bertea, P. C., & Zemp, E. (2010). Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Archives of Women's Mental Health, 13(6), 485-494. https://doi.org/10.1007/s00737-010-0165-3
Ussher, J. M., & Perz, J. (2013). PMS as a process of negotiation: Women's experience and management of premenstrual distress. Psychology & Health, 28(8), 909-927. https://doi.org/10.1080/08870446.2013.765004
Ussher, J. M., & Perz, J. (2017). Evaluation of the relative efficacy of a couple cognitive-behaviour therapy (CBT) for premenstrual disorders (PMDs), in comparison to one-to-one CBT and a wait list control: A randomized controlled trial. PLoS One, 12(4), e0175068. https://doi.org/10.1371/journal.pone.0175068
Ussher, J. M. (2013). Diagnosing difficult women and pathologising femininity: Gender bias in psychiatric nosology. Feminism & Psychology, 23(1), 63-69. https://doi.org/10.1177/0959353512467968
Verkaik, S., Kamperman, A. M., van Westrhenen, R., & Schulte, P. F. J. (2017). The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 217(2), 150-166. https://doi.org/10.1016/j.ajog.2017.02.028
Weise, C., Kaiser, G., Janda, C., Kues, J. N., Andersson, G., Strahler, J., & Kleinstäuber, M. (2019). Internet-based cognitive-behavioural intervention for women with premenstrual dysphoric disorder: A randomized controlled trial. Psychotherapy and Psychosomatics, 88(1), 16-29. https://doi.org/10.1159/000496237
Welz, A., Huffziger, S., Reinhard, I., Alpers, G. W., Ebner-Priemer, U., & Kuehner, C. (2016). Anxiety and rumination moderate menstrual cycle effects on mood in daily life. Women & Health, 56(5), 540-560. https://doi.org/10.1080/03630242.2015.1101739
Wikman, A., Sacher, J., Bixo, M., Hirschberg, A. L., Kopp Kallner, H., Epperson, C. N., Comasco, E., & Sundström Poromaa, I. (2022). Prevalence and correlates of current suicidal ideation in women with premenstrual dysphoric disorder. BMC Women's Health, 22, 35. https://doi.org/10.1186/s12905-022-01612-5
Wittchen, H.-U., Becker, E., Lieb, R., & Krause, P. (2002). Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychological Medicine, 32(1), 119-132. https://doi.org/10.1017/s0033291701004925
World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders (CDDR). World Health Organization.
Wyatt, K. M., Dimmock, P. W., Ismail, K. M. K., Jones, P. W., & O'Brien, P. M. S. (2004). The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: A meta analysis. BJOG: An International Journal of Obstetrics & Gynaecology, 111(6), 585-593. https://doi.org/10.1111/j.1471-0528.2004.00135.x
Wyatt, K. M., Dimmock, P. W., Jones, P. W., & Shaughn O'Brien, P. M. (1999). Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ, 318(7195), 1375-1381. https://doi.org/10.1136/bmj.318.7195.1375
Yang, J., Joe, S. H., Lee, M. S., Kim, S. H., & Jung, I. K. (2014). Survey of premenstrual symptom severity and impairment in Korean adolescents: premenstrual dysphoric disorder, subthreshold premenstrual dysphoric disorder and premenstrual syndrome. Asia-Pacific Psychiatry, 6(2), 135-144. https://doi.org/10.1111/appy.12024
Yang, M., Wallenstein, G., Hagan, M., Guo, A., Chang, J., & Kornstein, S. (2008). Burden of premenstrual dysphoric disorder on health-related quality of life. Journal of Women's Health, 17(1), 113-121. https://doi.org/10.1089/jwh.2007.0417
Yen, J.-Y., Wang, P.-W., Su, C.-H., Liu, T.-L., Long, C.-Y., & Ko, C.-H. (2018). Estrogen levels, emotion regulation, and emotional symptoms of women with premenstrual dysphoric disorder: The moderating effect of estrogen receptor 1α polymorphism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 82, 216-223. https://doi.org/10.1016/j.pnpbp.2017.11.013
Yonkers, K. A., & Simoni, M. K. (2018). Premenstrual disorders. American Journal of Obstetrics and Gynecology, 218(1), 68-74. https://doi.org/10.1016/j.ajog.2017.05.045
Yonkers, K. A., Brown, C., Pearlstein, T. B., Foegh, M., Sampson-Landers, C., & Rapkin, A. (2005). Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics & Gynecology, 106(3), 492-501. https://doi.org/10.1097/01.aog.0000175834.77215.2e
Yonkers, K. A., Kornstein, S. G., Gueorguieva, R., Merry, B., Van Steenburgh, K., & Altemus, M. (2015). Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: A randomized clinical trial. JAMA Psychiatry, 72(10), 1037-1044. https://doi.org/10.1001/jamapsychiatry.2015.1472
Yonkers, K. A., O'Brien, P. M. S., & Eriksson, E. (2008). Premenstrual syndrome. The Lancet, 371(9619), 1200-1210. https://doi.org/10.1016/S0140-6736(08)60527-9
Zachar, P., & Kendler, K. S. (2014). A diagnostic and statistical manual of mental disorders history of premenstrual dysphoric disorder. The Journal of Nervous and Mental Disease, 202(4), 346-352. https://doi.org/10.1097/nmd.0000000000000128